var title_f32_13_32976="Ivermectin: Drug information";
var content_f32_13_32976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ivermectin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F13855938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F13855939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=see_link\">",
"       Ivermectin (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=see_link\">",
"       Ivermectin (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8641 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32976=[""].join("\n");
var outline_f32_13_32976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=related_link\">",
"      Ivermectin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=related_link\">",
"      Ivermectin (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32977="Patient information: Bell's palsy (The Basics)";
var content_f32_13_32977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15818\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/14/41189\">",
"         Bell's palsy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/13/41168\">",
"         Patient information: Bell's palsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bell's palsy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bells-palsy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18409054\">",
"      <span class=\"h1\">",
"       What is Bell&rsquo;s palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bell&rsquo;s palsy is a condition that causes one side of a person&rsquo;s face to become weak or droop. This can happen when one of the nerves that control the muscles in the face gets damaged or stops working. Damage to this nerve usually happens when the nerve becomes swollen or inflamed because of an infection with a virus.",
"     </p>",
"     <p>",
"      Most people with Bell&rsquo;s palsy recover completely. But some people have symptoms of Bell&rsquo;s palsy for the rest of their life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409061\">",
"      <span class=\"h1\">",
"       What are the symptoms of Bell&rsquo;s palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An eyebrow that sags on one side",
"       </li>",
"       <li>",
"        Drooping of one eye and one corner of the mouth",
"       </li>",
"       <li>",
"        One eye that will not close completely (",
"        <a class=\"graphic graphic_picture graphicRef59425 \" href=\"UTD.htm?40/14/41189\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with Bell&rsquo;s palsy even lose the ability to taste on the front of their tongue. And some become sensitive to loud noises on the affected side.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409068\">",
"      <span class=\"h1\">",
"       Is there a test for Bell&rsquo;s palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. Even so, your doctor or nurse might order tests to check whether you have a different medical problem that could be confused with Bell&rsquo;s palsy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409075\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have any symptoms of Bell's palsy, see your doctor or nurse right away. Effective treatments exist, but they work best if you start them soon after your symptoms start.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409082\">",
"      <span class=\"h1\">",
"       How is Bell&rsquo;s palsy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Protection for your eyes",
"        </strong>",
"        &ndash; Bell's palsy sometimes makes it impossible for you to close one of your eyes. If that happens, it's important that you keep your eye moist and protected. Otherwise your eye can get damaged. Your doctor might prescribe eyedrops or ointments to protect your eye. You should also wear glasses or goggles during the day, and an eye patch at night.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Medicines to reduce inflammation and swelling",
"        </strong>",
"        &ndash; Many people with Bell's palsy get medicines called steroids. These are not the same steroids athletes take to build up muscle. These steroids help bring down the swelling that is often the cause of Bell&rsquo;s palsy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Medicines that help fight viruses",
"        </strong>",
"        &ndash; The swelling that causes Bell&rsquo;s palsy seems to be triggered by viruses. For this reason, some people get &ldquo;antiviral medicines,&rdquo; which help them fight infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409089\">",
"      <span class=\"h1\">",
"       Will my face go back to normal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Most people with Bell&rsquo;s palsy start to get better within 3 weeks of when their symptoms start. But it can take them up to 6 months to get completely back to normal. Some people do not recover completely. They can have some weakness in their face that never goes away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18409186\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=see_link\">",
"       Patient information: Bell's palsy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/13/32977?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15818 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-E5FD8A8851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32977=[""].join("\n");
var outline_f32_13_32977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409054\">",
"      What is Bell&rsquo;s palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409061\">",
"      What are the symptoms of Bell&rsquo;s palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409068\">",
"      Is there a test for Bell&rsquo;s palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409075\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409082\">",
"      How is Bell&rsquo;s palsy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409089\">",
"      Will my face go back to normal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18409186\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/14/41189\">",
"      Bell's palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=related_link\">",
"      Patient information: Bell's palsy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32978="Urate-lowering treatment of gout";
var content_f32_13_32978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Urate-lowering treatment of gout",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 791px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In the absence of tophi, CKD, urolithiasis, or uric acid overproduction.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Initiation of urate-lowering therapy should be accompanied by gout flare prophylaxis, as discussed in the UpToDate topic review on the prevention of recurrent gout.",
"      <br>",
"       &Delta; Reduction in flare rate, resolution of tophi, reduction in pain and of impairment in function.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and revised from: Algorithms for the diagnosis and management of musculoskeletal complaints. Am J Med 1997; 103:49S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32978=[""].join("\n");
var outline_f32_13_32978=null;
var title_f32_13_32979="Gestational diabetes mellitus";
var content_f32_13_32979=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Gestational diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/13/32979/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32979/contributors\" id=\"au4692\">",
"       Lois Jovanovic, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/13/32979/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32979/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32979/contributors\" id=\"se4922\">",
"       Michael F Greene, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/13/32979/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32979/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?32/13/32979?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Gestational diabetes mellitus (GDM) is a condition that develops during pregnancy when the body is not able to make enough insulin. The lack of insulin causes the blood glucose (also called blood sugar) level to become higher than normal. Gestational diabetes affects between 2 and 10 percent of women during pregnancy.",
"    </p>",
"    <p>",
"     It is important to recognize and treat gestational diabetes as soon as possible to minimize the risk of complications in the baby. In addition, it is important for women with a history of gestational diabetes to be tested for diabetes after pregnancy because of an increased risk of developing type 2 diabetes in the years following delivery.",
"    </p>",
"    <p>",
"     More detailed information about gestational diabetes is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"      \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GESTATIONAL DIABETES TESTING",
"     </span>",
"    </p>",
"    <p>",
"     We recommend that all pregnant women be screened for gestational diabetes. Identifying and treating gestational diabetes can reduce the risk of pregnancy complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"      \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Complications of gestational diabetes can include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Having a large baby (weighing more than 9 lbs or 4.1 kg), which can increase the risk of injury to the mother or baby during delivery and increase the chance of needing a cesarean section",
"      </li>",
"      <li>",
"       Preeclampsia (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"        \"Patient information: Preeclampsia (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Timing of test",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening for gestational diabetes is usually done between 24 and 28 weeks of pregnancy. However, screening may be done earlier in the pregnancy if you have risk factors for gestational diabetes, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A history of gestational diabetes in a previous pregnancy",
"      </li>",
"      <li>",
"       Obesity",
"      </li>",
"      <li>",
"       Glucose (sugar) in your urine",
"      </li>",
"      <li>",
"       A strong family history of diabetes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Test procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a few ways to test for gestational diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3156573\">",
"     <span class=\"h3\">",
"      Two part test",
"     </span>",
"     &nbsp;&mdash;&nbsp;On the day of the screening test, you can eat and drink normally. You will be given 50 grams of glucose, usually in the form of a specially formulated orange or cola drink. You should drink the whole amount within a few minutes. One hour later, you will have a blood test to measure your blood sugar level.",
"    </p>",
"    <p>",
"     If your blood sugar level is normal, no other tests are done.",
"    </p>",
"    <p>",
"     Most doctors and nurses consider your blood sugar level to be high if it is higher than 130 to 140",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (7.2 to 7.7",
"     <span class=\"nowrap\">",
"      mmol/L).",
"     </span>",
"     If your blood sugar level is very high (higher than 200",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     [11.1",
"     <span class=\"nowrap\">",
"      mmol/L]),",
"     </span>",
"     there is a very good chance that you have gestational diabetes.",
"    </p>",
"    <p>",
"     If your blood sugar level is higher than normal, you will need another test to know for sure if you have gestational diabetes. This test is called an oral glucose tolerance test (GTT). The test is done by measuring your blood sugar level before you eat anything in the morning (fasting), then again one, two, and three hours after you drink a glucose drink that contains 100 grams of glucose (twice the amount in the one-hour test). Similar to the one-hour test, this is usually in the form of a specially formulated orange or cola drink.",
"    </p>",
"    <p>",
"     Gestational diabetes is diagnosed if you have",
"     <strong>",
"      two or more",
"     </strong>",
"     elevated blood sugar values.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3156587\">",
"     <span class=\"h3\">",
"      One part test",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some doctors screen for diabetes with a different type of oral glucose tolerance test (GTT). The test is done by measuring your blood sugar level before you eat anything in the morning (fasting), then again one",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     two hours after you drink a glucose drink that contains 75 grams of glucose. This is usually in the form of a specially formulated orange or cola drink.",
"    </p>",
"    <p>",
"     Gestational diabetes is diagnosed if you have",
"     <strong>",
"      one or more",
"     </strong>",
"     elevated blood sugar values.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      GESTATIONAL DIABETES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     After you are diagnosed with gestational diabetes, you will need to make changes in what you eat, and you will need to learn to check your blood sugar level. In some cases, you will also need to learn how to give yourself insulin injections. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"      \"Medical management and follow-up of gestational diabetes mellitus\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The main goal of treatment for gestational diabetes is to reduce the risk that the baby will be large (weigh greater than 9 lbs at birth). A large baby can be difficult to deliver through the pelvis (called &ldquo;shoulder dystocia&rdquo;). A vaginal delivery increases the risk of injuring a large baby (eg, broken bones or nerve injury). A large baby is also more likely to cause injury to the mother during the delivery.",
"    </p>",
"    <p>",
"     You are more likely to have a large baby if your blood sugar levels are higher than normal during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Changes in diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;To learn what changes you should make in your diet, you will meet with a dietitian or nurse. The following are some general dietary recommendations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid high-calorie snacks and desserts, including soda with sugar, fruit punch, candy, chips, cookies, cakes, and full-fat ice cream",
"      </li>",
"      <li>",
"       You can use artificial sweeteners, such as aspartame (Nutrasweet&reg;), sucralose (Splenda&reg;), stevioside (Stevia&reg;), or acesulfame potassium (Sunnet&reg;).",
"      </li>",
"      <li>",
"       These sweeteners have not been linked to an increased risk of birth defects.",
"      </li>",
"      <li>",
"       Eat a lot of vegetables and fruits, at least five servings a day. Some fruits (like grapes, dried fruit) can increase your blood sugar level excessively and should be eaten in limited amounts. Don&rsquo;t eat a lot of starchy vegetables (eg, potatoes), but eat as many non-starchy fruits or vegetables as you like.",
"      </li>",
"      <li>",
"       Choose foods with whole grains. This includes whole-wheat bread, brown rice, or whole-wheat pasta instead of white bread, white rice, or regular pasta.",
"      </li>",
"      <li>",
"       If you eat red meat, eat a small amount and only a few times during the week. Choose lean cuts of meat that end in \"loin\" (eg, pork loin, tenderloin, sirloin). Remove skin from chicken and turkey before eating.",
"      </li>",
"      <li>",
"       Choose low- or fat-free dairy products, such as skim milk, nonfat yogurt, and low-fat cheese",
"      </li>",
"      <li>",
"       Use liquid oils (olive, canola) instead of solid fats (butter, margarine, shortening) for cooking",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Blood sugar monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;You will learn how to check your blood sugar level and record the results (",
"     <a class=\"graphic graphic_figure graphicRef82247 \" href=\"UTD.htm?27/53/28511\">",
"      figure 1",
"     </a>",
"     ). Instructions for choosing a blood sugar meter, checking blood sugar levels at home, and ways to record the results are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Initially, most women should check their blood sugar level four times per day:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Before eating in the morning",
"      </li>",
"      <li>",
"       One hour after breakfast, lunch, and dinner",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This information can help to determine whether your blood sugar levels are on target. If your levels stay higher than they should be, your doctor will probably recommend that you start using insulin. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Insulin'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Once on insulin, you need to check your blood glucose levels six times a day: before and one hour after each meal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although exercise is not a necessary part of gestational diabetes treatment, it might help to control blood sugar levels. If you were exercising before, you should continue after being diagnosed with gestational diabetes.",
"    </p>",
"    <p>",
"     If you did not previously exercise, ask your doctor or nurse if exercise is recommended. Most women who do not have medical or pregnancy-related complications are able to exercise, at least moderately, throughout their pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 15 percent of women with gestational diabetes will require insulin. Insulin is a medicine that helps to reduce blood sugar levels and can reduce the risk of gestational diabetes-related complications. Insulin is the most common medicine for treating gestational diabetes.",
"    </p>",
"    <p>",
"     You must give insulin by injection because it does not work when it is taken by mouth. Most women start by giving one shot of insulin per day. If your blood sugar levels are high after eating, you may need to give a shot two or three times per day. Instructions for drawing up and giving insulin shots are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you take insulin, you should check your blood sugar level at least six times per day. You also need to write down your results and how much insulin you give and review these records at each prenatal visit (",
"     <a class=\"graphic graphic_figure graphicRef82247 \" href=\"UTD.htm?27/53/28511\">",
"      figure 1",
"     </a>",
"     ). Keeping accurate records helps to adjust insulin doses and can decrease the risk of complications.",
"    </p>",
"    <p>",
"     Oral diabetes medicines, such as those taken by people with type 2 diabetes, are sometimes used during pregnancy in the United States. These medicines are not as safe and as effective as insulin.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      MONITORING DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Prenatal visits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women who develop gestational diabetes have more frequent prenatal visits (eg, once every week or two), especially if insulin is used. The purpose of these visits is to monitor your and your baby's health, discuss your diet, and adjust your dose of insulin to keep your blood sugar levels near normal. It is common to change the dose of insulin as the pregnancy progresses. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=see_link\">",
"      \"Obstetrical management of pregnancies complicated by gestational diabetes mellitus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Nonstress testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may need tests to monitor the health of the baby during the last trimester of pregnancy, especially if your blood sugars have been high, you are using insulin, or if you have any pregnancy-related complications (eg, high blood pressure). The most commonly used test is the nonstress test. This test is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"      \"Patient information: Postterm pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      LABOR AND DELIVERY WITH GESTATIONAL DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     If your blood sugar levels are close to normal during pregnancy and you have no other complications, the ideal time to deliver is between 39 and 40 weeks of pregnancy.",
"    </p>",
"    <p>",
"     If you do not deliver by your due date, you may need additional testing to monitor your and your baby's health. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"      \"Patient information: Postterm pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In most women with a normal-size baby, there are no advantages to a cesarean delivery over a vaginal delivery. The risks and benefits of cesarean delivery are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Your blood sugar levels will be monitored during labor. Most women have normal blood sugar levels during labor and don&rsquo;t need any insulin. Insulin is given if your blood sugar level becomes high. High blood sugar levels during labor can cause problems in the baby, both before and after delivery. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=see_link\">",
"      \"Intrapartum and postpartum management of insulin and blood glucose\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      AFTER-DELIVERY CARE",
"     </span>",
"    </p>",
"    <p>",
"     After delivery, most women with gestational diabetes have normal blood sugar levels and do not require further treatment with insulin. You can return to your prepregnancy diet, and you are encouraged to breastfeed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, it is important to check your blood sugar level the day after delivery to be sure that it is normal or near normal. Pregnancy itself does not increase the risk of developing type 2 diabetes. However, having gestational diabetes does increase your risk of developing type 2 diabetes later in life.",
"    </p>",
"    <p>",
"     If your blood sugar level is normal after delivery, you should have testing for type 2 diabetes at six weeks postpartum. Testing usually includes a two-hour glucose tolerance test (GTT).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Risk of gestational diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;One-third to two-thirds of women who have gestational diabetes in one pregnancy will have it again in a later pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Risk of type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with gestational diabetes have an increased risk of developing type 2 diabetes later in life, especially if the woman has other risk factors (eg, obesity, family history of type 2 diabetes).",
"    </p>",
"    <p>",
"     The risk of developing type 2 diabetes is greatly affected by body weight. Women who are obese have a 50 to 75 percent risk of type 2 diabetes, while women who are a normal weight have a less-than-25 percent risk. If you are overweight or obese, you can reduce your risk of type 2 diabetes by losing weight and exercising regularly.",
"    </p>",
"    <p>",
"     The American Diabetes Association (ADA) recommends that all women with a history of gestational diabetes have testing for type 2 diabetes at least every three years after their pregnancy. Women who have gestational diabetes after age 45 should have testing once per year.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with a history of gestational diabetes can use any type of birth control after pregnancy. A review of all of the birth control options is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784931805\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H257471\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/46/12002?source=see_link\">",
"      Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H257464\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"      Patient information: Postterm pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"      Infant of a diabetic mother",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=see_link\">",
"      Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=see_link\">",
"      Intrapartum and postpartum management of insulin and blood glucose",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000896.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000896.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://diabetes.niddk.nih.gov/dm/pubs/gestational/\">",
"      file://diabetes.niddk.nih.gov/dm/pubs/gestational/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/gestational-diabetes.jsp\">",
"      www.diabetes.org/gestational-diabetes.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?32/13/32979/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?32/13/32979?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32979/abstract/1\">",
"      Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32979/abstract/2\">",
"      Dodd JM, Crowther CA, Antoniou G, et al. Screening for gestational diabetes: the effect of varying blood glucose definitions in the prediction of adverse maternal and infant health outcomes. Aust N Z J Obstet Gynaecol 2007; 47:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32979/abstract/3\">",
"      American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004; 27 Suppl 1:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32979/abstract/4\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001; 98:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32979/abstract/5\">",
"      L&ouml;bner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006; 55:792.",
"     </a>",
"    </li>",
"    <li>",
"     Jovanovic, L (Ed). Diabetes and Pregnancy: What to Expect, American Diabetes Association, Alexandria, VA, revised 2007.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_13_32979=[""].join("\n");
var outline_f32_13_32979=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GESTATIONAL DIABETES TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           GESTATIONAL DIABETES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           MONITORING DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           LABOR AND DELIVERY WITH GESTATIONAL DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           AFTER-DELIVERY CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/53/28511\" title=\"figure 1\">",
"           Blood glucose record PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32980="Atypical manifestations of hepatitis A virus infection";
var content_f32_13_32980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atypical manifestations of hepatitis A virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Catherine P Cheney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32980/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/13/32980/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatitis A virus (HAV) infection is usually a self-limited disease conferring lifelong immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .) Fulminant hepatitis is uncommon but has been described in some settings such as in patients with preexisting chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/1\">",
"     1",
"    </a>",
"    ]. Chronic liver disease does not occur except in rare individuals in whom hepatitis A virus infection serves as a trigger for the development of autoimmune hepatitis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Autoimmune hepatitis'",
"    </a>",
"    below.) Three atypical clinical manifestations of acute infection are recognized: prolonged cholestasis, relapsing hepatitis, and extrahepatic disease associated with acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOLESTATIC HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice develops in approximately 30 percent of adults with acute hepatitis A. The serum bilirubin concentration is usually less than 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (171",
"    <span class=\"nowrap\">",
"     micromol/liter),",
"    </span>",
"    and declines within two weeks of peak levels. However, occasional patients have prolonged cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The clinical course in this setting is usually characterized by marked jaundice, pruritus, fever, weight loss, diarrhea, and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Biochemical and serologic abnormalities typically show marked elevation of the serum bilirubin (often &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and alkaline phosphatase, an elevated serum cholesterol, minimal elevation of serum aminotransferases, and often IgM anti-HAV antibodies. Peak bilirubin levels may be reached in the eighth week or later. The jaundice and pruritus may last for 12 weeks or more, but are followed by complete recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of prolonged cholestasis in these patients is uncertain, but is usually reflected histologically by predominantly cholestatic features. In one series of five patients who underwent a liver biopsy, the most common finding was marked centrilobular cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/3\">",
"     3",
"    </a>",
"    ]. Active portal inflammation was observed in three of the specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestasis resolves spontaneously with no lasting sequelae; thus, treatment is usually supportive. Recognition of this variant of hepatitis A is important to avoid unnecessary testing. An ultrasound should be performed to exclude biliary obstruction. However, liver biopsy or cholangiography is not necessary in most patients.",
"   </p>",
"   <p>",
"    A short course of corticosteroids has been suggested (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with a taper) to hasten the resolution of pruritus, malaise, and lower serum bilirubin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this approach was of no apparent benefit in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/3\">",
"     3",
"    </a>",
"    ], and may predispose to the development of the relapsing form of hepatitis A [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     Cholestyramine",
"    </a>",
"    should be administered if the pruritus is bothersome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RELAPSING HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical illness and biochemical abnormalities resolve completely within two to six months in most patients with acute hepatitis A. Serum aminotransferases peak approximately one month after exposure to the virus, and then decline by 75 percent per week, reaching normal levels after approximately two to three months.",
"   </p>",
"   <p>",
"    A relapsing form of hepatitis is observed in 3 to 20 percent of patients with HAV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/2,7-10\">",
"     2,7-10",
"    </a>",
"    ]. The clinical course is usually preceded by an apparent full clinical recovery with near normalization of the serum aminotransferases lasting 4 to 15 weeks, followed by biochemical and, in some cases, clinical relapse, which is often milder than the initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/7\">",
"     7",
"    </a>",
"    ]. HAV can frequently be recovered from stool during relapse; thus, these patients remain infectious [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum aminotransferases may exceed 1000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    during the relapse, while IgM anti-HAV typically persist throughout the course of the disease. A cholestatic form can also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/7,12\">",
"     7,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple relapses occur in some patients. In one series that included 297 adults with acute hepatitis A, 13 percent had a relapsing course, of whom 22 percent had more than one relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately one-half of patients were asymptomatic during the relapses, while some patients developed extrahepatic disease during relapses, such as arthritis, vasculitis, nephritis, and cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of the relapsing form of hepatitis A is unknown. In one series of 14 cases and review of an additional 68 patients reported in the literature, no predisposing factors were identified in the patients who relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/7\">",
"     7",
"    </a>",
"    ]. The initial infection was typical of acute hepatitis A in all cases.",
"   </p>",
"   <p>",
"    Proper recognition of this entity is important as it should prevent unnecessary, expensive, and potentially invasive tests such as MRCP or ERCP. Ultrasonography should suffice in excluding extrahepatic obstruction in patients with significant jaundice.",
"   </p>",
"   <p>",
"    The prognosis in the relapsing form of hepatitis A is excellent, as complete recovery should be expected. The duration of clinical relapse is generally short, although biochemical relapses may last as long as 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/11\">",
"     11",
"    </a>",
"    ]. Only one fatality associated with relapsing hepatitis A has been reported in a pregnant patient [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXTRAHEPATIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many extrahepatic manifestations of hepatitis A virus have been described. An evanescent rash and arthralgias are the most common, occurring in approximately 11 and 14 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, several other conditions related to immune complex disease and vasculitis rarely occur, including [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/13,14,16-18\">",
"     13,14,16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocytoclastic vasculitis (often most apparent on the legs and buttocks; IgM anti-HAV and complement can be demonstrated in the blood vessel walls on biopsy)",
"     </li>",
"     <li>",
"      Glomerulonephritis",
"     </li>",
"     <li>",
"      Arthritis",
"     </li>",
"     <li>",
"      Cryoglobulinemia",
"     </li>",
"     <li>",
"      Toxic epidermal necrolysis",
"     </li>",
"     <li>",
"      Myocarditis",
"     </li>",
"     <li>",
"      Optic neuritis",
"     </li>",
"     <li>",
"      Transverse myelitis",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Aplastic anemia",
"     </li>",
"     <li>",
"      Red cell aplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of extrahepatic manifestations may be more common in patients who have protracted disease, such as relapsing or cholestatic hepatitis. In one report, for example, cryoglobulins containing IgM anti-HAV were found in two patients with relapsing hepatitis A, both of whom developed arthritis and cryoglobulinemia, and one of whom developed vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/14\">",
"     14",
"    </a>",
"    ]. In another report, cutaneous vasculitis developed in a patient with the cholestatic form of hepatitis A [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis is a chronic hepatitis of unknown etiology characterized by hyperglobulinemia, the presence of certain circulating autoantibodies, and inflammatory changes on liver histology. Several \"triggers\" for autoimmune hepatitis, particularly drugs and viral hepatitis, have been described, which may incite the development of autoimmunity in predisposed individuals. This was illustrated in a study in which 58 relatives of 13 patients with autoimmune hepatitis were monitored prospectively for four years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/19\">",
"     19",
"    </a>",
"    ]. Subclinical acute hepatitis A occurred in three patients, two of whom developed type 1 autoimmune hepatitis within five months. These two patients had a defect in suppressor-inducer T lymphocytes specifically controlling immune responses to the asialoglycoprotein receptor (located on the hepatocyte cell surface). Hepatitis A preceding the development of autoimmune hepatitis has been described in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32980/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=see_link\">",
"       \"Patient information: Hepatitis A (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"       \"Patient information: Hepatitis A (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three atypical clinical manifestations of acute infection are recognized: prolonged cholestasis, relapsing hepatitis, and extrahepatic disease associated with acute infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaundice develops in approximately 30 percent of adults with acute hepatitis A. The serum bilirubin concentration is usually less than 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171",
"      <span class=\"nowrap\">",
"       micromol/liter),",
"      </span>",
"      and declines within two weeks of peak levels. However, occasional patients have prolonged cholestasis. The clinical course in this setting is usually characterized by marked jaundice, pruritus, fever, weight loss, diarrhea, and malaise. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cholestatic hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A relapsing form of hepatitis is observed in 3 to 20 percent of patients with HAV infection. The clinical course is usually preceded by an apparent full clinical recovery with near normalization of the serum aminotransferases lasting 4 to 15 weeks, followed by biochemical and, in some cases, clinical relapse, which is often milder than the initial episode. HAV can frequently be recovered from stool during relapse; thus, these patients remain infectious. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Relapsing hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many extrahepatic manifestations of hepatitis A virus have been described. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Extrahepatic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/1\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/2\">",
"      Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/3\">",
"      Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/4\">",
"      Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/5\">",
"      Schiraldi O, Modugno A, Miglietta A, Fera G. Prolonged viral hepatitis type A with cholestasis: case report. Ital J Gastroenterol 1991; 23:364.",
"     </a>",
"    </li>",
"    <li>",
"     Terrault NA, Wright TL. Viral hepatitis A through G. In: Gastrointestinal and Liver Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia 1998. p.1129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/7\">",
"      Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992; 71:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/8\">",
"      Kassas AL, Telegdy L, M&eacute;hesfalvi E, et al. Polyphasic and protracted patterns of hepatitis A infection: a retrospective study. Acta Med Hung 1994; 50:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/9\">",
"      Bornstein JD, Byrd DE, Trotter JF. Relapsing hepatitis A: a case report and review of the literature. J Clin Gastroenterol 1999; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/10\">",
"      Gr&uuml;nhage F, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis--sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion 2004; 70:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/11\">",
"      Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987; 106:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/12\">",
"      Rachima CM, Cohen E, Garty M. Acute hepatitis A: combination of the relapsing and the cholestatic forms, two rare variants. Am J Med Sci 2000; 319:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/13\">",
"      Ilan Y, Hillman M, Oren R, et al. Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection. Am J Gastroenterol 1990; 85:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/14\">",
"      Inman RD, Hodge M, Johnston ME, et al. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 1986; 105:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/15\">",
"      Lysy Y, Furst A, Medina A, et al. Fatal relapsing viral hepatitis A infection during pregnancy. Isr J Med Sci 1988; 24:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/16\">",
"      Dan M, Yaniv R. Cholestatic hepatitis, cutaneous vasculitis, and vascular deposits of immunoglobulin M and complement associated with hepatitis A virus infection. Am J Med 1990; 89:103.",
"     </a>",
"    </li>",
"    <li>",
"     Lavine J, Bull F, Millward-Sadler G. Acute viral hepatitis. In: Wright's Liver and Biliary Disease, Millard-Sadler G, Wright R, Arthur M (Eds), WB Saunders, London 1992. p.681.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/18\">",
"      Shenoy R, Nair S, Kamath N. Thrombocytopenia in hepatitis A--an atypical presentation. J Trop Pediatr 2004; 50:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/19\">",
"      Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32980/abstract/20\">",
"      Skoog SM, Rivard RE, Batts KP, Smith CI. Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol 2002; 97:1568.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3634 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32980=[""].join("\n");
var outline_f32_13_32980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOLESTATIC HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RELAPSING HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXTRAHEPATIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=related_link\">",
"      Pathogenesis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=related_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=related_link\">",
"      Patient information: Hepatitis A (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32981="The path to safer home transfusion: Standardized procedures";
var content_f32_13_32981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The path to safer home transfusion: Standardized procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Joy L Fridey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32981/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/13/32981/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to increase the accessibility and convenience of care to chronically ill patients and to decrease associated costs, many therapies, including transfusions, are now occasionally given in patients' homes or physicians' offices. There is one major factor that distinguishes the administration of blood in a home setting from transfusion in a hospital: the decreased availability of emergency medical care in the event of a serious complication. This inherent difference compounds the already present and usual risks of transfusion; thus, increased convenience and decreased costs must be subsumed to patient safety.",
"   </p>",
"   <p>",
"    Another legitimate concern is one that underlies all of transfusion practice: the possibility that blood could be administered to the wrong patient. This phenomenon has been well-documented in tertiary care centers [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Causes range from mislabeling of the pretransfusion specimen to administering blood to a patient who is wearing either the wrong identification band or none at all. Any of these errors can be duplicated in a home transfusion setting.",
"   </p>",
"   <p>",
"    Transfusion safety derives from constructing clear standard operating procedures (SOPs), training the personnel who transfuse, and adhering to written procedures. Composing or reading about transfusion SOPs is not a glamorous or engaging enterprise. However, SOPs are the backbone of transfusion safety and, in view of the recent interest that nonhospital facilities and agencies have shown in out-of-hospital transfusions, it is appropriate that practical suggestions for writing SOPs be available.",
"   </p>",
"   <p>",
"    The procedures that should be written for the main activities associated with home transfusion and the general content of each of these procedures will be reviewed here. This document is intended to provide broad guidelines since a comprehensive discussion of all possible procedural details is beyond the scope of this overview; additional information is available in several reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The AABB (formerly the American Association of Blood Banks), now considered an international authority on transfusion practices and processes, also publishes a comprehensive and informative Technical Manual [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/7\">",
"     7",
"    </a>",
"    ], and every 18 months issues updated transfusion Standards [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general principles of home transfusion and the management of transfusion reactions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37174?source=see_link\">",
"     \"General principles of home blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COLLECTION AND LABELING OF PRETRANSFUSION SPECIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This standard operating procedure (SOP) defines the steps for performing the necessary pretransfusion functions; these include obtaining specimens for pretransfusion compatibility testing and affixing identification to the patient. This SOP (or a separate one) should also provide instructions for obtaining informed consent.",
"   </p>",
"   <p>",
"    The transfusionist who will be administering the blood is usually the individual responsible for obtaining informed consent, putting an identification band on the patient, and collecting the pretransfusion specimens. As in any other pretransfusion setting, the appropriate specimens, a clot tube and a purple-topped (EDTA) tube, should be collected within three days of the anticipated transfusion. The tubes should be labeled with the patient's name, an identifying number such as the date of birth or medical record number, the date of collection, and the initials or name of the transfusionist. If the specimen does not meet these requirements, the SOP should state that the specimens should be rejected and a new one, which conforms to the requirements, obtained. If these specifications are not met, the blood bank issuing the blood will probably reject it.",
"   </p>",
"   <p>",
"    An identification band, such as a wristband, should legibly show the patient's full name and at least two alphanumeric or numeric identifiers. The numeric identifier(s) on the wristband must be identical to those on the pretransfusion specimens. All of the above steps and activities should appear in the SOP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SITE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An SOP must be developed that lists other activities that should take place in the first visit to the patient's home. This procedure should require the transfusionist to determine if the home has a working landline or cell phone and assure that another responsible adult will be present during the transfusion. The area of the home in which the transfusion will be given should be accessible to emergency personnel. This information is important for ensuring that the transfusionist has assistance in carrying out the appropriate document checks and contacting help if a complication arises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ISSUING OF BLOOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;This SOP should specify the type and amount of each component that will be ordered by the physician and accepted by the transfusing agency for home transfusion. It is important to coordinate this procedure with that of the local blood provider. The author recommends use of the following guidelines:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Packed red blood cells and plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;No more than two units of each type of component should be issued per transfusion episode. If packed red blood cells (PRBCs) and plasma are issued simultaneously, only one unit of PRBCs and one unit of plasma should be issued. These limits are recommended in order to avoid volume overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plateletpheresis products (also known as \"single donor platelets\") are obtained from one donor with an automated cell separation device. Use of this product reduces the recipient's exposure to allogeneic donor blood. This is the recommended platelet component when apheresis and pooled platelet concentrates are both available. No more than two apheresis units should be issued per transfusion episode.",
"   </p>",
"   <p>",
"    If only pooled random platelet concentrates are available, only one pool of not more than 10 concentrates should be issued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558382031#H558382031\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet collection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryoprecipitate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoprecipitate can be administered in a home setting for patients with an isolated factor deficiency (eg, factor XIII deficiency). Because the volume of one unit is so small (about 15",
"    <span class=\"nowrap\">",
"     mL/unit),",
"    </span>",
"    use of 10 to 15 pooled units would not risk fluid overload. However, the intended dose should be calculated, which will determine the number of units that should be ordered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In keeping with standard practices, when components are released, the sign-out should be performed by laboratory personnel as well as by the party responsible for transporting or transfusing the products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each issuing facility, in consultation with the ordering physician community, should decide whether or not to leukoreduce cellular products (ie, packed red blood cells and platelets) that are transfused in a home or physician's office. Leukoreducing all cellular products with a leukocyte reduction filter can prevent the occurrence of febrile, nonhemolytic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/9\">",
"     9",
"    </a>",
"    ]. This can be especially useful in a nonhospital setting because, if such a reaction occurs, the transfusion will be aborted and the patient's therapy delayed. The use of leukoreduced products will prevent other complications such as alloimmunization to red blood cell antigens and other possible immunologic reactions associated with residual white blood cell contamination in cellular blood products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the decision is that all cellular products intended for home transfusion will undergo leukofiltration at the bedside, this should be stated in the standard operating protocol, the transfusionists should be trained in proper usage of the bedside leukocyte filter, and a mechanism for ensuring proper use and quality assurance should be developed.",
"   </p>",
"   <p>",
"    If bedside filtration is used, the transfusionist should be aware that hypotensive reactions have been observed in association with leukoreduction filters. There are over 80 reports of patients developing significant hypotensive events while receiving blood products (especially platelets) transfused through a bedside leukocyte reduction filter [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/10\">",
"     10",
"    </a>",
"    ]. The fall in blood pressure typically resolves rapidly once the transfusion is stopped. Because of concern about this complication, the Food and Drug Administration in the United States issued a series of recommendations, dated May 4, 1999, which included the preferred use of blood products that are leukoreduced (if leukoreduction is desired) at the time of collection or during laboratory storage whenever feasible. Additional information concerning FDA action on this issue can be obtained from their web site at:",
"    <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062284.htm\">",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062284.htm",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/11\">",
"     11",
"    </a>",
"    ]. Although these kinds of reactions are less commonly reported, isolated cases apparently do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TRANSPORTING AND STORING BLOOD COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transporting and storing blood for use in a nonhospital setting presents a special challenge because transport to a patient's home or other nonhospital facility may involve more time or unpredictable conditions than would normally be encountered in a hospital. The SOP should specify how the units will be protected and maintained at an appropriate temperature. A protective transport container such as an Igloo&trade; is appropriate for components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell units should be packed with a coolant that maintains a 1 to 10&ordm;C temperature range.",
"     </li>",
"     <li>",
"      Platelets can be maintained at the required 20 to 24&ordm;C range by shipping them at room temperature (for short distances) or by packing them with commercially available thermostable material.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to have a mechanism for verifying that the appropriate temperature has been maintained. This can be done by the issuing center either by placing a thermometer in close proximity to the components or by applying a colorimetric temperature sensitive device on the component. An example of such a device is the Hemotemp II&trade; (Biosynergy, Inc.), which changes from green to tan when the temperature exceeds 10&ordm;C.",
"   </p>",
"   <p>",
"    Because transporting of blood falls under FDA regulations, the issuing facility should validate its shipping procedures. Validation involves simulations that stress and test the shipping system to guarantee that products will be delivered intact and remain within acceptable temperature ranges.",
"   </p>",
"   <p>",
"    The SOP should also state the following: once at the final destination, the transporting container should not be opened until preparations for transfusion are complete. Under no circumstances should a component be placed in an unmonitored refrigerator, even one in a physician's office, a convalescent center, or other facility that may have refrigerators for storing pharmaceutical products. After the shipping container is opened, it is important that the transfusionist document the temperature of the component milieu. The SOP for transport should specify that, if the indicator shows a temperature above 10&ordm;C for red blood cells or above 24&ordm;C for platelets, the blood component should be returned",
"    <strong>",
"     untransfused",
"    </strong>",
"    to the issuing facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SOP for this procedure is one of the most important in the entire process. Failure of the procedure to accurately detail all steps, and failure of the transfusionist to follow the procedure can carry with it the same calamitous outcome as when blood is erroneously transfused to the wrong patient in a hospital setting. The one-to-one nurse-patient ratio found in home care or other settings is no insurance against such an error.",
"   </p>",
"   <p>",
"    The identification process in the home transfusion setting is distinctly dissimilar from that which takes place in the hospital since another nurse is usually not available to assist with the identification check of the patient and review of the documents. Nevertheless, patient identification procedures at home should involve two people, one of whom is",
"    <strong>",
"     not",
"    </strong>",
"    the patient (thus, the necessity of having another responsible adult present at the bedside).",
"   </p>",
"   <p>",
"    Immediately prior to the transfusion, the transfusionist and the other adult in attendance should carry out what is referred to as a \"clerical check.\" In this procedure, the patient's wristband (which presumably was applied in an earlier home visit and should still be on the patient) is checked for accuracy and compared with the patient's name and identification number that are affixed to the component and also listed on accompanying blood bank paperwork. This information should be matched item by item and, if any discrepancies, even seemingly minor ones, are observed, the transfusion should not take place, and the blood should be returned to the issuing facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This SOP should detail the patient monitoring and logistics associated with the actual transfusion. It should state the instructions that the patient must receive prior to the transfusion, especially the necessity of reporting any change in physical sensation or condition during the transfusion. It should outline how often the patient's temperature and vital signs should be taken and recorded (suggested minimum: immediately beforehand, every 15 minutes for the first hour, every 30 minutes thereafter, and 15 to 30 minutes after the transfusion is complete).",
"   </p>",
"   <p>",
"    The procedure should also specify what type of infusion tubing will be used, whether or not a leukoreduction filter is needed, and the type of infusing solution. The procedure should clearly say that the only solution acceptable for transfusion is sterile, physiologic saline. Other supplies such as medications and equipment (eg, appropriate-gauge needles) and their proper use should be listed.",
"   </p>",
"   <p>",
"    The maximum amount of time, four hours, during which the infusion takes place needs to be stated. Although no minimum amount of time for transfusing a component is suggested in the literature, the procedure should state that an infusion rate appropriate for the patient's age, cardiovascular status, and other underlying medical conditions, should be prudently individualized and selected.",
"   </p>",
"   <p>",
"    The proper disposal of used blood bags, tubing, needles, and other detritus should be addressed in this or a separate procedure. Any items that could potentially be contaminated with blood should",
"    <strong>",
"     not",
"    </strong>",
"    be discarded in the patient's home. Needles and other sharp devices with the potential to penetrate should receive special mention, and it is recommended that a sharps container be among the supplies. If the transfusing agency does not have an easily accessible, appropriate avenue for disposing of waste products, one possible approach is returning these materials to the issuing facility for disposal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical that the transfusion complications SOP contain specific and complete information for recognizing and managing adverse events in the peritransfusion period and beyond. Transfusing personnel should be well trained and intimately familiar with the details of this procedure. Some complications require pharmacological intervention; as a result, the SOP should list the medications, the method of administration, the dose, and the indications for which medication should be given. It should also specify the circumstances under which a medication should be given without prior approval from the attending physician, especially epinephrine for anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37174?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of home blood transfusion\", section on 'Management of reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful and most likely necessary to develop companion forms for the SOPs. Examples include documents for informed consent, transfusion locale assessment, the transfusion report, and post-transfusion patient instructions. Useful prototypes of these are found in the AABB monograph, Out-of-Hospital Transfusion Therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32981/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VALIDATION AND REVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;After procedures have been written, it is necessary and appropriate to test and stress them in simulations. This activity, known as validation, can be extremely useful for finding flaws or omissions. The procedures, which should have been based upon transfusion practice standards, should again be compared to those standards to ensure that they capture both the letter and intent.",
"   </p>",
"   <p>",
"    For practitioners, transfusionists, or home healthcare agencies that have not been previously involved in transfusion-related procedure development, it would also be prudent to seek input from transfusion medicine specialists prior to and after writing procedures. Medical directors of community blood centers and hospital-based transfusion services could serve as excellent resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Writing and validating standardized operating procedures (SOPs) for home transfusion are not guarantees of transfusion safety. SOPs are tools to safely accomplish transfusion goals; failure to use them may contribute to mortality in the recipient.",
"   </p>",
"   <p>",
"    Two final and necessary steps remain:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Training of the staff who use the procedures, and",
"     </li>",
"     <li>",
"      Putting mechanisms into place to ensure that SOPs are properly followed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This triad of activities &mdash; SOP",
"    <span class=\"nowrap\">",
"     writing/validation,",
"    </span>",
"    staff training, and procedure implementation &mdash; is the key to safer transfusion therapy.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/1\">",
"      Baele PL, De Bruyere M, Deneys V, et al. Bedside transfusion errors. A prospective survey by the Belgium SAnGUIS Group. Vox Sang 1994; 66:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/2\">",
"      Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/3\">",
"      Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992; 32:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/4\">",
"      Renner SW, Howanitz PJ, Bachner P. Wristband identification error reporting in 712 hospitals. A College of American Pathologists' Q-Probes study of quality issues in transfusion practice. Arch Pathol Lab Med 1993; 117:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/5\">",
"      Benson K. Home is where the heart is: do blood transfusions belong there too? Transfus Med Rev 2006; 20:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/6\">",
"      Fridey JL. Practical aspects of out-of-hospital transfusion. Am J Clin Pathol 1997; 107:S64.",
"     </a>",
"    </li>",
"    <li>",
"     Technical Manual, 17th ed, Roback JD, Combs MR, Grossman BJ, Hillyer CD (Eds), American Association of Blood Banks (AABB), Bethesda, MD 2011.",
"    </li>",
"    <li>",
"     Standards for Blood Banks and Transfusion Services, 27th ed, American Association of Blood Banks, Bethesda, MD 2011.",
"    </li>",
"    <li>",
"     Snyder EL. Component selection: The role of leukocyte reduction. In: Component Selection: Polemics and Politics, Fridey JL, Simpson MB (Eds), American Association of Blood Banks, Bethesda, MD 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/10\">",
"      Belloni M, Alghisi A, Bettini C, et al. Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE Inhibitors. Transfusion 1998; 38:412.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062284.htm (Accessed on March 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/12\">",
"      Lavee J, Paz Y. Hypotensive reactions associated with transfusion of bedside leukocyte-reduction filtered blood products in heart transplanted patients. J Heart Lung Transplant 2001; 20:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32981/abstract/13\">",
"      Sreelakshmi TR, Eldridge J. Acute hypotension associated with leucocyte depletion filters during cell salvaged blood transfusion. Anaesthesia 2010; 65:742.",
"     </a>",
"    </li>",
"    <li>",
"     Douglas L. Out-of-hospital transfusion: Home transfusion therapy programs. In: Out-of-hospital Transfusion Therapy, Fridey JL, Kasprisin CA, Issitt LA (Eds), American Association of Blood Banks, Bethesda, MD 1994.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7917 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32981=[""].join("\n");
var outline_f32_13_32981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COLLECTION AND LABELING OF PRETRANSFUSION SPECIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SITE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ISSUING OF BLOOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Packed red blood cells and plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryoprecipitate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TRANSPORTING AND STORING BLOOD COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VALIDATION AND REVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37174?source=related_link\">",
"      General principles of home blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32982="Overview of Rhesus (Rh) alloimmunization in pregnancy";
var content_f32_13_32982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Rhesus (Rh) alloimmunization in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32982/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/13/32982/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhesus (Rh) negative women who deliver an Rh positive baby or who are otherwise exposed to Rh positive red blood cells are at risk of developing anti-Rh antibodies. Rh positive",
"    <span class=\"nowrap\">",
"     fetuses/neonates",
"    </span>",
"    of these mothers are at risk of developing hemolytic disease of the fetus and newborn, which can be lethal or associated with serious morbidity.",
"   </p>",
"   <p>",
"    Implementation of programs for antenatal and postnatal Rh(D) immune globulin prophylaxis has led to a significant reduction in the frequency of maternal Rh alloimmunization and associated",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    complications [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, maternal Rh alloimmunization still occurs, particularly in low income countries where prophylaxis is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/3\">",
"     3",
"    </a>",
"    ]. Where appropriate monitoring and intervention are available, hemolytic disease of the fetus and newborn can be treated successfully in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE RHESUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetricians should be aware of the different Rh(D) phenotypes and their clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/4\">",
"     4",
"    </a>",
"    ]. The following discussion is a synopsis of key clinical issues related to the Rhesus system. A detailed discussion of the Rh system, including its variants, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H14#H14\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Rh blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard obstetrical nomenclature for designating a pregnant woman&rsquo;s blood type is the ABO type and either Rh positive or Rh negative. These terms are commonly used to describe a woman who has or does not have the Rh(D) antigen on her red blood cells (RBCs). However, this abbreviated nomenclature is not technically correct because the Rh blood system consists of numerous other antigens, most commonly C, c, E, e, and G (there is no d antigen). Thus, a woman who is \"Rh-negative\" (meaning no D antigen) but carries the C antigen on her RBCs can develop anti-c antibodies as a result of transplacental bleeding of c positive fetal RBCs. Since she is Rh(D) negative, she may have received prophylactic anti-D immune globulin in previous pregnancies, but this would not prevent c alloimmunization.",
"   </p>",
"   <p>",
"    The frequency of Rhesus antigens varies among populations. The following examples illustrate the ethnic variation of phenotypically Rh(D)-negative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basques &mdash; 30 to 35 percent",
"     </li>",
"     <li>",
"      Caucasians in North America and Europe &mdash; 15 percent",
"     </li>",
"     <li>",
"      African Americans &mdash; 8 percent",
"     </li>",
"     <li>",
"      Africa &mdash; 4 to 6 percent",
"     </li>",
"     <li>",
"      India &mdash; 5 percent",
"     </li>",
"     <li>",
"      Native Americans and Inuit Eskimos &mdash; 1 to 2 percent",
"     </li>",
"     <li>",
"      Japan &mdash; 0.5 percent",
"     </li>",
"     <li>",
"      Thailand &mdash; 0.3 percent",
"     </li>",
"     <li>",
"      China &mdash; 0.3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    About 40 percent of Rh-positive individuals are homozygous at the D locus (DD); the remainder is heterozygous (Dd).",
"   </p>",
"   <p>",
"    In Caucasians, the primary molecular basis of the Rh(D)-negative phenotype is absence of the D gene (",
"    <em>",
"     RHD",
"    </em>",
"    ). In other phenotypically D-negative ethnic groups, the gene may be present but not translated or expressed, weakly expressed, or partially expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/5\">",
"     5",
"    </a>",
"    ]. These D antigen variants, variously called partial D or D mosaic (one or more epitopes of the antigen are absent), weak D (epitopes of the antigen are weakly expressed), Rh mod, and D(el) may type as Rh(D)-negative or Rh(D)-positive by serologic reagents [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Patients with these variants are potentially at risk of developing anti-D antibody, and their RBCs may induce anti-D antibody formation in Rh(D)-negative recipients.",
"   </p>",
"   <p>",
"    Aberrations in the Rh system appear to be more common in the African-American population, particularly at the D and e loci. The Rh(D)-negative phenotype in Africans is often the result of genes&nbsp;that contain Rh(D) sequences but do not produce the complete D antigen (",
"    <em>",
"     RHD",
"    </em>",
"    pseudogene). The frequency of these gene distributions differs between black&nbsp;Africans, African Americans, and black South Africans. An",
"    <em>",
"     RHD",
"    </em>",
"    pseudogene has been described in 69 percent of South African blacks and 21 percent of African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/10\">",
"     10",
"    </a>",
"    ]. By comparison, only 0.96 percent of individuals in a Canadian study had a weak RhD response when serotyped [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/8\">",
"     8",
"    </a>",
"    ]. Most of these individuals express a reduced number of RhD antigens on the surface of their red cells, although a few have a partial D antigen (also known as D variant) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/11\">",
"     11",
"    </a>",
"    ]. Since the majority of these individuals possess the D antigen, they rarely form anti-D antibody. However, women with partial D antigen may develop antibodies against D epitopes absent on maternal cells but present on fetal red blood cells.",
"   </p>",
"   <p>",
"    In the United States, the AABB (formerly the American Association of Blood Banks) guideline for blood banks does not require that a test for weak D or variant D be performed on RhD-negative pregnant patients. However, some commercial laboratories perform prenatal blood typing using reagents that will detect the weak D or variant D phenotype, and thus report this result when present. More commonly, a monoclonal typing sera is used for Rh(D) typing that does not detect weak D or D variant phenotypes so these patients are reported as RhD-negative and will be candidates for anti-D immune globulin.",
"   </p>",
"   <p>",
"    Of note, women with weak D or partial D who donate blood will undergo indirect antiglobulin testing and will be reported as RhD-positive to ensure that their blood is not transfused into an RhD-negative recipient who could then form anti-RhD antibodies. The different blood typing policies for blood donors versus pregnant women and transfusion recipients result in some women being RhD-positive in one setting and RhD-negative in the other setting.",
"   </p>",
"   <p>",
"    Other unexpressed",
"    <em>",
"     RHD",
"    </em>",
"    gene variations have been observed in 12 percent of Japanese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/12\">",
"     12",
"    </a>",
"    ]. These individuals have the entire",
"    <em>",
"     RHD",
"    </em>",
"    gene on their chromosomes, but are Rh(D)-negative on serologic testing and their red blood cells are not affected by the presence of anti-D antibody in vivo.",
"   </p>",
"   <p>",
"    A change of a single amino acid in the extramembranous portion of both the Rh(D) and Rh(C) proteins results in the expression of the Rh(G) phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/13\">",
"     13",
"    </a>",
"    ]. The majority of patients who are Rh(D)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Rh(C) positive are also Rh(G) positive; if both Rh(D) and Rh(C) are absent, Rh(G) is also absent. Patients who lack all three antigens can become sensitized to the Rh(C) and Rh(G) antigen while not developing antibodies to Rh(D). When an Rh(D)-negative pregnant woman appears to have both anti-D and anti-C at a similar level of titer, the laboratory must determine whether the antibody is really anti-D or actually anti-G because a patient who develops anti-C and anti-G antibodies but no anti-D is a candidate for anti-D immune globulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of Rh(D) alloimmunization\", section on 'Additional considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3571754\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND CONSEQUENCES OF ALLOIMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;By 30 days of gestation, the Rh(D) antigen is expressed as part of the red blood cell (RBC) membrane, and, in contrast to most other antigens (eg, A,B,M,N), Rh(D) is only present on RBCs. Maternal Rh(D) alloimmunization develops as a result of maternal immune system exposure to Rh(D)-positive RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/14\">",
"     14",
"    </a>",
"    ]. Once anti-D IgG antibodies are present in the pregnant woman's circulation, they can cross the placenta and sensitize fetal RBCs for destruction by macrophages in the fetal spleen.",
"   </p>",
"   <p>",
"    Events that can cause maternal alloimmunization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transplacental fetomaternal hemorrhage during any pregnancy (",
"      <a class=\"graphic graphic_table graphicRef55779 \" href=\"UTD.htm?16/61/17371\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Injection with needles contaminated by Rh(D)-positive blood [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inadvertent transfusion of Rh(D)-positive blood",
"     </li>",
"     <li>",
"      D-mismatched allogeneic hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transplacental fetomaternal bleeding accounts for virtually all cases of maternal Rh(D) alloimmunization. Tiny (0.1 mL) quantities of fetal RBCs gain access to the maternal circulation in nearly all pregnancies, as demonstrated by studies using flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/17\">",
"     17",
"    </a>",
"    ]. The frequency and volume of spontaneous fetomaternal hemorrhage increase with advancing gestational age and are highest at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/18\">",
"     18",
"    </a>",
"    ]. Fetomaternal hemorrhage can also be associated with miscarriage, pregnancy termination, ectopic pregnancy, invasive in-utero procedures, fetal death, maternal abdominal trauma, antepartum maternal hemorrhage, and external cephalic version.",
"   </p>",
"   <p>",
"    Of note, there are six reports of alloantibodies to Rh(D) antigen without identifiable maternal exposure to red cells carrying the D antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/19\">",
"     19",
"    </a>",
"    ]. These cases may be the result of early pregnancy losses that were not clinically recognized. Alternatively, a \"grandmother theory\" has been proposed as the etiology. In these cases, Rh(D) positive red cells from the patient's mother gain access to the fetal circulation at birth (maternal-fetal hemorrhage). The Rh(D) negative neonate then forms a low level of antibody to these Rh(D) positive cells.",
"   </p>",
"   <p>",
"    Although the Rh(D) antigen is thought to elicit a strong immune response, the response varies considerably among individuals. As an example, studies in male Rh(D)-negative prison volunteers showed that intravenous injection of as little as 0.1 mL of Rh(D)-positive RBCs was sufficient to immunize some individuals, while 30 percent of the Rh(D)-negative men did not become sensitized despite two injections (first 10 mL, then 5 mL) of Rh(D)-positive blood over a six-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The percentage of Rh(D)-negative individuals developing an immune response to infusion of Rh(D)-positive RBCs depends, in part, on the volume of blood infused: 0.5 mL RBCs stimulates an anti-D response in some subjects, whereas one unit (450 mL) of RBCs results in the maximum percentage of responders (80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/22\">",
"     22",
"    </a>",
"    ]. The antibody response develops slowly, and is usually not detectable serologically until 5 to 15 weeks after immunization. Whether a primary immune response occurs depends upon several factors besides the volume of fetal blood to which the mother was exposed. These variables include the frequency of fetomaternal transfusion and whether the mother and fetus are ABO compatible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/14\">",
"     14",
"    </a>",
"    ]. Both the immunogenicity of the fetal RBCs and the immunogenic response capacity of the mother play a role in pathogenesis. Interestingly, individuals with acquired immune deficiency syndrome (AIDS) may not form alloantibodies to the D antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplacental transfer of maternal antibody leads to alloimmune hemolytic disease of the",
"    <span class=\"nowrap\">",
"     fetus/newborn.",
"    </span>",
"    The severity of fetal anemia is influenced primarily by antibody concentration, but also by additional factors that are not fully understood. These include the subclass and glycosylation of maternal antibodies; the structure, site density, maturational development and tissue distribution of blood group antigens; the efficiency of transplacental IgG transport; the functional maturity of the fetal spleen; polymorphisms which affect Fc receptor function; and the presence of human leukocyte antigen (HLA)-related inhibitory antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Rh(D) alloimmunization is based upon detection of anti-Rh(D) antibody in maternal serum.",
"   </p>",
"   <p>",
"    Rh(D) typing and an antibody screen should be performed at the first prenatal visit. For Rh(D)-negative women with an initially negative antibody screen and uncomplicated pregnancy, the antibody screen may be repeated at 28 weeks of gestation, and should be repeated at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A positive antibody test should be interpreted as a screening test, just as serum alpha-fetoprotein is a screening test for the detection of fetal neural tube defects. A positive test means that the fetus is at risk for hemolytic disease, not that it has occurred or will develop.",
"   </p>",
"   <p>",
"    The test most commonly used for diagnostic purposes is the indirect Coombs test (ie, determination of antibodies in the plasma), which is the most accurate technique for determining antibody titers. The indirect Coombs titer is the value used to guide obstetrical management of alloimmunized pregnancies.",
"   </p>",
"   <p>",
"    Incubation of known Rh(D)-positive red blood cells (RBCs) with maternal plasma is the first step in the indirect Coombs test. Any anti-Rh(D) antibody present will adhere to the RBCs. The RBCs are then washed and suspended in antihuman globulin (Coombs) serum. Red cells coated with maternal anti-Rh(D) will be agglutinated by the antihuman globulin, which is referred to as a positive indirect Coombs test.",
"   </p>",
"   <p>",
"    The gel microcolumn assay (GMA) card is a promising alternative to traditional tube agglutination tests for determining anti-D antibody titers. Advantages of GMA over tube tests include: it is less susceptible to inter-laboratory and intra-laboratory sources of variability, yields clear objective results that are stable, takes less time, and is compatible with automation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/27\">",
"     27",
"    </a>",
"    ]. However, GMA may yield higher titer values compared to tube tests. In several studies, the increase was usually only one or two dilutions, which is not clinically significant (a four-fold difference is clinically significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], but some studies reported greater discordancy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. More data are needed to establish the correlation between GMA titer and severity of fetal anemia before this assay can be used to manage alloimmunization in pregnancy. For this reason, standard tube titers should still be used for clinical management of the alloimmunized pregnancy.",
"   </p>",
"   <p>",
"    Use of automated enzymatic methods for screening for anti-Rh(D) antibodies is not recommended. These techniques are less accurate than manual methods and, in rare cases, detect clinically insignificant, naturally occurring Rh(D) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PREGNANCIES COMPLICATED BY ALLOIMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pregnancies complicated by maternal alloimmunization involves determining the fetal Rh(D) type and monitoring for fetal anemia if the fetus is Rh(D) positive [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/32\">",
"     32",
"    </a>",
"    ]. Monitoring may involve following maternal anti-D titers or ultrasound assessment of fetal middle cerebral artery peak systolic velocity. Severe fetal anemia near term is treated by delivery for neonatal treatment; remote from term, intrauterine fetal transfusions are performed. Serial combined maternal plasmapheresis and intravenous immune globulin therapy is a promising approach for decreasing the severity of fetal disease, but is investigational. These subjects are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NEONATAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of the evaluation and management of neonates of alloimmunized women is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most, but not all, Rh(D) alloimmunization can be prevented by administration of anti-D immune globulin to women exposed or at high risk of being exposed to Rh(D)-positive red blood cells (RBCs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once alloimmunization has occurred, anti-D immune globulin is not effective for preventing or reducing the severity of",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    disease. Alloimmune",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    anemia can be treated, but the only options for prevention of the disease are pregnancy by insemination with sperm from a D-negative donor, preimplantation genetic diagnosis for selection of Rh(D) negative embryos, or use of a gestational surrogate. Given the success of intrauterine fetal transfusion, these options are usually considered only by women at risk for very early, severe fetal anemia where intrauterine fetal transfusion is more risky and less successful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=see_link\">",
"     \"Donor insemination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5319429\">",
"    <span class=\"h1\">",
"     ALLOIMMUNIZATION OTHER THAN RH(D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis and management of pregnant women with alloimmunization to other red blood cell (RBC) antigens are reviewed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32982/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Rhesus (Rh) blood system consists of the C, c, D, E, e, and G antigens (there is no d antigen). Variants include weak D and partial D antigens. In addition, the D gene may be present, but not translated or not expressed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The Rhesus system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal Rh(D) alloimmunization develops as a result of maternal immune system exposure to Rh(D)-positive red blood cells (RBCs). Maternal immunization can occur as a result of transplacental fetomaternal hemorrhage during any pregnancy, injection with needles contaminated by Rh(D)-positive blood, or inadvertent transfusion of Rh(D)-positive blood (including during transplantation). (See",
"      <a class=\"local\" href=\"#H3571754\">",
"       'Pathogenesis and consequences of alloimmunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Rh(D) alloimmunization is based upon detection of anti-Rh(D) antibody in maternal serum. We recommend that Rh(D) typing and an antibody screen be performed at the first prenatal visit (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In Rh(D)-negative women, the antibody screen may be repeated at 28 weeks of gestation, and should be repeated at delivery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/1\">",
"      FINN R, CLARKE CA, DONOHOE WT, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1961; 1:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/2\">",
"      Gorman, JG, Freda, VJ, Pollack, W. Intramuscular injection of a new experimental gamma2 globulin preparation containing high levels of anti-Rh antibody as a means of preventing sensitization to Rh. Proc IXth Congress of the International Society of Haematology 1962; 2:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/3\">",
"      Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011; 96:F84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/4\">",
"      Sandler SG, Li W, Langeberg A, Landy HJ. New laboratory procedures and Rh blood type changes in a pregnant woman. Obstet Gynecol 2012; 119:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/5\">",
"      Wagner FF, Gassner C, M&uuml;ller TH, et al. Molecular basis of weak D phenotypes. Blood 1999; 93:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/6\">",
"      Lurie S, Rotmensch S, Glezerman M. Prenatal management of women who have partial Rh (D) antigen. BJOG 2001; 108:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/7\">",
"      Prasad MR, Krugh D, Rossi KQ, O'Shaughnessy RW. Anti-D in Rh positive pregnancies. Am J Obstet Gynecol 2006; 195:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/8\">",
"      Denomme GA, Wagner FF, Fernandes BJ, et al. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005; 45:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/9\">",
"      Scott ML. The complexities of the Rh system. Vox Sang 2004; 87 Suppl1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/10\">",
"      Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 2000; 95:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/11\">",
"      Flegel WA. Molecular genetics and clinical applications for RH. Transfus Apher Sci 2011; 44:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/12\">",
"      van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003; 17:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/13\">",
"      Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000; 95:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/14\">",
"      Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006; 46:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/15\">",
"      Bowman J, Harman C, Manning F, et al. Intravenous drug abuse causes Rh immunization. Vox Sang 1991; 61:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/16\">",
"      Cid J, Lozano M, Fern&aacute;ndez-Avil&eacute;s F, et al. Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. Transfusion 2006; 46:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/17\">",
"      Medearis AL, Hensleigh PA, Parks DR, Herzenberg LA. Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter. Am J Obstet Gynecol 1984; 148:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/18\">",
"      Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang 1986; 51:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/19\">",
"      Kudva GC, Branson KD, Grossman BJ. RhD alloimmunization without apparent exposure to RhD antigen. Am J Hematol 2006; 81:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/20\">",
"      Zipursky A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J 1967; 97:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/21\">",
"      Pollack W, Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion 1971; 11:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/22\">",
"      Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 2002; 82:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/23\">",
"      Boctor FN, Ali NM, Mohandas K, Uehlinger J. Absence of D- alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003; 43:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/24\">",
"      Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol 2002; 10:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/25\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy. Obstet Gynecol 2006; 108:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/26\">",
"      Geaghan SM. Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. Semin Perinatol 2011; 35:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/27\">",
"      Finck R, Lui-Deguzman C, Teng SM, et al. Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration. Transfusion 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/28\">",
"      Cheng D, Hao Y. Comparative evaluation of the microcolumn gel card test and the conventional tube test for measurement of titres of immunoglobulin G antibodies to blood group A and blood group B. J Int Med Res 2011; 39:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/29\">",
"      Novaretti MC, Jens E, Pagliarini T, et al. Comparison of conventional tube test with diamed gel microcolumn assay for anti-D titration. Clin Lab Haematol 2003; 25:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/30\">",
"      Thakur MK, Marwaha N, Kumar P, et al. Comparison of gel test and conventional tube test for antibody detection and titration in D-negative pregnant women: study from a tertiary-care hospital in North India. Immunohematology 2010; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/31\">",
"      Contreras M, de Silva M, Teesdale P, Mollison PL. The effect of naturally occurring Rh antibodies on the survival of serologically incompatible red cells. Br J Haematol 1987; 65:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/32\">",
"      Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32982/abstract/33\">",
"      Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008; 13:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6820 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32982=[""].join("\n");
var outline_f32_13_32982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE RHESUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3571754\">",
"      PATHOGENESIS AND CONSEQUENCES OF ALLOIMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF PREGNANCIES COMPLICATED BY ALLOIMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NEONATAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5319429\">",
"      ALLOIMMUNIZATION OTHER THAN RH(D)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/61/17371\" title=\"table 1\">",
"      Causes of fetomaternal transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32983="Colchicine: Drug information";
var content_f32_13_32983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colchicine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"    see \"Colchicine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"    see \"Colchicine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8108144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colcrys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13869718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Jamp-Colchicine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antigout Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Familial Mediterranean fever (FMF):",
"     </b>",
"     Oral: 1.2-2.4 mg/day in 1-2 divided doses. Titration: Increase or decrease dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum: 2.4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gout:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flare treatment: Initial: 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg (maximum: 1.8 mg within 1 hour). Patients receiving prophylaxis therapy may receive treatment dosing; wait 12 hours before resuming prophylaxis dose.",
"     <b>",
"      Note:",
"     </b>",
"     Current FDA-approved dose for gout flare is substantially lower than what has been historically used clinically. Doses larger than the currently recommended dosage for gout flare have not been proven to be more effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 0.6 mg once or twice daily; maximum: 1.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flare treatment: Initial: 1-1.2 mg at the first sign of flare, followed by 0.5-0.6 mg dose every 2 hours until pain relief; maximum: 3 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis:  0.5-0.6 mg 1-4 times/week (mild-moderate cases) or 0.5-0.6 mg once or twice daily (severe cases); maximum: 1.2 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pericarditis post-STEMI (unlabeled use):",
"     </b>",
"     Oral: 0.6 mg twice daily (Antman, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recurrent pericarditis due to previous autoimmune or idiopathic cause (unlabeled use):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosage strength not available in the U.S.: Oral: 0.5-1 mg every 12 hours for 1 day,  followed by 0.25-0.5 mg every 12 hours for 6 months (in combination with high-dose aspirin or ibuprofen) (Imazio, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients &lt;70 kg or unable to tolerate higher dosing regimen:",
"     </i>",
"     0.5 mg every 12 hours for 1 day followed by 0.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary biliary cirrhosis (unlabeled use):",
"     </b>",
"     Oral: 0.6 mg twice daily (Kaplan, 2005);",
"     <b>",
"      Note:",
"     </b>",
"     Use reserved for patients refractory to ursodiol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant therapy with CYP3A4 or P-glycoprotein (P-gp) inhibitors:",
"     </b>",
"     <i>",
"      Dosage adjustment also required in patients receiving CYP3A4 or P-gp inhibitors up to 14 days prior to initiation of colchicine.",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of gout flare with colchicine is not recommended in patients receiving prophylactic colchicine and CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Coadministration of",
"     <b>",
"      strong",
"     </b>",
"     CYP3A4 inhibitor (eg, atazanavir, clarithromycin, darunavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     FMF: Maximum dose: 0.6 mg/day (0.3 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout flare treatment: Initial: 0.6 mg, followed in 1 hour by a single dose of 0.3 mg; do not repeat for at least 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Coadministration of",
"     <b>",
"      moderate",
"     </b>",
"     CYP3A4 inhibitor (eg, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     FMF: Maximum dose: 1.2 mg/day (0.6 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     0.6 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout flare treatment: 1.2 mg as a single dose; do not repeat for at least 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Coadministration of P-gp inhibitor (eg, cyclosporine, ranolazine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     FMF: Maximum dose: 0.6 mg/day (0.3 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Gout flare treatment: Initial: 0.6 mg as a single dose; do not repeat for at least 3 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=see_link\">",
"      see \"Colchicine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Familial Mediterranean fever (FMF):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-6 years: 0.3-1.8 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 0.9-1.8 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gout prophylaxis/treatment:",
"     </b>",
"     Oral: Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; reduce prophylactic daily dose by 50% in individuals &gt;70 years (Terkeltaub, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is",
"     <b>",
"      contraindicated",
"     </b>",
"     in renal impairment. Fatal toxicity has been reported. Treatment of gout flares is not recommended in patients with renal impairment receiving prophylactic colchicine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      FMF:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Monitor closely for adverse effects; dose reduction may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: 0.3 mg as a single dose; use caution if dose titrated; dosing can be increased with close monitoring; monitor for adverse effects. Not removed by dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gout prophylaxis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: 0.3 mg twice weekly; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gout flare treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Dosage reduction not required but may be considered; treatment course should not be repeated more frequently than every 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: 0.6 mg as a single dose; treatment course should not be repeated more frequently than every 14 days. Not removed by dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Hemodialysis: Avoid chronic use of colchicine.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F154309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Concurrent use of colchicine and P-glycoprotein or strong CYP3A4 inhibitors is",
"     <b>",
"      contraindicated",
"     </b>",
"     in hepatic impairment. Fatal toxicity has been reported. Treatment of gout flare with colchicine is not recommended in patients with hepatic impairment receiving prophylactic colchicine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      FMF:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Use caution; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Consider dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gout prophylaxis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Dosage adjustment not required; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Dosage adjustment should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gout flare treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Dosage adjustment not required; monitor closely for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Dosage reduction not required but may be considered; treatment course should not be repeated more frequently than every 14 days.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colcrys&reg;: 0.6 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13113160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8097684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176363.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176363.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer orally with water and maintain adequate fluid intake. May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of acute gout flares; treatment of familial Mediterranean fever (FMF)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F154334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primary biliary cirrhosis; pericarditis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Colchicine may be confused with Cortrosyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Gastrointestinal disorders including abdominal pain, cramping, nausea, vomiting (up to 26%), diarrhea (up to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Respiratory: Pharyngolaryngeal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, ALT increased, aplastic anemia, AST increased, azoospermia, bone marrow suppression, CPK increased, dermatosis, granulocytopenia, hepatotoxicity, hypersensitivity reaction, lactose intolerance, leukopenia, maculopapular rash, muscle weakness, myalgia, myopathy, myotonia, neuropathy, oligospermia, pancytopenia, peripheral neuritis, purpura, rash, rhabdomyolysis, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to colchicine; serious gastrointestinal, hepatic, renal, and cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Myelosuppression (eg, thrombocytopenia, leukopenia, granulocytopenia, pancytopenia) and aplastic anemia have been reported in patients receiving therapeutic doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal symptoms: Dosage reduction is recommended in patients who develop gastrointestinal symptoms (anorexia, diarrhea, nausea, vomiting) related to drug therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular toxicity: Myotoxicity (including rhabdomyolysis) has been reported in patients receiving therapeutic doses; patients with renal dysfunction and elderly patients are at increased risk. Concomitant use of cyclosporine, diltiazem, verapamil, fibrates, and statins may increase the risk of myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Clearance is decreased in hepatic impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be considered depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in hepatic impairment. Fatal toxicity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Clearance is decreased in renal impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be required depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in renal impairment. Fatal toxicity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking P-gp or moderate or strong CYP3A4 inhibitors; significant increase in colchicine serum concentrations and fatal toxicity have been reported; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Protease inhibitors: Colchicine requires dosage adjustment with concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; literature suggests dosage adjustments should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Canadian labeling does not include recommendations for use in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Colchicine does not have analgesic activity and should not be used to treat pain from other causes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fatal overdose: Accidental and intentional fatal overdoses have been reported. Dosage associated with fatal toxicity is variable (eg, wide dosage range).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate), CYP2E1 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor like cobicistat.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanocobalamin: Colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May increase the serum concentration of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F154299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase colchicine serum concentrations. Management: Administer orally with water and maintain adequate fluid intake. Dose adjustment may be required based on indication if ingesting grapefruit juice. Avoid grapefruit juice with hepatic or renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Cyanocobalamin (vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     ) absorption may be decreased by colchicine and result in macrocytic anemia or neurologic dysfunction. Management: Consider supplementing with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Colchicine crosses the human placenta. Use during pregnancy in the treatment of familial Mediterranean fever has not shown an increase in miscarriage, stillbirth, or teratogenic effects (limited data).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10923645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Colchicine enters breast milk; exclusively breast-fed infants are expected to receive &lt;10% of the weight-adjusted maternal dose (limited data).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F154288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. May need to supplement with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     . Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F154287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Colcrys Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg (60): $349.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F154277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal and hepatic function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Artrichine (EC);",
"     </li>",
"     <li>",
"      Cholchicin &rdquo;Agepha&rdquo; (AT);",
"     </li>",
"     <li>",
"      Cocine (TW);",
"     </li>",
"     <li>",
"      Colchicin Agepha (AT);",
"     </li>",
"     <li>",
"      Colchicina Lirca (IT);",
"     </li>",
"     <li>",
"      Colchicina Phoenix (AR);",
"     </li>",
"     <li>",
"      Colchicine (IL);",
"     </li>",
"     <li>",
"      Colchicine capsules (NL);",
"     </li>",
"     <li>",
"      Colchicine Houde (AR, BE, ES, FR, LU, PT);",
"     </li>",
"     <li>",
"      Colchicum-Dispert (BG, DE, HU, PL, TR);",
"     </li>",
"     <li>",
"      Colchily (TH);",
"     </li>",
"     <li>",
"      Colchimedio (CO, CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Colchine (KP);",
"     </li>",
"     <li>",
"      Colchiquim (MX);",
"     </li>",
"     <li>",
"      Colchis (BR);",
"     </li>",
"     <li>",
"      Colchisol (PE);",
"     </li>",
"     <li>",
"      Colchysat Burger (DE);",
"     </li>",
"     <li>",
"      Colcine (TH);",
"     </li>",
"     <li>",
"      Colcitex (SG);",
"     </li>",
"     <li>",
"      Colgout (AU, HK, NZ);",
"     </li>",
"     <li>",
"      Conicine (TW);",
"     </li>",
"     <li>",
"      Goutichine (TH);",
"     </li>",
"     <li>",
"      Goutnil (IN, PH);",
"     </li>",
"     <li>",
"      Kolkisin (NO);",
"     </li>",
"     <li>",
"      Lengout (AU);",
"     </li>",
"     <li>",
"      Lennon-Colchicine (ZA);",
"     </li>",
"     <li>",
"      Prochic (TH);",
"     </li>",
"     <li>",
"      Recolfar (ID);",
"     </li>",
"     <li>",
"      Sixol (MX);",
"     </li>",
"     <li>",
"      Tolchicine (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disrupts cytoskeletal functions by inhibiting &beta;-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms. In familial Mediterranean fever, may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate activation of interleukin-1&beta;.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Pain relief: ~18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrates in leukocytes, kidney, spleen, and liver; does not distribute in heart, skeletal muscle, and brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 5-8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~39%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; 3 metabolites (2 primary, 1 minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 27-31 hours (multiple oral doses; young, healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% to 65% as unchanged drug); enterohepatic recirculation and biliary excretion also possible",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borstad GC, Bryant LR, Abel MP, et al, &ldquo;Colchicine for Prophylaxis of Acute Flares When Initiating Allopurinol for Chronic Gouty Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2004, 31(12):2429-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/15570646/pubmed\" id=\"15570646\" target=\"_blank\">",
"        15570646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Deaths From Intravenous Colchicine Resulting From a Pharmacy Compounding Error - Oregon and Washington, 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2007, 56(40):1050-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/17932481/pubmed\" id=\"17932481\" target=\"_blank\">",
"        17932481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emmerson BT, &ldquo;The Management of Gout,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(7):445-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/8552148/pubmed\" id=\"8552148\" target=\"_blank\">",
"        8552148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Imazio M, Brucato A, Cemin R, et al, \"Colchicine for Recurrent Pericarditis (CORP) A Randomized Trial,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2011, 155(7):409-414.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/21873705/pubmed\" id=\"21873705\" target=\"_blank\">",
"        21873705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kallinich T, Haffner D, Niehues T, et al, &ldquo;Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(2):e474-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/17242135/pubmed\" id=\"17242135\" target=\"_blank\">",
"        17242135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan MM and Gershwin ME, &ldquo;Primary Biliary Cirrhosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(12):1261-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/16177252/pubmed\" id=\"16177252\" target=\"_blank\">",
"        16177252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan MM, Schmid C, Provenzale D, et al, &ldquo;A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1999, 117(5):1173-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/10535881/pubmed\" id=\"10535881\" target=\"_blank\">",
"        10535881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M, Spino M, and Read SE, &ldquo;Colchicine: A State-of-the-Art Review,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(3):196-211.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/1862011/pubmed\" id=\"1862011\" target=\"_blank\">",
"        1862011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Majeed HA, Carroll JE, Khuffash FA, et al, &ldquo;Long-Term Colchicine Prophylaxis in Children With Familial Mediterranean Fever (Recurrent Hereditary Polyserositis),&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(6):997-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/2112191/pubmed\" id=\"2112191\" target=\"_blank\">",
"        2112191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Majeed HA, Rawashdeh M, el-Shanti H, et al, &ldquo;Familial Mediterranean Fever in Children: The Expanded Clinical Profile,&rdquo; 1999,",
"      <i>",
"       QJM",
"      </i>",
"      , 92(6):309-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/10616706/pubmed\" id=\"10616706\" target=\"_blank\">",
"        10616706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terkeltaub RA, &ldquo;Colchicine Update: 2008,&rdquo;",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 2009, 38(6):411-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/18973929/pubmed\" id=\"18973929\" target=\"_blank\">",
"        18973929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terkeltaub RA, &ldquo;Gout,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(17):1647-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/14573737/pubmed\" id=\"14573737\" target=\"_blank\">",
"        14573737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace SL, Singer JZ, Duncan GJ, et al, &ldquo;Renal Function Predicts Colchicine Toxicity: Guidelines for the Prophylactic Use of Colchicine in Gout,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1991, 18(2):264-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/13/32983/abstract-text/2023222/pubmed\" id=\"2023222\" target=\"_blank\">",
"        2023222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9293 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32983=[""].join("\n");
var outline_f32_13_32983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8108144\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13869718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154338\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154306\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154325\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154307\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154308\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154309\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154279\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13113160\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097684\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154281\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154334\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154336\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154285\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154267\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154332\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154299\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154275\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923644\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154314\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923645\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154288\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154287\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154277\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154289\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154284\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=related_link\">",
"      Colchicine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/50/14118?source=related_link\">",
"      Colchicine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32984="Malignant hyperthermia: Clinical diagnosis and management of acute crisis";
var content_f32_13_32984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Ronald S Litman, DO, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32984/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/13/32984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hyperthermia (MH) manifests clinically as a hypermetabolic crisis when an MH-susceptible individual is exposed to an inhalational anesthetic (eg, halothane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    ), or depolarizing muscle relaxant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the incidence, clinical manifestations and acute management of MH. Susceptibility to MH is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical incidence of acute MH for a given population depends upon the prevalence of MH-susceptibility, and use of triggering anesthetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H5#H5\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Genetic basis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of acute MH in the general population is estimated to be about 1:30,000 administered anesthetics, occurring in all ethnic groups in all parts of the world. The incidence is probably underestimated because unrecognized, mild, or atypical reactions likely occur due to variable penetrance of the inherited trait.",
"   </p>",
"   <p>",
"    Children under 19 years account for between 45 and 52 percent of reported events [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Reactions occur more frequently in males compared to females (2:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIGGERING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all known cases of MH have occurred while the patient was receiving an inhalational anesthetic agent (eg, halothane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    ), with or without administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . In MH-susceptible patients, these agents cause unregulated release of calcium from the sarcoplasmic reticulum leading to myocyte hypermetabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, MH has also been reported following administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    in the absence of an inhalational agent (eg, to facilitate endotracheal intubation). MH-susceptible patients exposed to heat stress or vigorous exercise can also develop acute MH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H8#H8\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Conditions associated with MH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MH-susceptible patients may not consistently develop the acute syndrome with each anesthetic exposure. An acute MH crisis may develop at first exposure to a triggering agent; however, on average, patients have had three exposures prior to having a documented reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANESTHESIA HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anesthesia history should include questions about prior adverse reactions to anesthetic exposure in the patient and their family members.",
"   </p>",
"   <p>",
"    The majority of patients will give a negative history, however, a negative family history, or previous uneventful exposure to triggering anesthetic agents are not reliable at excluding a susceptibility for MH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately half of patients who develop acute MH have prior uneventful exposures to triggering agents [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion a patient may offer specific information regarding a familial susceptibility with a known mutation, or may state they reportedly became rigid with anesthesia. Under these circumstances susceptibility to MH should be assumed and triggering agents avoided.",
"   </p>",
"   <p>",
"    Soliciting questions about temperature elevation is not useful given the common occurrence of non-MH related postoperative fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an acute event, diagnosis of MH is based upon clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef54539 \" href=\"UTD.htm?32/15/33020\">",
"     table 1",
"    </a>",
"    ), most importantly the presence of a mixed metabolic and respiratory acidosis, manifested as an increased end-tidal carbon dioxide (ETCO2) level, when all other reasonable causes have been ruled out. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach to hypercapnia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Triggering agents are discontinued and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    is administered to any patient suspected of having acute MH. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following an acute event, the determination of whether a suspected clinical event represents a true MH episode is estimated using the MH clinical grading scale (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/19/14642?source=see_link\">",
"     calculator 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H12#H12\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH clinical grading'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive diagnosis can be achieved through susceptibility testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H17#H17\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH-susceptibility testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions may present perioperatively with clinical manifestations (eg, hypercapnia, tachycardia, muscle rigidity, rhabdomyolysis, hyperthermia, arrhythmia) that are similar to those with acute MH (",
"    <a class=\"graphic graphic_table graphicRef82570 \" href=\"UTD.htm?21/36/22094\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Consideration of these diagnoses should not interfere with prompt treatment of suspected acute MH. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Approach to hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unexpected rise in the ETCO2 level is the earliest sign of MH; therefore, early exclusion of technical factors, sources of decreased carbon dioxide elimination, or increased carbon dioxide production that could account for hypercapnia is important.",
"   </p>",
"   <p>",
"    Hypercapnia during general anesthesia or sedation is usually due to hypoventilation from shallow breathing or a diminished respiratory rate. Patients who are machine ventilated may have sub-optimal ventilation parameters or a technical malfunction of the anesthesia machine, breathing circuit, ventilator, or monitor. Carbon dioxide accumulation is identified as a rise in ETCO2. Increasing minute ventilation with supplemental bag ventilation, or correcting ventilator settings or malfunction should correct the ETCO2 in the setting of hypoventilation.",
"   </p>",
"   <p>",
"    Any condition that impairs the elimination of carbon dioxide, such as bronchial obstruction or pneumothorax, will increase the ETCO2. These conditions should be corrected as soon as recognized. During laparoscopic surgery, ETCO2 can also rise due to carbon dioxide retention. Temporarily releasing the pneumoperitoneum should restore CO2 levels to normal within a reasonable timeframe; however, carbon dioxide that has insufflated into the subcutaneous tissues may be slower to clear.",
"   </p>",
"   <p>",
"    Sources of increased carbon dioxide production may be difficult to distinguish from MH. Carbon dioxide production is increased in patients with thyrotoxicosis, pheochromocytoma, or sepsis and these conditions may be accompanied by tachycardia and alterations in blood pressure. While these signs mimic the early signs of MH, other signs of MH, such as mixed acidosis, rigidity or rhabdomyolysis, will be absent. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of a vascular clamp (eg, aortic cross clamp), or tourniquet for prolonged periods of time leads to retention of metabolic products (ie, CO2, lactate), which are then released into the circulation when the clamp or tourniquet is released. The resulting acidosis is usually transient and not likely to be confused with the mixed acidosis of acute MH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations vary, but early clinical findings typically include hypercapnia, sinus tachycardia, and masseter or generalized muscle rigidity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. The earliest sign is an unexpected rise in the ETCO2; therefore, early exclusion of other sources of decreased carbon dioxide elimination, or increased carbon dioxide production that account for hypercapnia is important. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach to hypercapnia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a widespread misconception that acute MH may begin in the postoperative period with hyperthermia as the initial presenting sign. Hyperthermia is a later sign of MH and is typically absent when the diagnosis is initially suspected. Hyperthermia and signs of tissue hypoxia can be accompanied by hypotension, complex dysrhythmias, rhabdomyolysis, electrolyte abnormalities, disseminated intravascular coagulation (DIC), and mixed acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical signs present perioperatively in one of the following patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraoperatively, within one hour of anesthetic induction, though delayed intraoperative reactions do occur [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/13-16\">",
"       13-16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      After the cessation of the anesthetic agent, usually within minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/16-20\">",
"       16-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Postoperatively, as delayed rhabdomyolysis in an otherwise asymptomatic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Following successful treatment, recrudescence occurs in up to 25 percent of patients and is more likely in patients with increased muscle mass [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Early signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most reliable initial clinical sign heralding the development of acute MH is hypercapnia resistant to increasing the patient's minute ventilation. With acute MH, hypercapnia is due to cellular hypermetabolism, which causes metabolic acidosis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disproportionate increases in minute ventilation are required to normalize ETCO2 levels in the setting of MH. The greatly increased exhaled CO2 heats the CO2 absorbent (ie, exothermic reaction) warming the ventilator absorbent canister (",
"    <a class=\"graphic graphic_picture graphicRef54970 \" href=\"UTD.htm?28/54/29539\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach to hypercapnia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia is another early sign of acute MH and may be associated with hypertension. However, tachycardia is relatively nonspecific. Other causes of tachycardia and hypertension that need to be distinguished from MH include inadequate depth of anesthesia, sepsis, thyrotoxicosis, pheochromocytoma, cocaine toxicity, alcohol withdrawal, amphetamine toxicity, and sympathomimetic toxicity. A discussion of these disorders is found in individual topic reviews. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Calcium channel blockers are absolutely contraindicated in the acute management of MH since they can worsen hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Masseter muscle rigidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masseter muscle rigidity (MMR) is the inability to open a patient's mouth after the administration of a triggering agent. This sign is not specific enough to make a definitive diagnosis in the absence of additional signs of hypermetabolism, however, when MMR is observed, all triggering agents should be discontinued and the patient carefully monitored for additional signs that may indicate development of acute MH. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Masseter muscle tension normally increases after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , but typically lasts only a few seconds. When it persists, MMR indicates the initiation of acute MH in up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/27\">",
"     27",
"    </a>",
"    ]. In the pediatric population, MMR has occurred in up to one percent of children who received succinylcholine, and is more common in children with strabismus or a subclinical myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who exhibit MMR subsequent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    administration should undergo diagnostic testing for MH-susceptibility. Up to 50 percent of these patients will have a positive contracture test [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Counseling after acute MH'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H17#H17\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH-susceptibility testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;Generalized muscle rigidity &mdash; Generalized muscle rigidity in the presence of neuromuscular blockade is considered pathognomonic for MH, provided other confirmatory signs of hypermetabolism are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Later signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ECG changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG changes and arrhythmias due to elevated potassium levels from muscle breakdown can occur rapidly in muscular patients. The presence of hyperkalemia greatly strengthens a diagnosis of MH. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of premature ventricular contractions may indicate life-threatening hyperkalemia, and is an ominous sign as it may degrade into ventricular tachycardia or ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak creatine kinase (CK) levels depend upon the muscle mass of the patient, and severity of muscle breakdown. Plasma CK and urine myoglobin levels peak around 14 hours after an acute MH episode. A postoperative (within 24 hours) rise in CK (&gt;20,000",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    is predictive of MH-susceptibility in over 80 percent of patients who had an episode suspicious for acute MH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/30\">",
"     30",
"    </a>",
"    ]. In muscular patients, levels may exceed 100,000",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"   </p>",
"   <p>",
"    Brownish",
"    or tea-colored urine indicates the presence of myoglobinuria, which should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398978#H25398978\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of reports of seemingly normal patients with postoperative rhabdomyolysis and myoglobinuria without any of the other classic signs of MH. MH contracture testing in these patients may be positive, however, it is unclear whether they have true MH-susceptibility or a subclinical muscle disease resulting in false-positive test results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H17#H17\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH-susceptibility testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, there is a widespread misconception that acute MH may begin in the postoperative period with hyperthermia as the initial presenting sign, but hyperthermia is a later sign of MH and is typically absent when the diagnosis is initially suspected.",
"   </p>",
"   <p>",
"    Sustained muscle contraction from unregulated calcium release generates more heat than the body is able to dissipate. Marked hyperthermia occurs minutes to hours following the initial onset of symptoms. In some cases, core body temperature may rise 1&ordm;C every 5 minutes. Severe hyperthermia (up to 45&ordm;C [113&ordm;F]) leads to a marked increase in carbon dioxide production, and increased oxygen consumption can cause widespread vital organ dysfunction. Severe hyperthermia is associated with development of disseminated intravascular coagulation (DIC), a poor prognostic indicator and often terminal event [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Causes of fever other than acute MH are much more common perioperatively. Fever can be due to transient bacteremia or the effects of anesthetics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery on the hypothalamic thermoregulatory system [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Patients undergoing surgery involving endothelial surfaces (GI tract, urogenital tract, etc) are particularly prone to develop fever. Sepsis may be accompanied by fever, metabolic acidosis and elevations in CK, making it difficult to distinguish from MH. Consideration of these diagnoses should not interfere with proceeding to an acute MH management protocol based upon the developing clinical scenario. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute MH is strongly suspected when the anesthesiologist cannot control a rising ETCO2 level despite compensatory increases in minute ventilation. The diagnosis is further supported by muscle rigidity (masseter muscle or generalized), or an otherwise unexplained metabolic acidosis. When these clinical signs occur,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    is administered immediately and triggering agents are discontinued. Additional anesthesia personnel are summoned to assist in preparing the dantrolene and initiating the MH protocol. As recommended by the Malignant Hyperthermia Association of the United States (MHAUS), an appropriately stocked MH treatment cart should be immediately available at all times (",
"    <a class=\"graphic graphic_table graphicRef67323 \" href=\"UTD.htm?17/46/18157\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Efficient management of the patient suspected of having malignant hyperthermia includes all of the following (",
"    <a class=\"graphic graphic_table graphicRef68918 \" href=\"UTD.htm?23/50/24365\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Optimize oxygenation and ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increase inspired oxygen to 100 percent. Increase ventilation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tidal volume to maximize ventilation and reduce the ETCO2. If the patient is not intubated, endotracheal tube placement should be performed simultaneously with the remainder of the protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Discontinue triggering agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately discontinue triggering agents and inform the operating surgeon of the diagnosis and the need to complete the surgical procedure as quickly as possible. If the surgical procedure cannot be aborted, it should be completed while the patient receives intravenous anesthesia with non triggering agents, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H24#H24\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Anesthesia in MH-susceptible patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Administer dantrolene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    is the only known antidote for MH. Dantrolene binds to ryanodine receptors (RYR1) and directly inhibits sarcoplasmic reticulum calcium release thereby reversing skeletal muscle hypermetabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Prior to the introduction of dantrolene, mortality was as high as 70 percent, but is now estimated to be between 1 and 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    is supplied as a lyophilized powder (20 mg) vial that also contains 3 g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and sodium hydroxide to maintain pH of 9 to 10. It should be mixed in warmed sterile water to enhance its solubility [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/39\">",
"     39",
"    </a>",
"    ]. A newer formulation is available that solubilizes much more readily [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/40\">",
"     40",
"    </a>",
"    ]. The importance of summoning additional personnel to assist with drug preparation and administration, and to assist with patient management cannot be overstated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    is administered as a loading bolus of 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, with subsequent bolus doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously until the signs of acute MH have abated; the ETCO2 should normalize as the dantrolene takes effect. In most cases, dantrolene reverses the acute hypermetabolic process within minutes. The need to use higher doses is uncommon and the clinician should question the accuracy of the diagnosis if a rapid response is not seen; however, some patients, especially muscular males, may require initial dantrolene doses approaching 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously.",
"   </p>",
"   <p>",
"    All facilities where general anesthesia is administered should have an adequate stock of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    in the event that MH occurs. The Malignant Hyperthermia Association of the United States (MHAUS) recommends each facility have a treatment protocol, and dedicated MH treatment cart containing dantrolene (36 vials available at all times), along with other medications and equipment needed to immediately treat an acute episode (",
"    <a class=\"graphic graphic_table graphicRef67323 \" href=\"UTD.htm?17/46/18157\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Monitor for hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is treated (ie, calcium, bicarbonate, and insulin-glucose) based upon the presence of abnormal ECG waveforms (ie, peaked t waves) to prevent the development of life-threatening arrhythmias or cardiac arrest. Individuals with greater muscle mass are at an increased risk for hyperkalemia from rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers are absolutely contraindicated in the acute management of MH since they can worsen hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Check labs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measure electrolytes,",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    status, creatine kinase (CK), coagulation parameters and fibrin split products. Arterial or venous blood gases should be collected initially as needed until pH and potassium levels trend toward normal values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initiate supportive care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continue to monitor the patient's core temperature (eg, esophageal, ear, rectal probe). Institute cooling measures and continue them until the patient's temperature drops below approximately 38.5&ordm;C (101.3&ordm;F). In a review of the North American MH Registry database, the median maximal temperature of patients who developed disseminated intravascular coagulation (DIC) was significantly greater than those who did not (40.3&ordm;C versus 39.0&ordm;C) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H11#H11\">",
"       \"Severe hyperthermia (heat stroke) in adults\", section on 'Cooling measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Place a Foley catheter (if not in place) to monitor urine color and volume. In the absence of red blood cells, a urine dipstick positive for heme indicates myoglobinuria. Urine output should be kept at 1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"      until the urine color returns to normal and the CK begins to decrease (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Creatinine kinase (CK) values will usually peak around 14 hours after the initiation of MH and should be measured twice daily until decreasing levels are observed. The patient's muscle compartments should be monitored carefully; rhabdomyolysis can result in acute compartment syndrome especially if the patient has developed DIC. Muscle compartment release (ie, four compartment fasciotomy) may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"       \"Acute compartment syndrome of the extremities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Institute measures to prevent myoglobinuria-induced renal failure (ie, hydration, diuretics, bicarbonate). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398978#H25398978\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     MHAUS hotline and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;24 hour support is available from consultants at the Malignant Hyperthermia Association of the United States (MHAUS) 1-800-MH-HYPER.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://medical.mhaus.org/index.cfm/fuseaction/Hotline.Home.cfm\">",
"       medical.mhaus.org/index.cfm/fuseaction/Hotline.Home.cfm",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Their acute management algorithm can be found at:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://medical.mhaus.org/PubData/PDFs/treatmentposter.pdf\">",
"       medical.mhaus.org/PubData/PDFs/treatmentposter.pdf",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about MHAUS is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H28#H28\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH resources'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ONGOING CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the completion of the surgical procedure, the patient should be transferred to an intensive care unit for ventilatory support and hemodynamic monitoring.",
"   </p>",
"   <p>",
"    Because recrudescence occurs in up to 25 percent of patients after initial treatment, maintenance doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 6 hours) should continue for 48 hours after the last observed sign of acute MH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/26,41\">",
"     26,41",
"    </a>",
"    ]. If recurrent signs appear in spite of ongoing treatment, additional dantrolene boluses may be required. Alternatively, a dantrolene infusion (0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg/hour)",
"    </span>",
"    can be used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    has no effect on cardiac or smooth muscle. Its most common local adverse reaction is venous irritation or thrombosis at the site of administration due to its high pH. Side effects include nausea, malaise, lightheadedness, and mild to moderate muscle weakness. Respiratory muscle weakness may occur when larger doses are used especially in patients who are debilitated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality from MH has declined significantly and is estimated to be between 1 and 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A study from the North American Malignant Hyperthermia Registry (NAHMR) reported a mortality rate of 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32984/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients with advancing age, greater comorbidities, heavy muscular build (eg, young males), and those who develop disseminated intravascular coagulation are at greater risk for cardiac arrest or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COUNSELING AFTER ACUTE MH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following recovery from an acute MH event, patients are informed that until evaluation for MH-susceptibility can be performed they should:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not have anesthesia with triggering agents.",
"     </li>",
"     <li>",
"      Avoid excessive heat and humidity as these may trigger an event.",
"     </li>",
"     <li>",
"      Inform their family members. MH-susceptibility is a genetic condition and family members may also need to be evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MH-susceptible patients are encouraged to learn as much as possible about the nature of their condition and should be directed to the appropriate educational resources. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H24#H24\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'Anesthesia in MH-susceptible patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link&amp;anchor=H28#H28\">",
"     \"Susceptibility to malignant hyperthermia\", section on 'MH resources'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant hyperthermia (MH) is a genetic disorder of skeletal muscle metabolism that can manifest clinically as a hypermetabolic crisis in genetically predisposed individuals who are exposed to inhalational anesthetics or depolarizing muscle relaxants. Rarely, susceptible individuals may trigger a reaction when exposed to extremely hot conditions or during vigorous exercise. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anesthesia history should include questions about prior adverse reactions to anesthetic exposure in the patient or their family members in an effort to identify potentially MH-susceptible individuals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anesthesia history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately half of patients who develop acute MH have had prior uneventful exposure to the anesthetic agents known to trigger MH (ie, inhalational agents, depolarizing neuromuscular blockers). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Triggering agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the initial clinical signs of MH typically occur within one hour of anesthesia induction, the onset of MH can occur any time during the administration of triggering agents. The onset of MH in the postoperative period is extremely rare and does not manifest solely as temperature elevation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of acute MH is based upon clinical signs, the most reliable of which is hypercapnia that is due to a mixed metabolic and respiratory acidosis and is resistant to increasing the patient's minute ventilation. Other early clinical signs include sinus tachycardia and muscle rigidity. Hyperthermia is a later sign of MH and may be absent when the diagnosis is initially suspected. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early exclusion of technical factors as a cause of decreased carbon dioxide elimination, or increased carbon dioxide production that could account for hypercapnia is important. Many other conditions also have clinical signs (ie, hypercapnia, tachycardia, muscle rigidity, rhabdomyolysis, hyperthermia, arrhythmia) in common with acute MH, but consideration of these diagnoses should not interfere with proceeding to an acute MH management protocol based upon the developing clinical scenario and clinician judgment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with suspected acute MH, triggering agents are immediately discontinued and additional anesthesia personnel are summoned to assist with initiation of the MH protocol. If the surgery must continue, non-triggering agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ) are used. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with suspected acute MH, we recommend immediate administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The initial dose of dantrolene is 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously, with subsequent bolus doses of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously until the signs of acute MH have abated; the end-tidal carbon dioxide (ETCO2) should normalize as the dantrolene takes effect. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Administer dantrolene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      , the patient's oxygenation and ventilation are optimized. Blood gases, potassium, core temperature, creatine kinase, urine output, urine color, electrolytes, coagulation parameters and fibrin split products are monitored for the remainder of the operation, and postoperatively in the intensive care unit. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Ongoing care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following an acute event, the determination of whether a suspected clinical event represents a true MH episode is estimated using the MH clinical grading scale. Definitive diagnosis is achieved with susceptibility testing. While waiting for further evaluation, the patient is counseled to not have anesthesia with triggering agents, limit exposure to excessive heat and humidity, and to inform their family members. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Counseling after acute MH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/1\">",
"      DENBOROUGH MA, FORSTER JF, LOVELL RR, et al. Anaesthetic deaths in a family. Br J Anaesth 1962; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/2\">",
"      Denborough M. Malignant hyperthermia. Lancet 1998; 352:1131.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenberg, H, Fletcher, JE. International Malignant Hyperthermia Workshop and Symposium, Hiroshima, Japan, July 16-19, 1994. 82, 803-805. 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/4\">",
"      MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/5\">",
"      Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/6\">",
"      Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/7\">",
"      Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/8\">",
"      Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009; 109:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/9\">",
"      Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg 1993; 77:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/10\">",
"      Bendixen D, Skovgaard LT, Ording H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997; 41:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/11\">",
"      Rubiano R, Chang JL, Carroll J, et al. Acute rhabdomyolysis following halothane anesthesia without succinylcholine. Anesthesiology 1987; 67:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/12\">",
"      Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/13\">",
"      Simon HB. Hyperthermia. N Engl J Med 1993; 329:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/14\">",
"      Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med 2003; 10:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/15\">",
"      Papadimos TJ, Almasri M, Padgett JC, Rush JE. A suspected case of delayed onset malignant hyperthermia with desflurane anesthesia. Anesth Analg 2004; 98:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/16\">",
"      Litman RS, Flood CD, Kaplan RF, et al. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology 2008; 109:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/17\">",
"      Beldavs J, Small V, Cooper DA, Britt BA. Postoperative malignant hyperthermia: a case report. Can Anaesth Soc J 1971; 18:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/18\">",
"      Newson AJ. Malignant hyperthermia: three case reports. N Z Med J 1972; 75:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/19\">",
"      Britt BA. Combined anesthetic- and stress-induced malignant hyperthermia in two offspring of malignant hyperthermic-susceptible parents. Anesth Analg 1988; 67:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/20\">",
"      Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; 2:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/21\">",
"      Evans TJ, Parent CM, McGunigal MP. Atypical presentation of malignant hyperthermia. Anesthesiology 2002; 97:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/22\">",
"      Harwood TN, Nelson TE. Massive postoperative rhabdomyolysis after uneventful surgery: a case report of subclinical malignant hyperthermia. Anesthesiology 1998; 88:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/23\">",
"      McKenney KA, Holman SJ. Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible. Anesthesiology 2002; 96:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/24\">",
"      Birmingham PK, Stevenson GW, Uejima T, Hall SC. Isolated postoperative myoglobinuria in a pediatric outpatient. A case report of malignant hyperthermia. Anesth Analg 1989; 69:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/25\">",
"      Fierobe L, Nivoche Y, Mantz J, et al. Perioperative severe rhabdomyolysis revealing susceptibility to malignant hyperthermia. Anesthesiology 1998; 88:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/26\">",
"      Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/27\">",
"      Van der Spek AF, Fang WB, Ashton-Miller JA, et al. The effects of succinylcholine on mouth opening. Anesthesiology 1987; 67:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/28\">",
"      Carroll JB. Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine. Anesthesiology 1987; 67:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/29\">",
"      O'Flynn RP, Shutack JG, Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. Anesthesiology 1994; 80:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/30\">",
"      Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesth Analg 1986; 65:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/31\">",
"      Nelson TE. Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. Anesthesiology 1990; 73:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/32\">",
"      Frank SM, Kluger MJ, Kunkel SL. Elevated thermostatic setpoint in postoperative patients. Anesthesiology 2000; 93:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/33\">",
"      Halsall PJ, Ellis FR. Does postoperative pyrexia indicate malignant hyperthermia susceptibility? Br J Anaesth 1992; 68:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/34\">",
"      Paul-Pletzer K, Yamamoto T, Bhat MB, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002; 277:34918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/35\">",
"      Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975; 47:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/36\">",
"      Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/37\">",
"      Larach MG, Brandom BW, Allen GC, et al. Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 2008; 108:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/38\">",
"      Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/39\">",
"      Mitchell LW, Leighton BL. Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 2003; 50:127.",
"     </a>",
"    </li>",
"    <li>",
"     www.dantrium.com/faq.php (Accessed on February 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32984/abstract/41\">",
"      Podranski T, Bouillon T, Schumacher PM, et al. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth Analg 2005; 101:1695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 401 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-113.53.254.124-74B16A17D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32984=[""].join("\n");
var outline_f32_13_32984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIGGERING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANESTHESIA HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Approach to hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Early signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Masseter muscle rigidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Later signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ECG changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Optimize oxygenation and ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Discontinue triggering agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Administer dantrolene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Monitor for hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Check labs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initiate supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MHAUS hotline and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ONGOING CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COUNSELING AFTER ACUTE MH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/401|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/54/29539\" title=\"picture 1\">",
"      Anesthesia machine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/15/33020\" title=\"table 1\">",
"      Clinical indicators of acute malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/36/22094\" title=\"table 2\">",
"      Differential diagnosis of acute malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/46/18157\" title=\"table 3\">",
"      Suggested supplies and equipment for the MH treatment cart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/50/24365\" title=\"table 4\">",
"      Malignant hyperthermia rapid response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/19/14642?source=related_link\" title=\"calculator 1\">",
"      Calculator: Clinical indicators for malignant hyperthermia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32985="Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children";
var content_f32_13_32985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Cindy Christian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     V Jordan Greenbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/13/32985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/13/32985/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/13/32985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 40 percent of deaths from child abuse occur among children younger than 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/1\">",
"     1",
"    </a>",
"    ]. Abusive head trauma is the most common cause of lethal child abuse. Most fatal head injuries in children less than two-years old are secondary to abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/2\">",
"     2",
"    </a>",
"    ]. Head-injured infants frequently present with nonspecific clinical features and no history of trauma. As a result, as many as 30 percent of children with inflicted head injuries may be misdiagnosed at the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early identification of abusive head trauma can be lifesaving. In one retrospective review describing missed cases of abusive head injury, four of five deaths may have been prevented if the inflicted mechanisms had been recognized during prior medical evaluations for symptoms related to undisclosed head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, mechanisms, and types of head injury found in abused children are reviewed here. The clinical features, evaluation, and diagnosis of abusive head trauma in infants and children, including ophthalmologic aspects, and the management of suspected child abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abusive head trauma includes inflicted cranial, cerebral, and spinal injuries resulting from blunt force trauma, shaking, or a combination of forces [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The injuries themselves may be primary or secondary. The classic injury pattern that is associated with shaking includes diffuse unilateral or bilateral subdural hemorrhage, diffuse multilayered retinal hemorrhages, and diffuse brain injury. This pattern has been referred to as the \"shaken baby syndrome\" and",
"    <span class=\"nowrap\">",
"     \"shaken/impact",
"    </span>",
"    syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The absence of a history of trauma and a paucity of external manifestations of injury can make recognition of the inflicted nature of these injuries difficult. The AAP has recommended that the term \"shaken baby syndrome\" be replaced in medical records with the broader term &ldquo;abusive head trauma&rdquo;, which allows for consideration of multiple mechanisms of injury in any child [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/5\">",
"     5",
"    </a>",
"    ]. Generic terms, such as \"head injury\", also serve to distinguish the diagnosis of injury from the investigation of how the injury occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of brain injury is only one factor that must be considered in making the diagnosis of abusive injury. The significance of the diagnosis (with regard to child protection and criminal prosecution) may be similar, regardless of whether injury resulted from direct blows or from shaking [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, much of the evidence to support the mechanism of injuries that result from shaking is retrospective and indirect. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mechanisms of injury'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H15#H15\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child abuse occurs most often among children less than four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/1\">",
"     1",
"    </a>",
"    ]. In one population based study, the most common mechanism of injury for infants three to five months of age was battering [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/10\">",
"     10",
"    </a>",
"    ]. Among young children, head injury, in particular, is often inflicted. This is illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In several case series describing children who were admitted to the hospital with head injury, between 21 and 33 percent of injuries were inflicted [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective report, injury was inflicted in 53 percent of children two years of age or younger with traumatic brain injury, who were admitted to a pediatric intensive care unit, or died [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among infants younger than one year of age admitted to the hospital with head injury, 64 percent had been abused [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of abusive head trauma (AHT) among children is similar in the United States and Europe. In a population-based study conducted in the United States, the incidence of AHT among children younger than two years was 17 per 100,000 person-years (95% CI 13-21 per 100,000 person-years); the incidence was greater in the first than in the second year of life (30 versus 4 per 100,000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/14\">",
"     14",
"    </a>",
"    ]. Population-based studies from Europe report similar incidences of AHT in the first year of life (25 and 29 per 100,000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000783\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of AHT occur during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/14,18-22\">",
"     14,18-22",
"    </a>",
"    ]. In three studies comparing children with AHT to those with an unintentional mechanism, the median age of those who had been abused was four months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/13,14,23\">",
"     13,14,23",
"    </a>",
"    ]. Children with unintentional head injury were significantly older. Abusive head injury in older children has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000790\">",
"    <span class=\"h2\">",
"     Prior history of abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many victims have a history of having been shaken, or otherwise abused in the past. In one large series describing children with inflicted head injury, a history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical evidence of previous maltreatment was noted in 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/18\">",
"     18",
"    </a>",
"    ]. Child welfare agencies had been previously involved with 22 percent of families. In another study of AHT involving perpetrator confessions, repeated episodes of shaking were reported in 55 percent of cases and ranged from 2 to 30 events [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited evidence suggests that it is not unusual for clinicians to initially misinterpret nonspecific signs and symptoms of AHT (as an example, vomiting or irritability), leading to a delay in diagnosis. In one retrospective series, the diagnosis of AHT was missed in 31 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/3\">",
"     3",
"    </a>",
"    ]. The most frequent diagnoses applied to children with missed abusive head trauma included viral gastroenteritis or influenza, accidental head injury, and \"rule out sepsis.\" Of those whose injuries were not recognized as inflicted, 28 percent were reinjured. Four of these children died as the result of their subsequent injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000797\">",
"    <span class=\"h2\">",
"     Perpetrators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perpetrators of AHT are usually male and most commonly, the father of the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/18,26-28\">",
"     18,26-28",
"    </a>",
"    ]. In one retrospective study, the perpetrator was identified in 240 cases (66 percent); in decreasing order of frequency, the perpetrator was the father (50 percent), stepfather or male partner of the mother (20 percent), and mother (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/18\">",
"     18",
"    </a>",
"    ]. Similar results were found in another review of 151 cases; in addition, female babysitters were identified as perpetrators in 17 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000804\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with child abuse generally include young",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    single parents, those with lower levels of education; unstable family situations; stress factors within the family including perceived financial, food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    housing stresses; domestic violence,",
"    <span class=\"nowrap\">",
"     alcohol/drug",
"    </span>",
"    abuse, and parental depression. One study of household composition in child maltreatment fatalities showed that the increased risk in single-parent households was present only when other unrelated adults also resided in the home, particularly stepfathers and maternal boyfriends [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H3#H3\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following risk factors have been associated specifically with AHT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal illness (prematurity, obstructed labor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospitalization after birth) and antecedents of familial dysfunction (ie, drug or alcohol abuse, history of violence, or a psychiatric illness) were significantly associated with abuse in a prospective study comparing infants with accidental versus inflicted head injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family disruption and separation, as well as a prior history of abuse of the index child or other family members, was associated with inflicted head injury in one case series [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incessant crying is a common trigger for inflicted injury [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4,31-33\">",
"       4,31-33",
"      </a>",
"      ]. Thus, \"colicky\" babies or those infants whose caregivers have limited ability to tolerate crying may be at increased risk for AHT. In one study perpetrators often reported shaking the infant as an effective way to make the baby stop crying [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, economic factors at a population level may have an impact on the frequency of AHT. As an example, an increase in AHT coincident with the economic recession beginning in 2007 was observed in a trauma database analysis. The mean monthly incidence of AHT increased by 101 percent from the nonrecession to the recession period, while the rate of unintentional head trauma decreased by 3.5 percent over the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with abusive head trauma may have severe brain injury, often in the absence of a history of significant trauma and with minimal or no signs of external injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/23\">",
"     23",
"    </a>",
"    ]. In comparison, patients with unintentional mechanisms more commonly present with a history of trauma and external signs of injury around the head [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H2#H2\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific injuries that are associated with abuse include subdural hemorrhage (typically diffuse, thin-layered, and often along the falx",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    over the bilateral cerebral convexities), diffuse multilayered retinal hemorrhages, and diffuse brain injury. Mechanisms involving shaking with or without impact have been proposed to explain this pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4,6,19,21,35\">",
"     4,6,19,21,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000868\">",
"    <span class=\"h2\">",
"     Susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggests that the brains of infants are more vulnerable to injury as the result of angular (rotational) deceleration than are those of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, experimental evidence from studies with neonatal piglets suggests that brain injury increases with repetitive rotational events in comparison to a single event [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/37\">",
"     37",
"    </a>",
"    ]. Particular features that may contribute to this susceptibility include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/6,19,38\">",
"     6,19,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The base of the infant skull is relatively flat, permitting the brain to move more readily in response to acceleration-deceleration forces.",
"     </li>",
"     <li>",
"      The infant skull is thin and pliable. Because of this, forces are transferred more effectively across the shallow subarachnoid space to the brain.",
"     </li>",
"     <li>",
"      The head of an infant is relatively large, heavy, and unstable. The brain of an average two-year old child is approximately 75 percent the weight of an average adult brain. The large head and weak neck musculature (particularly prominent in young infants) permit greater movement when the head is acted upon by acceleration-deceleration force.",
"     </li>",
"     <li>",
"      Infants and young children have relatively soft brains with high-water content. In addition, the newborn central nervous system is not completely myelinated. These features make the developing brain more susceptible to injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000825\">",
"    <span class=\"h2\">",
"     Primary injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the types and severity of head injuries sustained by an infant or child are related to the relative contributions of rotational and translational forces, and it should be noted that most head injuries result from combinations of these forces. Evidence from biomechanical models is controversial. Experimental models suggest that angular deceleration forces (that cause rotation of the head on its axis, with differential movement of the",
"    <span class=\"nowrap\">",
"     skull/dura",
"    </span>",
"    and intracranial contents) cause subdural hemorrhage and traumatic axonal injury. Biomechanical forces have been shown to be greater with shaking and impact than with shaking alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/19\">",
"     19",
"    </a>",
"    ]. In comparison to shaking, injury from a short fall (ie, from a changing table or bed to the floor) is primarily the result of translational deceleration (movement of the head in a straight line) and cranial impact [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/39\">",
"     39",
"    </a>",
"    ]. Injuries from this unintentional mechanism are typically focal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12000818\">",
"    <span class=\"h2\">",
"     Secondary injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to direct injury from traumatic forces, the brain can also be injured by secondary hypoxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/40\">",
"     40",
"    </a>",
"    ]. Both clinical and neuropathologic studies support the importance of secondary hypoxic-ischemic injury in the pathogenesis of cerebral injury in abused children [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This may be the result of various mechanisms, including central apnea from injury to the brainstem and cervical spinal cord during shaking, prolonged seizure activity, aspiration from loss of airway protective reflexes, and other contributors. Hypoxic ischemic cerebral injury occurs three times more frequently following abusive head trauma than after serious unintentional head trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H11#H11\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The minimal amount of force required to produce the pattern typically associated with inflicted injury (diffuse subdural hemorrhage, extensive retinal hemorrhages, and diffuse brain damage) is unknown and obvious ethical considerations preclude experimental studies to address this question. Experts generally agree, however, that normal handling and minor trauma do not cause this pattern of serious injury, and that violent forces are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/8,43,44\">",
"     8,43,44",
"    </a>",
"    ]. Perpetrator confessions also indicate the use of violent forces [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries associated with inflicted head trauma in infants and children include retinal hemorrhages, intracranial bleeding, skull fractures, and skeletal fractures. Some or all of these injures may be present in any given child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retinal hemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal hemorrhages are frequently noted in children with abusive head trauma, including fatal cases. In comparison, they occur much less commonly among those with unintentional head injury. In one literature review with a prevalence of 47 percent for AHT, the presence of retinal hemorrhages in an infant with intracranial injury had a positive predictive value of 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/45\">",
"     45",
"    </a>",
"    ]. Retinal hemorrhages associated with abusive head trauma are characteristically numerous, involve multiple layers of the retina, and extend beyond the posterior pole to the peripheral retina (",
"    <a class=\"graphic graphic_picture graphicRef69754 \" href=\"UTD.htm?38/62/39919\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64277 \" href=\"UTD.htm?21/18/21795\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"     figure 2",
"    </a>",
"    ). Less severe retinal hemorrhages are less specific for abuse and are occasionally identified after unintentional injury and in a variety of other medical conditions. Retinal hemorrhages as a result of abusive head trauma and the differential diagnosis of retinal hemorrhages is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link&amp;anchor=H12#H12\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\", section on 'Retinal hemorrhages'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link&amp;anchor=H19#H19\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intracranial bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH) is one of the characteristic features of abusive head trauma and may include subdural hemorrhage (SDH), intraparenchymal bleeding, epidural hemorrhage (EDH), subarachnoid hemorrhage (SAH), or a combination of these. Concomitant skull fracture may or may not be present.",
"   </p>",
"   <p>",
"    Significant intracranial injury rarely occurs as the result of low impact trauma, such as a short vertical fall. Several studies of short falls in infants and young children confirm the rarity of serious intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. According to a review of published data, including literature reviews and multiple databases, the annual risk of death from short falls involving infants and young children is less than 0.48 deaths per 1 million young children per year [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One retrospective series evaluated the injuries sustained by 167 infants (less than 10 months of age) in short vertical falls (4 ft or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/50\">",
"     50",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients (85 percent) had no or only minor injuries (without fracture or loss of consciousness).",
"     </li>",
"     <li>",
"      Twelve children (7 percent) had skull fractures, all of which were isolated and linear.",
"     </li>",
"     <li>",
"      Two infants who had intracranial bleeding were later confirmed to have inflicted injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Subdural hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hemorrhage (SDH) is an unusual accidental injury in children, except when severe forces are involved (eg, a motor vehicle collision or fall from significant height) or the SDH is small and localized to the site of cranial impact [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/11,51-55\">",
"     11,51-55",
"    </a>",
"    ]. Subdural hemorrhages are significantly associated with abusive head trauma, occurring almost three times more frequently in abused children than patients with serious unintentional head trauma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83196 \" href=\"UTD.htm?36/25/37268\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78781 \" href=\"UTD.htm?3/1/3094\">",
"     image 2",
"    </a>",
"    ). Additional characteristics of subdural hemorrhages seen in inflicted head trauma include multiple hemorrhages with differing density, interhemispheric or posterior fossa location, and extension over the convexity of the brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H11#H11\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically silent SDH may occur in term neonates as the result of birth trauma. In a prospective study in which 111 newborn infants underwent magnetic resonance imaging (MRI) within 48 hours of birth, subdural hemorrhage was present in nine (8 percent) (three vaginal deliveries, five forceps deliveries, and one traumatic vacuum-assisted delivery) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/56\">",
"     56",
"    </a>",
"    ]. None of the infants required intervention, and SDH was resolved in all cases by the time of follow-up MRI at four weeks of age.",
"   </p>",
"   <p>",
"    In most cases of abusive head trauma, the subdural hemorrhage is eventually resorbed, but in some, the hyperdense blood seen on computed tomography evolves into a hypodense fluid collection, which may gradually increase in size. The time required for this evolution varies from a few days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/57\">",
"     57",
"    </a>",
"    ]. A sizable proportion of abused infants with head injury present with chronic subdural collections with or without additional acute injuries, suggesting prior episodes of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/52,57-59\">",
"     52,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Epidural hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural hemorrhage (EDH) denotes bleeding into the space between the dura and the inner surface of the skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"     image 3",
"    </a>",
"    ). EDH occurs significantly more frequently following unintentional head trauma than after abusive head trauma. Falls are the typical mechanism of injury for EDH in children with unintentional head injury and the hemorrhages that result are typically small (1 cm thick and isolated) and without associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/52,60\">",
"     52,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H11#H11\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Subarachnoid hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subarachnoid hemorrhage (SAH) is present in nearly all fatal cases of inflicted head trauma, it may be difficult to detect when small in size or located on the interhemispheric surfaces of the brain and does not occur more frequently after inflicted head trauma than following unintentional head trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H11#H11\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Parenchymal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and severity of parenchymal injury in AHT varies with the mechanism of injury and magnitude of forces involved [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/61\">",
"     61",
"    </a>",
"    ]. Parenchymal damage occurs as the result of contact forces, inertial forces, and global",
"    <span class=\"nowrap\">",
"     hypoxia/ischemia.",
"    </span>",
"   </p>",
"   <p>",
"    Contact",
"    forces may cause small cerebral contusions from deformation of the overlying skull. Massive contact forces may cause extensive underlying cerebral contusion and laceration. Other parenchymal changes associated with contact forces may result from compression by an enlarging extra-axial mass lesion (EDH or SDH) compromising blood flow to the underlying parenchyma and leading to focal parenchymal edema.",
"   </p>",
"   <p>",
"    Inertial forces with angular (rotational) deceleration can cause traumatic axonal injury (either focal or diffuse), gliding contusions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal parenchymal tears. Such injuries are especially common in the subcortical white matter, corpus callosum, periventricular regions, and dorsolateral aspect of the rostral brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/38,39,62,63\">",
"     38,39,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Global",
"    <span class=\"nowrap\">",
"     hypoxia/ischemia,",
"    </span>",
"    as the result of AHT, can also cause parenchymal brain injury and is believed to be an important contributor to poor outcome. Axonal injury from hypoxia has been noted in series of fatal inflicted neurotrauma, suggesting that local traumatic damage to the corticospinal tracts of the lower pons, medulla, and cervical spine may be responsible for the apnea, respiratory distress, and resultant hypoxia so often encountered in children with AHT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/41,42,64,65\">",
"     41,42,64,65",
"    </a>",
"    ]. Thus, severe AHT may cause primary damage to the brainstem, including the respiratory centers (possibly from",
"    <span class=\"nowrap\">",
"     hyperflexion/hyperextension",
"    </span>",
"    injury), which initiates widespread secondary hypoxia, leading to global",
"    <span class=\"nowrap\">",
"     hypoxic/anoxic",
"    </span>",
"    changes and brain swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Hypoxic/ischemic",
"    </span>",
"    changes may also result from secondary hypotension, prolonged seizure activity, and other mechanisms.",
"   </p>",
"   <p>",
"    Subacute and chronic parenchymal changes associated with inflicted head injury include infarction, atrophy, and encephalomalacia with ventriculomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/7,64,65\">",
"     7,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures are frequently seen in children with AHT, but are also common in those with unintentional head injury. For example, in an observational study of 218 children with traumatic brain injury (54 with AHT), skull fractures were reported in 57 and 30 percent of children with unintentional head injury and AHT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/55\">",
"     55",
"    </a>",
"    ]. In a systematic review of seven studies that reported skull fractures in 520 children (predominantly infants and toddlers), the probability of abuse in children with a skull fracture was 30 percent (95% CI 19-46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/66\">",
"     66",
"    </a>",
"    ]. In children with a clear history of trauma, no extracranial injuries and no social concerns, most skull fractures are unintentional [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Linear, parietal skull fractures are the most common type of skull injury following both unintentional and inflicted trauma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83197 \" href=\"UTD.htm?35/29/36309\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Given the similar clinical features of unintentional and abusive skull fractures, these injuries should be evaluated in the context of the history that is provided by the child's caregiver(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/67\">",
"     67",
"    </a>",
"    ]. Abusive injury should be suspected if the history is inconsistent with the physical examination findings. If the mechanism of injury is a fall, it is important to determine the height of the fall and the type of surface of impact (eg, concrete, wood, carpet). In general, falls from 2 ft or less are unlikely to produce head injuries more serious than linear skull fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complicated skull fractures (ie, complex [eg, stellate, branching], multiple, bilateral, crossing suture lines, depressed, or diastatic) are reported by some to be suggestive of abusive head trauma. However, the specificity of complicated skull fractures as an indicator of child abuse varies as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one observational study of skull fractures in 89 children younger than two years (29 with AHT), fractures that crossed suture lines or were multiple, diastatic, growing, depressed, complex [eg, stellate, branching], or bilateral were much more common among children who were abused than those who had unintentional injuries (83 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/72\">",
"       72",
"      </a>",
"      ]. The majority of unintentionally injured children had single linear fractures (78 percent).",
"     </li>",
"     <li>",
"      Another observational study of 134 young children (39 with AHT), who in general, had injuries of minor severity, found no significant difference between abusive and unintentional trauma in the incidence of complex, diastatic, or depressed fractures (39 versus 42 percent); however, fractures that were multiple, bilateral, or crossed suture lines were significantly more common in abused children (52 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another review of 94 children with skull fractures (26 with AHT), the parietal region was the most common fracture site in cases of abuse and unintentional injury (81 and 77 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/68\">",
"       68",
"      </a>",
"      ]. Linear fractures were found in a majority (54 percent) of the abuse cases. Complicated fractures (eg, multiple, bilateral, diastatic, or depressed) were more common in the abuse than the accidental group (46 versus 26 percent). In addition, among the 14 children who sustained a complicated skull fracture after unintentional falls, six were injured in falls from relatively short heights (60 to 119 cm [2 to 4 ft]).",
"     </li>",
"     <li>",
"      Bilateral, symmetrical parietal skull fractures were reported in a six-week old infant who had midline head impact after a short witnessed fall onto concrete; the midline impact was felt to be responsible for the bilateral fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that the clinician should suspect abuse in infants and young children with complicated skull fractures when the history of injury is absent or implausible, but should recognize that unintentional trauma may cause such injuries.",
"   </p>",
"   <p>",
"    The clinical manifestations, radiologic evaluation, and management of skull fractures in children are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H8#H8\">",
"     \"Skull fractures in children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H15#H15\">",
"     \"Skull fractures in children\", section on 'Radiologic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H20#H20\">",
"     \"Skull fractures in children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skeletal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 50 percent of victims of AHT have extracranial skeletal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/14,18,35,74-76\">",
"     14,18,35,74-76",
"    </a>",
"    ]. In one retrospective study of 71 children younger than three years of age with SDH caused by inflicted injury, 32 percent of victims had extracranial fractures; 87 percent of these had multiple bony injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/76\">",
"     76",
"    </a>",
"    ]. In a prospective study comparing young children with serious AHT versus unintentional head injury, the abused patients were more likely to have rib, long-bone, and metaphyseal fractures than those who had sustained accidental trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/23\">",
"     23",
"    </a>",
"    ]. Two types of fracture often are found in infants with inflicted head trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic metaphyseal lesions (CML) of the long bones were one of the early injuries described in infants with AHT and are strongly associated with child abuse (",
"      <a class=\"graphic graphic_figure graphicRef50274 \" href=\"UTD.htm?28/62/29667\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83116 \" href=\"UTD.htm?42/18/43311\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79186 \" href=\"UTD.htm?8/12/8399\">",
"       image 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/6,46,76-78\">",
"       6,46,76-78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H18#H18\">",
"       \"Orthopedic aspects of child abuse\", section on 'Location and type of fracture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rib fractures, especially posterior fractures near the costovertebral articulation, in infants with normal bones are also highly specific for child abuse and may occur when the torso is grasped and compressed during shaking (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83198 \" href=\"UTD.htm?13/42/13987\">",
"       image 7",
"      </a>",
"      ). In one literature review where the prevalence of AHT was 47 percent, the presence of rib fractures in an infant with intracranial injury had a positive predictive value of 73 percent for AHT [",
"      <a class=\"abstract\" href=\"UTD.htm?32/13/32985/abstract/45\">",
"       45",
"      </a>",
"      ]. Inflicted rib fractures usually are nondisplaced and may involve single or multiple sequential ribs, and may occur unilaterally or bilaterally. Acute rib fractures are often difficult to detect clinically and radiographically when they are acute. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H15#H15\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H19#H19\">",
"       \"Orthopedic aspects of child abuse\", section on 'Rib fractures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other orthopedic injuries associated with child abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H13#H13\">",
"     \"Orthopedic aspects of child abuse\", section on 'Fracture patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abusive head trauma (AHT) is an important cause of morbidity and mortality in young children, particularly among those younger than 12 months of age. Cranial injury may be the result of direct blows or shaking (particularly of an infant), dropping, throwing the child, or a combination of mechanisms. The injury pattern that is associated with shaking includes subdural hemorrhage, retinal hemorrhage, and brain injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AHT occurs most often in the first year of life. The incidence of inflicted traumatic brain injury among children is similar in the United States and Europe. Many victims have a history of previous abuse, and the diagnosis is frequently delayed. The perpetrators of AHT are usually male and most commonly, the father of the infant. (See",
"      <a class=\"local\" href=\"#H12000783\">",
"       'Age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12000790\">",
"       'Prior history of abuse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12000797\">",
"       'Perpetrators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angular deceleration, with or without impact, results in differential movement of intracranial contents that causes axonal injury and intracranial bleeding. The infant brain is more susceptible to this type of injury. Normal handling and minor trauma typically do not generate sufficient force to cause serious injury. (See",
"      <a class=\"local\" href=\"#H12000868\">",
"       'Susceptibility'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12000825\">",
"       'Primary injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoxic-ischemic injury is also an important contributor to the types of brain injury seen after AHT. (See",
"      <a class=\"local\" href=\"#H12000818\">",
"       'Secondary injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injuries associated with AHT include skull (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83197 \" href=\"UTD.htm?35/29/36309\">",
"       image 4",
"      </a>",
"      ), metaphyseal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79186 \" href=\"UTD.htm?8/12/8399\">",
"       image 6",
"      </a>",
"      ), and rib fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83198 \" href=\"UTD.htm?13/42/13987\">",
"       image 7",
"      </a>",
"      ); retinal hemorrhages (",
"      <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"       figure 2",
"      </a>",
"      ); and intracranial bleeding, especially subdural hemorrhage (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83196 \" href=\"UTD.htm?36/25/37268\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Administration for Children &amp; Families. Child Maltreatment 2010. Annual Report, US Government Printing Office; US Department of Health and Human Services, Washington, DC 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/2\">",
"      Gill JR, Goldfeder LB, Armbrustmacher V, et al. Fatal head injury in children younger than 2 years in New York City and an overview of the shaken baby syndrome. Arch Pathol Lab Med 2009; 133:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/3\">",
"      Jenny C, Hymel KP, Ritzen A, et al. Analysis of missed cases of abusive head trauma. JAMA 1999; 281:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/4\">",
"      Adamsbaum C, Grabar S, Mejean N, Rey-Salmon C. Abusive head trauma: judicial admissions highlight violent and repetitive shaking. Pediatrics 2010; 126:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/5\">",
"      Christian CW, Block R, Committee on Child Abuse and Neglect, American Academy of Pediatrics. Abusive head trauma in infants and children. Pediatrics 2009; 123:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/6\">",
"      Caffey J. The whiplash shaken infant syndrome: manual shaking by the extremities with whiplash-induced intracranial and intraocular bleedings, linked with residual permanent brain damage and mental retardation. Pediatrics 1974; 54:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/7\">",
"      Duhaime AC, Christian CW, Rorke LB, Zimmerman RA. Nonaccidental head injury in infants--the \"shaken-baby syndrome\". N Engl J Med 1998; 338:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/8\">",
"      Richards PG, Bertocci GE, Bonshek RE, et al. Shaken baby syndrome. Arch Dis Child 2006; 91:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/9\">",
"      Reece RM. Highlighting violent and repetitive shaking. Pediatrics 2010; 126:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/10\">",
"      Agran PF, Anderson C, Winn D, et al. Rates of pediatric injuries by 3-month intervals for children 0 to 3 years of age. Pediatrics 2003; 111:e683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/11\">",
"      Bechtel K, Stoessel K, Leventhal JM, et al. Characteristics that distinguish accidental from abusive injury in hospitalized young children with head trauma. Pediatrics 2004; 114:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/12\">",
"      Hettler J, Greenes DS. Can the initial history predict whether a child with a head injury has been abused? Pediatrics 2003; 111:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/13\">",
"      Reece RM, Sege R. Childhood head injuries: accidental or inflicted? Arch Pediatr Adolesc Med 2000; 154:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/14\">",
"      Keenan HT, Runyan DK, Marshall SW, et al. A population-based study of inflicted traumatic brain injury in young children. JAMA 2003; 290:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/15\">",
"      Billmire ME, Myers PA. Serious head injury in infants: accident or abuse? Pediatrics 1985; 75:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/16\">",
"      Barlow KM, Minns RA. Annual incidence of shaken impact syndrome in young children. Lancet 2000; 356:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/17\">",
"      Talvik I, Metsvaht T, Leito K, et al. Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) in Estonia. Acta Paediatr 2006; 95:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/18\">",
"      King WJ, MacKay M, Sirnick A, Canadian Shaken Baby Study Group. Shaken baby syndrome in Canada: clinical characteristics and outcomes of hospital cases. CMAJ 2003; 168:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/19\">",
"      Duhaime AC, Gennarelli TA, Thibault LE, et al. The shaken baby syndrome. A clinical, pathological, and biomechanical study. J Neurosurg 1987; 66:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/20\">",
"      Ludwig S, Warman M. Shaken baby syndrome: a review of 20 cases. Ann Emerg Med 1984; 13:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/21\">",
"      Hadley MN, Sonntag VK, Rekate HL, Murphy A. The infant whiplash-shake injury syndrome: a clinical and pathological study. Neurosurgery 1989; 24:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/22\">",
"      Ettaro L, Berger RP, Songer T. Abusive head trauma in young children: characteristics and medical charges in a hospitalized population. Child Abuse Negl 2004; 28:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/23\">",
"      Keenan HT, Runyan DK, Marshall SW, et al. A population-based comparison of clinical and outcome characteristics of young children with serious inflicted and noninflicted traumatic brain injury. Pediatrics 2004; 114:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/24\">",
"      Mierisch RF, Frasier LD, Braddock SR, et al. Retinal hemorrhages in an 8-year-old child: an uncommon presentation of abusive injury. Pediatr Emerg Care 2004; 20:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/25\">",
"      Salehi-Had H, Brandt JD, Rosas AJ, Rogers KK. Findings in older children with abusive head injury: does shaken-child syndrome exist? Pediatrics 2006; 117:e1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/26\">",
"      Starling SP, Holden JR, Jenny C. Abusive head trauma: the relationship of perpetrators to their victims. Pediatrics 1995; 95:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/27\">",
"      McCabe CF, Donahue SP. Prognostic indicators for vision and mortality in shaken baby syndrome. Arch Ophthalmol 2000; 118:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/28\">",
"      Ghahreman A, Bhasin V, Chaseling R, et al. Nonaccidental head injuries in children: a Sydney experience. J Neurosurg 2005; 103:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/29\">",
"      Stiffman MN, Schnitzer PG, Adam P, et al. Household composition and risk of fatal child maltreatment. Pediatrics 2002; 109:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/30\">",
"      Vinchon M, Defoort-Dhellemmes S, Desurmont M, Dhellemmes P. Accidental and nonaccidental head injuries in infants: a prospective study. J Neurosurg 2005; 102:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/31\">",
"      Krugman, RD. Fatal child abuse: analysis of 24 cases. Pediatrician 1983-1985; 12:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/32\">",
"      Barr RG, Trent RB, Cross J. Age-related incidence curve of hospitalized Shaken Baby Syndrome cases: convergent evidence for crying as a trigger to shaking. Child Abuse Negl 2006; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/33\">",
"      Reijneveld SA, van der Wal MF, Brugman E, et al. Infant crying and abuse. Lancet 2004; 364:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/34\">",
"      Huang MI, O'Riordan MA, Fitzenrider E, et al. Increased incidence of nonaccidental head trauma in infants associated with the economic recession. J Neurosurg Pediatr 2011; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/35\">",
"      Alexander R, Sato Y, Smith W, Bennett T. Incidence of impact trauma with cranial injuries ascribed to shaking. Am J Dis Child 1990; 144:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/36\">",
"      Raghupathi R, Margulies SS. Traumatic axonal injury after closed head injury in the neonatal pig. J Neurotrauma 2002; 19:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/37\">",
"      Raghupathi R, Mehr MF, Helfaer MA, Margulies SS. Traumatic axonal injury is exacerbated following repetitive closed head injury in the neonatal pig. J Neurotrauma 2004; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/38\">",
"      Case ME, Graham MA, Handy TC, et al. Position paper on fatal abusive head injuries in infants and young children. Am J Forensic Med Pathol 2001; 22:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/39\">",
"      Ommaya AK, Gennarelli TA. Cerebral concussion and traumatic unconsciousness. Correlation of experimental and clinical observations of blunt head injuries. Brain 1974; 97:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/40\">",
"      Ichord RN, Naim M, Pollock AN, et al. Hypoxic-ischemic injury complicates inflicted and accidental traumatic brain injury in young children: the role of diffusion-weighted imaging. J Neurotrauma 2007; 24:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/41\">",
"      Geddes JF, Hackshaw AK, Vowles GH, et al. Neuropathology of inflicted head injury in children. I. Patterns of brain damage. Brain 2001; 124:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/42\">",
"      Geddes JF, Vowles GH, Hackshaw AK, et al. Neuropathology of inflicted head injury in children. II. Microscopic brain injury in infants. Brain 2001; 124:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/43\">",
"      Harding B, Risdon RA, Krous HF. Shaken baby syndrome. BMJ 2004; 328:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/44\">",
"      American Academy of Pediatrics: Committee on Child Abuse and Neglect. Shaken baby syndrome: rotational cranial injuries-technical report. Pediatrics 2001; 108:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/45\">",
"      Maguire S, Pickerd N, Farewell D, et al. Which clinical features distinguish inflicted from non-inflicted brain injury? A systematic review. Arch Dis Child 2009; 94:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/46\">",
"      Nimityongskul P, Anderson LD. The likelihood of injuries when children fall out of bed. J Pediatr Orthop 1987; 7:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/47\">",
"      Helfer RE, Slovis TL, Black M. Injuries resulting when small children fall out of bed. Pediatrics 1977; 60:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/48\">",
"      Lyons TJ, Oates RK. Falling out of bed: a relatively benign occurrence. Pediatrics 1993; 92:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/49\">",
"      Chadwick DL, Bertocci G, Castillo E, et al. Annual risk of death resulting from short falls among young children: less than 1 in 1 million. Pediatrics 2008; 121:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/50\">",
"      Tarantino CA, Dowd MD, Murdock TC. Short vertical falls in infants. Pediatr Emerg Care 1999; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/51\">",
"      Tzioumi D, Oates RK. Subdural hematomas in children under 2 years. Accidental or inflicted? A 10-year experience. Child Abuse Negl 1998; 22:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/52\">",
"      Wells RG, Vetter C, Laud P. Intracranial hemorrhage in children younger than 3 years: prediction of intent. Arch Pediatr Adolesc Med 2002; 156:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/53\">",
"      Jayawant S, Rawlinson A, Gibbon F, et al. Subdural haemorrhages in infants: population based study. BMJ 1998; 317:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/54\">",
"      Feldman KW, Bethel R, Shugerman RP, et al. The cause of infant and toddler subdural hemorrhage: a prospective study. Pediatrics 2001; 108:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/55\">",
"      Adamo MA, Drazin D, Smith C, Waldman JB. Comparison of accidental and nonaccidental traumatic brain injuries in infants and toddlers: demographics, neurosurgical interventions, and outcomes. J Neurosurg Pediatr 2009; 4:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/56\">",
"      Whitby EH, Griffiths PD, Rutter S, et al. Frequency and natural history of subdural haemorrhages in babies and relation to obstetric factors. Lancet 2004; 363:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/57\">",
"      Dias MS, Backstrom J, Falk M, Li V. Serial radiography in the infant shaken impact syndrome. Pediatr Neurosurg 1998; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/58\">",
"      Ewing-Cobbs L, Kramer L, Prasad M, et al. Neuroimaging, physical, and developmental findings after inflicted and noninflicted traumatic brain injury in young children. Pediatrics 1998; 102:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/59\">",
"      Alexander R, Crabbe L, Sato Y, et al. Serial abuse in children who are shaken. Am J Dis Child 1990; 144:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/60\">",
"      Shugerman RP, Paez A, Grossman DC, et al. Epidural hemorrhage: is it abuse? Pediatrics 1996; 97:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/61\">",
"      Hymel, KP. Child Maltreatment 1998; 3:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/62\">",
"      Gennarelli TA. Mechanisms of brain injury. J Emerg Med 1993; 11 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/63\">",
"      Gennarelli TA, Thibault LE, Adams JH, et al. Diffuse axonal injury and traumatic coma in the primate. Ann Neurol 1982; 12:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/64\">",
"      Sinal SH, Ball MR. Head trauma due to child abuse: serial computerized tomography in diagnosis and management. South Med J 1987; 80:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/65\">",
"      Gilles EE, Nelson MD Jr. Cerebral complications of nonaccidental head injury in childhood. Pediatr Neurol 1998; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/66\">",
"      Kemp AM, Dunstan F, Harrison S, et al. Patterns of skeletal fractures in child abuse: systematic review. BMJ 2008; 337:a1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/67\">",
"      Wood JN, Christian CW, Adams CM, Rubin DM. Skeletal surveys in infants with isolated skull fractures. Pediatrics 2009; 123:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/68\">",
"      Leventhal JM, Thomas SA, Rosenfield NS, Markowitz RI. Fractures in young children. Distinguishing child abuse from unintentional injuries. Am J Dis Child 1993; 147:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/69\">",
"      Meservy CJ, Towbin R, McLaurin RL, et al. Radiographic characteristics of skull fractures resulting from child abuse. AJR Am J Roentgenol 1987; 149:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/70\">",
"      Harwood-Nash DC, Hendrick EB, Hudson AR. The significance of skull fractures in children. A study of 1,187 patients. Radiology 1971; 101:151.",
"     </a>",
"    </li>",
"    <li>",
"     Albert MJ, Drvaric DM. Injuries resulting from pathologic forces: Child abuse. In: Pediatric Fractures: A Practical Approach to Assessment and Treatment, MacEwen GD, KasserJR, Heinrich SD (Eds), Williams &amp; Wilkins, Baltimore 1993. p.388.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/72\">",
"      Hobbs CJ. Skull fracture and the diagnosis of abuse. Arch Dis Child 1984; 59:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/73\">",
"      Arnholz D, Hymel KP, Hay TC, Jenny C. Bilateral pediatric skull fractures: accident or abuse? J Trauma 1998; 45:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/74\">",
"      Atwal GS, Rutty GN, Carter N, Green MA. Bruising in non-accidental head injured children; a retrospective study of the prevalence, distribution and pathological associations in 24 cases. Forensic Sci Int 1998; 96:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/75\">",
"      Merten DF, Osborne DR, Radkowski MA, Leonidas JC. Craniocerebral trauma in the child abuse syndrome: radiological observations. Pediatr Radiol 1984; 14:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/76\">",
"      Lazoritz S, Baldwin S, Kini N. The Whiplash Shaken Infant Syndrome: has Caffey's syndrome changed or have we changed his syndrome? Child Abuse Negl 1997; 21:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/13/32985/abstract/77\">",
"      Caffey J. On the theory and practice of shaking infants. Its potential residual effects of permanent brain damage and mental retardation. Am J Dis Child 1972; 124:161.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman PK. Diagnostic Imaging of Child Abuse, 2nd, Mosby, St. Louis 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6609 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32985=[""].join("\n");
var outline_f32_13_32985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000783\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000790\">",
"      Prior history of abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000797\">",
"      Perpetrators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000804\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000868\">",
"      Susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000825\">",
"      Primary injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12000818\">",
"      Secondary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intracranial bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Subdural hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Epidural hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Parenchymal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skeletal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6609|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/25/37268\" title=\"diagnostic image 1\">",
"      Acute subdural hematoma in an abused infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/1/3094\" title=\"diagnostic image 2\">",
"      Inflicted subdural hematomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/52/26432\" title=\"diagnostic image 3\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/29/36309\" title=\"diagnostic image 4\">",
"      Skull fracture in an abused infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/18/43311\" title=\"diagnostic image 5\">",
"      Distal femoral metaphyseal corner fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/12/8399\" title=\"diagnostic image 6\">",
"      Metaphyseal corner fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/42/13987\" title=\"diagnostic image 7\">",
"      Multiple healing rib fractures in an abused infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6609|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/18/21795\" title=\"figure 1\">",
"      Deep retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35497\" title=\"figure 2\">",
"      Retinal hemorrhage types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/62/29667\" title=\"figure 3\">",
"      Corner fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6609|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/62/39919\" title=\"picture 1\">",
"      Dome shaped hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_13_32986="Pulm AVM CXR II";
var content_f32_13_32986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50043%7EPULM%2F57719%7EPULM%2F64406%7EPULM%2F77195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50043%7EPULM%2F57719%7EPULM%2F64406%7EPULM%2F77195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows multiple small nodular arteriovenous malformations with distorted peripheral vascularity of the lungs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwATUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDJ0HTFkiHmKyg8j/arWOjMqruXcOSMc8V6FHoaWLsdoMRB+QDoajlsxvYYztXIAFAHASWfkoqkDd3A7is2+VY4H+TLFTg+ldvcWQJB2sR24rG1qwUQHb+Oe1AHiOqaYzXDsEADE4qkdMG4ArzXp11pYkfcqKe1VJ9JAPCA5xxQB54ukKXZio29MYrQ0nw899c7QAEB+Y+1dvpfhi5v7kJHGQhIG4jivXfDPhC0soUjjhEjKOZGHVu/FAHlmh+GLseV9jjeFFI2tnb+NeoaVrX9jW6Qam/2iU9Co7e9amv/AGPQNKmvr2VI0RSRuOK+ZvGHxLkubmZLD5FPG9epFAH0JqOt6VLG8waMv2ycmvNvEmqzyMyWcbIm48gYzXg8niPUTN5sdxIjeu7NaVj4qu52WPULiVl9d1AHUX1pcTzuJ1BJOcPzWTf6LGyYeAfN6CsubV7jzN0c75B4Oasw+JrwgLMwlUf3hQBD/wAI0RGrwS4yM4apBpFzFLDux1+Ug1q2Gr210UjlHlODwe1dJJYxCW33N8rjsPagDIgsCsKysvQ8kdq6LaksKsU+YoOaqWzNaXRWdPMhztK+1d3B4UlvrcTac6NC6jCHqDQB5xewiJgGKBgen1rNvLiG3idZyAHUjgdK6bxL4Q1G0czSx8g8jqa4DxBDIpCuCMDuKAKDPYv8nmHIPJ9aW2EUtwNqYOcDmsvy/mzWtpULeapXOe1AGrHZo00fHfpnpXaaZpXmIpjIA7VyaiczoFbBz0xzXpmiwSLZJlSXx3HAoAo6hHJBBHFHLyx5IHauc1vYGUMNznnHvXV3dpPcXQjiUnaAPpUj+ErmZBJGquSOCfWgDzS6WZoiX+RMduKwJ7ra2Fy3ua9UvvBV9IjfaJY40xk4OcCsiDwhaxzLHM/mOewFAHDWcksjjbFuPTNd94U0yWSaNnnEIJxt65qc6Fb2bJmIkE87TWvp9nb+bHHGTG5PBzQB6z4U0PRHii+12yTTjGHbkGu0/sSNCBBFGkWOiDFeeeF7ee3iQrOkiZGSTXcQeLrKwMdrM5kdzhSOxoAqa54eitla5yqwgbmB/hryfxj42it43tNI5Y5BcdBXqHie4utQidSc2zjBQH7wrxbxR4Zk0+43BcxSfMh9vSgDzbUhLeTvJdMzuecnmsq4tF4wOK7ebTvM4C4PTms6XSGVxgbhQBN4H0WJ7xbidNypyARwTXpulWQvboB22qeMkYwK5fwXAVleMgnuK7vT4CpUr8mRyaAJr6Kz03y4bRPMBGWZh3oqG8jeaYsgYr6jvRQB6/ew4tWjfG8cAnnBrMl09xEEQoznqc8Gur1iyPmZUHj73PBrNjsXJLnjuTQBz8WnvDIAUAXHIrlNWiEtxNgcZIHpXZ6reAn7Pbk47vWXZ6NLfzKsCnLdjQByFpo7TSfu42L4wFArobPwmiqr3ILORnZivQNL0GOxjCqoaU9WAqt4h1TT/D9kZb51M4PEYOfpmgCj4e0CGEvPOoRUHGeAKpa54v03SBJHZgTygcgfdH+Nedar8RLrVWuI0cLFu2qicDFcbf6i8kjCRgM9z1FAGN8Ydc1TxHOfMdvIAysak7R+FeKTLtkYHrXqet364aNcs47k9q861S3bzy45z1oAzaUcU7Y2cAH0qUWsrAbUYn6UAJbyBWw5OD39KsjIOc8VX+ySAZIA/GnoJQmNpyOfrQBailKtxnGK7zwprDSW0NtK26SJjs3HPGORXARZdFznd3q3YzzWV/FJF1Bx+FAHrlvqFpdTgTps8tgGK9DXoUNkYWU2l+PLwu0g4x714Vp1/wDvCQxyTlj616to90J7ZEDY2oM+9AG74seQossMxdiuJATnJ9a8n8THdMd8av2Py16ZaBZbzZgMH6dfyrnfE+jxSyN5bbSCcqOwoA8whgtWcmS3H4cV1Wg6Xp8qB9hzjkDtViLw+7RSFCvrz6VueFdFYSSGQgqB0PegC14Z0XSpdYhWSFmywGa9NmTTEzBa2TABtuW71x2hWYg1pPLfJz0I4FeqwwW3mRyzwKGXvmgDkBpgluHRI/KjDDoPvVqT6aAPLROFHQVBqWvLDejeiHe3yoOMDtWZ4i8XG204x2zIsrf6xh29hQBna7FY2it9pnCbR93Oc1xU3ibSLOcuilscZ9a5DxJrbs0rPIzSEnvXISXbS43E5x60Ad5feMLKS6JWOUKTngimDxhpVv5ckyTIwOQBg153PIIwXbnHAFY1zK00hZzzQB6xN47mvJdtreCGDONvQmuk8KeI5Ir2NbkrLAeCTzXz+rMOc1u6FfXUc6CCRhnHHagD7v8ADdvaaxpMcsGAMVQ1/wAKtd2NxGyhx95cDoa4H4O+M10+zS1vZBg4ye1e86dc21/CJbeRXU+h6UAfM99orRFonTaVODgVQk0gDDcZ7jFe8eKPDlvNcTMI9rsM7hXG3/h2W2Qsyfu+mR6UAcJpmnCOdXX5S3Ga7S10XEabtzvjqOgqnHZeU+AAcevtXXafvMKFMtleMc0AYqWMiDaEBHrRW/HbzDPzMOe3NFAHq0kauMMBVO4jCxMMVcDDHJqG5+dcDg5oA5QaIkl1tVBuJya6TT9OjsoQkSqWI+Zu5qzawCEEnlz3p9xKsEDyN0UZoA5nxpr8fh/T2aPHnsOD6fT3r5h8ZeJrjU7qXfIzZJ4NeyeMkuNZuWWR1RSeATnH4V53qnhrTrJi0oLSdTk8UAeZ6feNDclFG4uP1qxNHdyyB5cIuepPUVNqloUuybf5VU8c1VWaTD7mXJHGTkA0AUdQsLZWWR5XlyM7VGMGs6bT4fLZ4kG7H3HGTRf6wqABQA3fA61jS65NHNkbSCMc+lAFaa3VrjKgbCewqGa5kSXbH8qr8tVpLqY3JYNgDJAFQ+bJy5Ynk/jQBYk5CmrNspdsgjHpWW1xIDyRVu2u2j+bj24oA3bGzjkY8AHI5xninXmlAXK7SMEEgis601Xy2bcAc9cGuy06WG7s4poC0hB2MAPu5oAxNJsHkuCisN4/h9a9P8O2lw1p5bBlYDJGOeK5J4BHcjblCRwfevUfBmoyR3UMFxDHMvyjlfmAxzk0AUrOWSC8YshCqvHvTzcWN0VWQGOR24kI6H0rsNa0GCeG5NvJ5TIcD0PtXCTaPfqQI4/M291OcUAaVrpLPOkZmRE2neQOlamh6dbhn8mZWwMHtWFZ2OsSEKIXUng9q77w14XvFt99xtjTIz60AR6DpsUup8lWYEDOK7bVoktLLMgzxhQBVrw34fRZmuNoRAcDI6mrXib7PHCVVizkEDHQGgD571m+ma+d3A3A7V9q43xVfskZ2k72HLV6prPhzfcPdhfl9COteb+JreIXJzkEclTQB5bqEzFz8xOetUd+F9zXV38FvgssQY9/aue1LyRJiOPacUAZl85kOecAYFUgCTng1bkQPnnH401ITn2FAFaOIsenFbukIIWDY/H0qjFHnjvV23O3jp3oA7jw9qTISgbB9fSvUfCXji60iRSsx2jA254NeE2TzRqsijj2610OmXsxKAgj1oA+u9C8aab4gmS2Z1ivCPuseG+hrem04OCpQGMjkGvkHT7+6GpLLG7rtPBXsa+kvhv42S8tobLVGPmAALK3X6GgC1rHhsKvmWykjjK+lZNhHPp1wAq7kJwR7V6m8YI3DBU81kahpKNIJYk4HUUAZaWKSqHjDDI5GelFbllb+XGQw/rRQBHZXeGRM5Ru/pWpbZd2Eg+ZTXL6RbyPJ+5Y7fccAV18ahRx1PU0AOrG8STt/Zs6RnDY5Na8hwjY64rzzxX4jhs2lXeCyjkUAc3fzeXHLK5LCMEuwHAH1rx/xR4uR5WCMDk4GfSqfxD8VXhn/wBEkkS3ySQpwM+9eZ6lfPeZkwFKt823ofegC1q2tSTzuRKwBJ6d6xW1eeNcLIQe3NU72bLkLx3wfSstm3MT60AaL3Bckt972qGQ7jknORjNVVYqODTkbLnPQ0AWY0Ahds4xke9QKQQeuM81NGj+U4xkHvVeNSx4HAoAJBjHBximiQ4AJ4HpUhVvwHrUZRgDx0oAduO7gD1rX8PalNZXoZXZUIwVHesRc5461oW0D+Ypz1GfegDvYdUa6wGbJj6NXsHg/WIGtbW4NunnFcOw68cdK8G0SJ5ZFVCck17X4JtNsEakfNjjFAHolwou9NeRGfc2CAK5y3tJVkwoYEnOMmupuojbaWBGTuIx14rJsN8lwQGJbPQD370AWrC2kFwA3m7c9C2a9At4itooTdzjg1ytkzPcsdpKKTyRjBrurVC9mqOOcDBFAGpYqr2SKCFK9q5HxRIsdyESQfuhgknAzXTBjbwPzyBivJvGOolXdWJyZDuoAuX9zCYZN9xGkKjLMT0FfPHjTxHBc6tcm2AaJWIGfSuv8caw505oI2YRE5bHf614Xql1+8kxksSaALV7rBk4UBfXHesqSdWJyDVNny2c4NO64zQBY3KelTRjcSuccVSUDJJ79KejkEEUAaFuPLc5OTWhBClzgfdPtWP55z6mrNndBZRluD1oA1Vhmjz5WHVfSr9ndtbxkOCpPtWfHdgt+7Yj8cZrQilWVN5CjBxzzQBqaTfhpOCRj1rsNB1t7eVSj4bNcGqW3G3cmecitbTY5gwkiO9f89qAPqf4f+LxcRpa3b54+XJ6V6LEAfmU5Ujg18qeCZLp72EIzBsjOQelfS/h67WS1ihZv3oXkZ6UAaTQgkkYoqXp3ooAhgt44lCIoAH61S1LW7LTpBHPKvmHogPJrO8beIRoWmsYSDcvwv8As+9eD3mszNqRuZmaRmbc27v7UAeua74nmjuXRCFTblfcGuc8WWtrqvh9rmHAuxy2D3rjk8RNq8M0UOfNjJ8sqMnGeRUelTXDWkyS3AjiLHIJyQfTFAHmHiiyZpmDkqwPQ96414I42ZHjIB+U4r1XxPHZht8is0nJOeM1xd0YpZtyRrEFIHHXHrQBwV1pU8d3sjRnHQZHrVGXT3hJEmVI6ivQ9fMa30UwkO0qCCBkkiuc1sR7Vlixsk55PINAHNiBAoY5I6ZpSigABRn2q0AGiII56gCnrCJEjWHLE8MAOaAJrDKWkzSfdIwMVTIG3K5APWtDUf3dpHbwRnI+9ms9w4jGQFHpQBWk5PJPPFMc5QZ605pVGTuJ9BionlJ6AADp7UAT20WW5BxXV6TpnnBZw3zcLg8DFchFdSI2c5B7V02g6iGt5I92DjIz60AdRpWluupjYyLjk5Ne2eA9NaeIRBsyKu4AYrwbRb4G5Ub8s1fRnwvillmtCkZEgCnOCOO9AF3xFNJZWkKlyCx7iqmh3PnQyOBgswQ13fjTS7e8tRHMm1wSVb0rl9N0U2e0GePbuydwoAv2bRIR5m4AnGM5ya7e0uP3a7Uz2Az2rk9I06K8vUImBRDn5QRiu6sLWBXRUJbbyc0AV9URktGYAncM4NeM+KIZL3UJVVPkjPJHavaNffEEhKlsEDHauMktkupA5gUBm/u0AeE+MNNaLRZ3IbOemK8Mv7cidic5r60+Jdon2CW3jQLx0Hc18ta/EYLqRTxzjmgDC8vHfP4UeXwO9LzUkZwDQBEcr1FIMk4B/OpDuPpTtgA4GDQARrjJJ6VEQwfNSiJjkryaf5bZGRQAiSMMY4rY06U7ApYknoKzAYo0+fk9KiWZkkDITgUAdZFMULLwHHUGug0PfdSRxRDljyQa8+F87yruAA/nXXaBqYsVMkbYk6DPSgD6B8LSQaVbKpeKScqASDkrXd+BWebUnnV2EaDLBj69s14L4QvG1W7SGNSkhOS/avftElgs7NIEcEjlmGPmPrQB6Ajhxu6UVk2F8wjO5s89aKAPIfiBqUuq6m0UQZ8vgY7CuUkt0gYJdbWIbJQdT9TXV6wyRbxAgjGcM56mua+zxzTgRN5jjqCef/r0ARvBHZI1xp8ZCfeKjqPrVG7LJC19bjajHLj+61aDXJsbkuzAqv31c/Lj0NZGsI05/wBCvYBDKuVhDdc9qAMbxDqcUtjBPcn50bGc9q881PW4mul+UKhwGK1Y8ZG6sBNaXCeW+VZcNnIPeuIBJPzZ46H1oA6fWblzZqwk3orEIw9KxEld2Ks25D2NWrYy/YEhDEq5JxUsiGe1iaDHmoMSYHJ96AKkFhLLJi3IdieADzXovhPwf9h0fUdQ1tfsl3HFviSQbfk78Vh/DvR5tS1+J41yIjvP1rc+K2satNK2lzyu6KBkAdFHQUAec6peedcu8BIQZxxjIrMkZ2U5JJPr2qxJC4TODz7U2GFjuBHA55NAGcfekNaFxaGMK2Qd3OKpOjAAkYFAEdT2zyK/7s4qEc1btLd3YADJ9KAOg0J2a5idTgg+lfYPw4vpU0SyLEGURgE7eSK+WPBGmGW8iEi8A5xX1h4RtE/sq3YIVbAPFAHQ6lfJellBywO2q32WIQsJD2/DNV4JIVvHwc7c8461ZurmNLcAFee/40AXfDNohuXWJvlOeBXaRRrEoAAz6+tc14OdG89wOQAM47da6ESFgGOevSgCpr6L9hZypJBHIrjLm/hsLbdJIN/8Kn1rubkGexmQ85BFeYXFi1zqRjKHA45oA4DxjdzX0sjyMzY59BXgnjLT3juWcKTuOa+svEmjxW0QMsajd0GOK8i8WaHHKrkorbsjgUAfPTjBx6UgJHetrX9Kk0+7ZXX5SflrHYAE0AORyOSOKeZMnpUYHpQM5xQBZt3w2R0rQzuBIAHFZYG08cVYjkZCM0ARSKrsSRj0oWzlYjyxnNWHKE7vU8ipklGRsP4d6AI4rUjBcYbOMVtaZF8yqsZbI6E5qOJy8Y4z2wa19PjiCkozJIVIAPQUAbuk6g+nxL5DBZG6nPFeg+E/FhgdUupGGOWbtXjirdQTZPzrngrzkV0en3Jt4AzOF3DnP8qAPpnR/ENvPblkcEZor55t/EFxGm2zkaJB1560UAeleP7iPSJJVc7QScLnJavKbvxTPbyZt2ELEEAhume1dD40up9bkkklPlxgn5icc15pq2lzRTtCZoSVXgh8+9AGlNrj6jLLBNcANINqIp4Ldsn1rQ8KW11LqMcDW7yyM+zaw5U+ue1cLFBdRXUZCMrIR8wGefavVPC11qdzBDpZXbE/JmYYkyxznPWgCT4neHJ72G3tzCou4cAsCCSPciuEg8C3wkiieNcuw6ngDpk16/rGmab4K0Z7m+nm1C5uGG07/b9K8+1X4iXO1fs1lAiAYGeSKAF8VfDXVbbUbWPTTE9v5YIIyAD3+tdB4X+Cuqagr3K6lbpMMERxruHvmuKb4oazM4DmMAD1OK6b4afGbUND8QB76KKWzuP3cgHBXJ6igD3HwD8LbPw9PJdNI8802FkUqAFx6fWsv4w/D43sTaj4ehhW9gQrJGVz5nfHsa8+1D4563pnia7d4YJLPzDtRCfu54r1PwH8WtJ8XRrAEWK7/ijkYAn/ABoA+VNZu722L2Wq2ixkHDKU2kVp6F4KstYsPtNvfNFIBu2sOPcetfVvj7wFpPifQpFjt4I74qWjkKjOa+ONfsdY8Ia3caffGWGRWIDDIDD1FAEXirTLe1mZIZjIg+7xiuWlIQYYfN2Fak9zNuYySbweeeeaxLp2eQlqAFtwGnwBXo/h/RxcWQWOMFx1bvXm9oSJ1xXr3gjUI/IdXGHC/dz2oA3/AAl4buodZR3TapI2nrnNfRdpGsHh0eWgVox5bDofrXj/AIQu4jfgktuVgQD3Fe4QL59lcNwFOAu4deaAOMvYri3YMQ3lyDr3FK0VxNOAcmPIwT6V0V1pkd1bBJZWRhnBXmsFdOvIpiIruNk9Gz1oA9F0wWsWmBrOPDhcMAOener1pI8gVWGMjgDtXMeBoLlEmW6nSQE7vl/WutVcB9o24BxQBCZAjui5YgZxWBaaa/8AaU0iLj5ic1r+Z5N2DjB2dfWrds3mzyEjPAoA57WrP7Qw82NZABgVwOvaRtDiKIkdckdK9N1nbakeZIFDciuC1e8gM7pHOc9wM0AeYat4asdWtpotTAh44YLg59c14B4h0eXSdQlgkG5Ax2tj7w9a+oddks54vLdyZFzjYOvtXmXjHTbTUYWwr+YoxnHNAHioj6Dk5qbyG25HSr95pz2s5jl3J6EikdfLjHzBvSgDOwVqa2YFwsnfjNJI2W4GDSEhSKALWoW3lorpgg1miRlNbpCS2a7X/eKMFWrIuIWQ5dDjPWgC3aXzRqN35Gtqzuo5pfvFWA4HauVXLD5fzqeB2ibIYk+tAHc6bJtfAOCMncw7VpGL7UBvUsFH3l61xmnawBIBMRgcEGu80PUrZ0+UrlgFKk8AUASWulyeWDC4ZTzz1FFdRp8cKw8BsH0NFAGfry3F7IYgpdT1I6YrGh8L7pzLeMSnVsnr7V6ZFp66jbCVVSNUOAmcZFYniCaG1WSOFixQemPzoAzdPl06CCS2FkHhT7gz8wPrmtDTtY0vT7O7u445IbqEbBuGQ49j7VwM2sGCWXyirOTwqg1H4l1NjoSYYGQcNjqT70Aamq+IV1SM2F5JlZSSJG6Kx6YFcBqsEltcPFJnIOMnofcVjG7uzIGcnOcjNXZdUOox+TcyZmRcIwGfwNAGfMyRHO/K+3eoluMHbGApPPPWqskxDFcdOBntSxumPQ0AXZZi7q0jMTjrmrukXk1rdpNbzvDLGdyuvBBrOETSRCReVU1NbFlYEAjHWgD6u+CvxBufEdtJpuoyRvexKCDnBde5xWV+0No8V54fF3JCXntzkSD7wH+FeXfB9rj/AIWPo4t875HKkKOoKmvrXx74TGs+Dby2CjzXiyd3bFAHwhNJYLaRwGOUSnlnz19qW60ywj06OZL8TXLsc25XBRfUmuij8OT319NaqIVblUYn0461g33hTULS4aK4QRyDrzQBjWkWy5JwCPYcV7R8NrnS98QvkiBIwHHb615fa+HZvNVQGOevNdHpVnbW+BvO4cHDY5oA+kbHQra9uoG06BEKsCZF/OvWI9NeezVQQjAdD0NeKfDTxdZwrHBc3AO1dq7m7V7fpGv2F+irby5OOgU0AY11p+oWokYReZnjcpyMfSuUmuXV5EZQrAkEMMYr1wEEAjoarXenWl2CLi3jcnuV5/OgDhvB97m5YZxnpjnIrsYLrZMY3VjmnWOjWFi5e2t0Vj361fwoOcCgDC1ZJpLuIW0DkBeuOOlaenQPFETLxI2Mj0q3RQBz/iaxub5EaCHLR5xyORXnWqeGtXaUubGUknlgM4/KvYnlRM7jjAzXKa/4ju9OlQQLFIGPdT0oA8sfw9eMSJYJI3HIZhjNUrnwm87CQqQ2QG4r2HT/ABSLn5NQsgh/2eR+RrUhTSdRGYljDn0GDQB8w+MvBQuEZymQo/GvFNa06SxneORcAHANfdfiHwXHdxO0DnPXFfN/xd8MtaMcx4AbG7FAHhUoIpEOcCrd3AUkZSBUUMX55oAsIkqw7gOPfvVgDdH+8BzjpipuijcflQYAPc0Rv9pSQD5So6mgCi9vBg7cg1WltZNjFSSPUdRVpFzJh/51bltTDHuJOMUAYEaEH/Oa1NNupLdgwJOOg9akWOKUHzEHTqvBBqL7JImWQFlI4OOlAHf6P4oZbbExO4YGF7UVwdvuK4XP4UUAew6xqc2hSmKPUzcgDAhlXp9GFZH9prrKYKuj4+cqwauNuLibUJ3NzJ8zN1PUVettbt9OCWsECvGeGfPLH1oArXbxx/ubEYYE7pHPUewrOvG/e5LOE/rW9Jbpcyi5t1JR2xgdR6giqs2ltdXIjjdYnJGFboaAOUvo0SV9rhkPIzxWaYZUcPECe+RXTatpqQt5Wws4JBz3NZ4hkMiKAEI4x0oAptp8lzGLhRgfx+xqBbZVYgkn6V7d8KfByeIY7q3ul8pZEwsxTK5rT1r4V6fo95LFd3mGQDcxwtAHh9lZzSxOLeN2A+Zj6Ct/StCubtkEIjZz2z/nNde+i+HbS48iXU+vDKj5yPSvR/DHhzwZaT291HIptkUSsWmxgjnBoA6T4I/De28O6jp+q6pIJdTZX2DOFTI4H1xXt+uW813ot/b2pUTywOkZbpuKkD9a+efiF460KLUtI1nT7nd9hkBjjjlOGxz90f1r27wZ410XxZpMF7pt5CWdQXhZwHjPcEUAfLdp8HvHk9yVl057fB/1nnIBn14NdtcfCjxo2jZkFjPfIcAFxkqPc96+kDLGACXTB6HNPHI4oA+U7P4MeMtSnMV6lnp8LDBkDAkfgK6vSv2dbSNAdR1OSaT+LyxtB+lfQNFAHDeF/hb4W8PxoYdPW4nXnzZyXP5dK7aGGOFdsMaRr6KoAp9FABRRRQAYoooGcc9aACiiobu6htITLcSLGg6ljigDN162Jj85HIYEcVifZhcASzscgYGe/wBKnvPFOn3cQjgcsc9qq2t1Fcn94zEDoTQBOLYAlgoJxznuKntbNEIygVj12jpSC5t40A3YCnkbetaVpd2rxgbiD7rQBdtpAoClmI/2q5fx/wCDbbxHp8gVFExGTx19/rXTRSW7kbXXIHTNWVkQgbWBzwMUAfF/ir4ValZXDmKIyRljjHNcQPC13E0gaFg6E5XHIr7p17ToFDTEKN2eMcZrxX4giOytZpLeJJJ3BXGOaAPmK8Z0ZoyMYOM1DbRyk5Tp6etauvJCs7F/kYnop71kwXrWzExgNxjnqKALUVqyTBpF29634rNLu1D7mJHYVycmoT78yE/Q10Xh6+jmBiLMpIOeeKAILax8+8eONhhTitSOyFrMEO1j2+tZN+ZbS6ZofuGtHRL+Oe7SK5ViD/FmgDVttLjmQsU2t3wvWiusisYeTDIxUgfdNFAHF2+nXF+4EFnmIngqh5NdVZ+CNMtrNbrX4mjfd8oRtq/j7100utjTHWOzjgRlGNoAJ/OuV1zVGuJGS4JL5LeWTwT/AI0Abuny+G5ZZrXTrV0u3XdG3ChmA6CudW80mGa7gv8ARWS4VCzAtyMfyrKtruOS7WKJ5Y7p2AQKMkHt+tdRbT6DCPL8dXDSXUq+WixcPjtuxQBkvYaN4hjDWZltHC/UN+NPt/Bmk6LAl/rdwrqCSquwA49qwPGHi63srw2WjWCwQwfKoz2+tcNqOpX2pzCW7lZgASo7CgDufEnxNuoYvs/hxhbQqMGRRg/hXn2peItW1ad5tQv7m4lfq0khOazJ+GIJyOtWNPRi23YXLdAKAJVt2aIMXIbqcmtFvPi02NxLuDvzhjxjsahMLKV3qducH1Fb9zpb2+kQxyISZT5iEfxCgChYwiezcs+COgxnNdb4Y0u71O8jtNItriS8kHyiHOSPXjpV/wCFfgfVvFerQwWVn/okTqZ5nGEUZ5ye59hX2foHhjSNBG7TLCC3lZQryImC2BQBw3wm+Gr+HYFv9buprrUJF4iZyUiHoAT1969TAAGAMCiqmq6hb6ZZSXN3MkUaDO5zgUAQavqP2IdB0zyaj0vUlltzLdFYe/zNgY9a82bWNX8VXcr+GbRry3GQt1K2yFW9ifvfhXP+Ivh94+vtkt3fw3cY5aCGTaAPQDjNAHq91488PQXDwJfrPOgyUhG/H4jiiz8Y2155nk20uUz94jmvI9A8J3Wn6mUubaS3OejDj6Zrv/D+miO4kHJ39T6UAb7+JZQDttQSBnkmo/8AhKpNm77H2z96ka0T5wCDkdzVe5tEMYUHAHdaALkXiKeVSfIVOcDnNW4NUmZgJAAfYVm2kSgKV+btWisWcLjr60AVdQu7mW8KJKyRheinFcjryXD+alzMzRKxI3sa7h4FLqxAwBXK6tbPeXMhOdgYgCgDzqWRbO4XyJGwTnOMf/rrrvDmqCQAS4IxjOeaxtX0d0u0kjQsB2A4FXNLjit4gfL2OeM47UAdiXgbbtbBPYmrVupBBVhj1rmNjlw8TkndyK0LOZ4lQEHrk55oA6AM0ZDAgHHAqm9+8O8xkhlBPBpkQaRARkYPPtSu9vEzGQYyMMKANDUmuNW8IPJGAtyF3cjuOv6V4T4uvHW3fzVKt3IFfQPh+5huIpbZMbVGcD0NeK+OtLuJLqePAEYc4BHXBoA+a/FdiRdvOhYq3PIrn44+SRnFew+IdDChgYmAb17V5tq2nSWMkhRf3OetAGIxDEg8j3qeyPl3CbSU5x14qHdkkNgGrdtjhjzxQB1Nlb+erLImQRx3qA6Y8EpVDyelSaDOySh8swxzXd+TaXtrmUJHKRww4JFAGFpWoz2kTIG4OOporL1iwktboogMq/3gKKAN7xBrtpbOB5wGMlcLyffNcPeeIQ1wcSKSxySE5zWTfyzmdjOGIPQn0qlGqDdNMMKvTPBagDsNG1REujdTKpii5aTGGJ9AKz75ZtY1jzoZBJmQbFLYKj0rHtZpp2MQQhM8KvNXNO029nvtsaeWAclidoFADNWsZkkunuFP2lJRlWyOD3rOkLpbNJwcnb7mvefhbYDVvElrDqgtZ5oyTC05DeaB/C3rT/it8JJ9O1V7y2jt47C4mZ0VeNrHnbQB896dZPeXcaN8qswDMRwoPevefDnw+02y00XM7IJNoIdm5/8ArVylz4D1rTrMXEliVs3OBLkHJFalpBd3FpJbT3zo5GEVs7Tx046UAX7zw5pGoXa2dk/nahIMqIhkH6mvZfAHwytfLsW1B4L1bdSJEZchCe31rzL4f6LetdzHy/s7QID5rDDMO4BP/wCuvqPwnZPY6FaxzkGdlDyEep/+tigC5pWmWWk2gttNtYbaAc7IlCjPr9auUUhIAyaAMPxl4q0zwjo0uo6tKEjUfKg+859AK+bLLxLrPxk8dWNhcyPBowmLfZ4vlURDkk+rY9azP2hvEq+JPF0ljbTtNZWjbMp0LdP0rrP2YNMW28R3ZcHzY7UvgjpuIH8qAPRfFPiptFvU0TQVS1tLJAhKDqcfdHpisefxJrsUtvLFezncM4bofrWa09ovie/+0SSu8kjMNwyF5rqXW2uoUZYY2VUxyM5oA2vCPi2PXI0g1SBBMR/rAPlP+FdC2nxWZMkWRGTnPXFcbpOm5hlCx7Bwi44wOtdjpMjwW8cM7hkxjnmgCo8tq7MfOO3Pp1pk0dq6cXJwDzkcVNqOkwxOZoiVic8gdBVM2ELDAkbPAwKAFt5rWBBsnBYg4BBrVtXWVAEIZ/UjpWJBpMTyhxI4VeMHvW7FAIo2MZ68dKAEf5iF6HP4VlTIqxOx5LE4GOla67RI2ehqtdxxiIdMD3oA58WwlkYP3P40XFlHFKo2HaeOP61ejMW/IcbM88c1NKi3UEoLjOCc0AMs7G1kQthQ59BVptKVMPDg/wCyO9c7phlhvWQzKIh0APT3rorq5+zwq6XCKo55NAFS4tWLMI5FSTHQ96x9T0q/xvBL/SuhN3Zag8bCWIXWOobhqsNJNCAJR9GxQBh+BGmTUriOeNkJj7jHeqHijTkl1Kf5gQXJ212mmOrXMmBhtvPHvTdS062u5SZY13jHPQ0AeS61oKPbgsiBsfxV5X4l8OqjGIICj/e44+tfR3iHSl27lkYEDGGGRXn2q6QclplRgPTvQB8neJdHm0y8YMD5R+6e1ZUErIVwxB65r2zx/psNzE6JEQw9a8Zv7Z7KZkYdDwaANjStThgfFznH94da2P7UlZhslUwk8Eda86uZJC+SxxU1nfTRsqhuKAPUImkKB87t3OSc0VR8NeILJ7ErcZV1Pc9aKAEmNqyKvkefOSRgn5RzyajvPDkF2gkDZlBJKoPlA9Klmk2pGyQLt5xjtUmlXUkVyxmIaBTlj2xQBixaT9nkV4pFjkX+FuDUyW0z7/tFwFHu+f0q7rWr2BvfOi5APUnFc9NrMbZMKqQTk+uaAOp0fUv7A1KC8gukWSFgUyT1+lfTfhT4h+HPF/h+JtZkgS4jYB4ZiMFv7wz2r4vnM13c+YeEPJJro9He3tN0rzkgpt2r70AfYPi7w1F4s06JdH1EWqxptjjhwYvqQOtfPHjLw34i8K6gbG9ct5jeZFMh+U/n/KqHgr4mXfg/UW+wiSay+6YZGOCM/oa9+0Xxx4a+I+iSWtzHF9tdcfZ5R8yn1U/1FAHlPgiG7vL2HTNWmmZmcATAnIBI49xX14ihEVV6AYFcD4P+Hun6XdQX8kstxNCmyMP0UZzn3Nd/QAVi+Iruwk02/s7i7ET+S24K+1gMetaWoXSWVjPcyAlYlLYHf2r5P+Inj3VNWv8AWdDjxFmQtkL82OuM0AXNP8HaZJG8lmkcd84Pl+dNlD7/AFru/gRo9xpXiC9Mk8cyywEMVfOCGGK8f8O6BrOraRE8dvcyFcmNoweR3H6V6t8L9Cm0XUdP1C8Z4Zy5jETNgtkYORQBDr8I0vVbyO9VVladjFngkE/yrW0jzv7P+XMVuFDE5zk56Ve+IlpFe+K1tL9CrOqyQzBNy7R2P41qW8enR28dmruqZwcrgE+w9KANfw9PGivG7KBjtzzWjdToFVQOh4xWTb2i2rkxPuTjkVejQykFvzHagDWsbpZAIZeQehNR3CJDNjaBkcGqnliMKR1HNaUird2gY8svpQBQSTlvrV62kBDBjxVCJVBPABzVmHPI65FACTsRu2Yz2PrWRqEr7GIG9gMBScDNa7xkrkcHmuc1lpFOyLcAT94CgCuZG+YAk/jjin2Esw3ojYU53Enn6CqFq06S7ZOeeKtyExzoVJKdOtAFi0Vbe4UOu8k8sav6vDFe2BQkB+gwKpQDcrIzZcZIOP0pLidgRK3AwFoA5m70iSFnbcwGMgjrWpoOsTxhba8lYqBiN8549DWrcxrPbDClXx+dZrW0USDChWX24NAHV+Hbh5rqVWA4TO78amg1SGbUZ4MlSrFdx6Gs/wAFDIuXy3GFwe1VtqJeSyqOHYt9aAOg1K0ae2KqwPBxXnOtWM0cj7gRtru7fVI2AUMB25rE1WaO4lfaBlf1oA8h1ix88vG8QYt83I6V5N458OqUZYQVZTkZ9a+jdUtYlhLrkHuPU1wXijQJL23a4QAkDpQB8uXtvJGzo6/MpwaptEQeDXceMtJks7tp1Ug5+YYrlplVhhuD7CgCtbZQHax564NFWFt5NxKYZT6CigDupdQtrVGiJVtwyD6fWsG9vmZfvuGBO0DpWLdM8RMgYnJ5zWjprrqUAhCMZUIwAMnmgDKvFZmJ2naw3YPQf/WqoJCCQePTHavUNd8K21n4UsbwXURuizLLAx2uq9jXl10gWdwoIXPGaAJnnIg+Unrjr0rTsr4BIUuQMferMgtHkIAPPXFb6aQroGJcsMYGOooAmjga6uSYMFW6AdQK2tDe50zUYZYBLHLEwOVODRpMbWzLHFEDJgDK9ck11Fno+qTavIpRQccKedo+hoA+vPAGqPrHhi1u3yrugJUnO04rpIzuRTkHI7Vx/wAJNKl0nwLp8Nx/rmBdvxPFdZbxiGIRqSQp6n86AC7ZEtpWlTfGFJK4zkV82aJ4JfU/itreo6tasbJQ8ykD5GHZc+uK+l3UOjKehGDWXo+nfZ7WSKYI6sCCR/EKAPILO8EmoW8MPmW0cJ2QwxnCjHatTxF4WlvplvtNmmSQHzmLMcFvSrur6XoOkagZZrljeeaTHCxwB6njtVy81N5JoFVw6MoOxTwMe1AFrxVaNqWhadqTgrLGoWY4yQD1/WsuURxG3ZgrNjrmu20iSC/0+S0dcoVwQfQ1g3Ph54X6h1jyQSen4UAFi29AxH4VqiSFERtwU++axNPVracljvUYGD3ravrJrlVZCqhhnBNAEgkiZcm4TB9at6bNErbRMpDcAYrHTT3KqryRgD371NFZSRzowlQlTzzQBeuRDDOytIMk55p8DJjcG+nFN1ez854pEZQ3vTrSHyoySQ3FAElwcQscHODisW4HmLjYM44rdcbkG44BFU7u2McZaPAPJyaAOdisJmdhgfXuKui3hXbuGW79qRvM87ezAkelTxFZZMNjj0oAdFbxSOTgjHQ5qpc2p5MbKdp3FWFaFydkG6MZ7H0psT+dbA7QGxigDHM01wh8hATGdu6qcrThB50bZ4zxmt5Fjh3bUG5uvNOe3LIpxwetAFvw0nk6NLJjDNk/kKqW0ImjJPbr7GtmQeRpAVsZK46VkpEu8FSY/bPWgCpNan51j+QgE1nQcMVuF+YHr61032eQpmPDg5HuKx5bd/OBlBRs0AYusWDm0Jzlj19xXOtZSfZZCGfODx2Ar0j7NuhIlAMQHQc1mx20Fv5gmCmIj5RQB8z+NBbzyzJLEDg43D+teTahZsk8kSbTnkH0r6J8f6DbXF9O1spUE9q8O8YWMlhNvTdwepHWgDkkM0DMuWz9KKvR3MEyDzQQw60UAamg6b/bUlvZvIkTuQquemPeujitJfCniJla3he3t5QjMF5Zf7wq3Nc+HZoI/sMbac65ygG7JPcmtazuNM1S2WCXUkN0w8rzmAyy9s5oAm8W+G0t/D/2+1R7y2uiZopMZC+1eQS2sks5TZtHbIr3+4l1TQ/DdpDEBeWMed+3BAye3tXJtqh1K48yLSLaRo+oU8kZ96AOL0PToluoJWAUjksemR2NHiK6Uam1vCAnkuRvQYzXps/9latbrpwsJbDUZVDK7LtBPeoL74LeK7/xGqRWBNo6oftJYBSMAE59aAOT8F2FxqmpvFaEtMdhUDPzc9M9q+gPCvg+50q8k1nxNLCzBgyRscqgHQ+9db8OfhnD4V0/aFRbhlwxzkk/Wp/EHg4a4gj1/U5BbxNmO3hPlqR6HuaALT/FPwtAGhW6kkmjwvlxQlsn0GK6Hwnfz6rYyX89vLbJNITFHKMMEHQkds1gabpPhzQ9JVJLe0tYz9zpuYj+ddOl0sVpGyELbhCdx4yMUAZWv+PPD2i/a47vUoEurdQWhJ556VU0H4leGdYdY7fUYhKV3YJ+X86+LvGWsDU9e166aR5I2u2YMxxuXccDFO0aZbjTUIVI4zkjaD94dKAPs3xPo2meK9Ca9tJIpJBlo7iPkkjtn0zXg+geIni8Qi3u2mzG2xlftzzXb/APWZjGmk3AdAdzRxsfTGT+tZPxE8NyWHjSaa1tdiSYlEgGASeooA9Q8L3SebHcIcBu2egrtLpC6Blxg9fpXhHhPUr3TowJEd03YPJ45r2nQ9QivbZY9wL7QdpPNACx2sW5iIx15FS3MaqMKBx29qY7NFM4yeT0xTJpMjk8+3agCvJCNu5D+fSoJkIlG0HGc8CrBBWAgsQc881TeRt+NxwOKANqdQbSEsabAFCEDk+9PuRttIRk54qCIkMBQA69YJEGweoFUry5/wBH5JA7kVc1Ibrbn2rBunRLMvJuCjk45oAqtFEZXZCSTzgnqaYXkSRSjFfTNN+2KR+6jYseOFoilZpQqxHn2/WgBZbqX7Ix8xjyScZ6UmgxzTySlbh9nZcng0uoMY7YhRyepAqhpF1LD5jQsTk4K80AXLqW9gvRA0h4wwPWtaK5mdI0dlYl8EY/wrE1FZZHaSXIYrx7VoeConmuyJ8Ewck9c9hQB0Ot3sVuYoG6kZwPSq5mgZUwVINc/wCKWkm1iVlZgF+UYHYVDDE8yqC2CvORQB1UVwY2JLDZ3FFzmZC0RBI9RxWEPORlwQydM96uRTOM9VNAF61kEqPFKhRh6Via3ptx5T+SNygcFeK6KylaUBJVDED73Sp5IGMZBYlOxHUUAeH3FqSzi5Rw5zk/4V5z4w0sTxyxNErMAdpr6K1zTBcIYzGA2ch8YJrzjxF4WuCN64kVc59R+FAHyZeWMsN1JGowFPeiuw8caU0GrkRwMoIOfrRQA+68NS21ii4O/Jzk/oah021s7SO5PzG4QE7n6A+3rXs/irSdF8Y28csOuQWF599Rjarj6eteT+PPA1/o1klwl4l7EpxI0IOF+pFAFXQvF13ZXQQzh7bPKSMQMV6P4V1jw7r98LGeyl+2XZ8tZrZfmjJ/iGPevIvC/h3VNbukitbR3GeXdcAetfVPwh8KaZ4UtJbmaNI7iGMvJK+Cx7nntQB0Xhn4RaPZtaXepSXF7cQj5fObIHOa6LxP4/8ADnhV1t9RvY0kXA8pOSo+gr5t+Iv7QWr3d3NaaC/2S08wqJFGWZBx+teU61r93qsn2u4leW6kwzMRkn3oA+uvHnxat9Igs7rSIDeW83y+ZnaAx6CvAvGHxG8Q6lqt2txP9jQSEMsechfTJ711fwolh8f+Fn8OaxFHGLFlnEsK/MQORn+VeaeNYtNvtavbjTnmG2RgIHBGccf0oA+jfhB4a0jVrGz1GW4a/FqdyPM5Zt5HIOa9M8ZR+T4O1d4TskitJWQgdCFNfLfwE1ywtvEFjHqVzNbPFPujIJ8tsjBDD+tfYFxEs9vJDIAUkUqQe4IxQB+b0+mzjTLq8uA65kCgbcZJPNaPhi2nlkhjOQWP7tOhXnrXReNrLULbxTq8d/ZSI8czJHEwIVQDwffiqXhi1kbxDahPMLFh2OTQB7T8NPD+pDxnY3kUhS3t1O18khh3H1r3/V7L7ZbIzxR3G3nDDr9K8n+GM97Bqy2E6lVGY1JXpx3NekHXoNMm8iYuVU7Dx39aAMs+HbGO4LRsqbuTGx/rVxLFrK++0wKTgAqF6VeubHT9eXzrW5AOPvRnv7ii9NroGjqLiRncfKr4ySf8KANJgLmFbhDhgOaoyYdCFK57nNQeHtXa4X/SAqK3H41JrNg4YyQEkHsKAJUjdkIbGD0qFLV5Jl3DvWfBBcxg/K/05NX9CtJhcyXE4YIo+UGgDTvs7kQcADNQrw2MisSWS8nvHkKOqlvl+laGnLJJhXBGB1IoA07nb5BDYwa5q9G5pUb7h4xXQagdlsT1rCfdLKcjBIFAGL5TwuRGzA9zmrMEkyYIfeuPTGKvyQxicAkfNTJ4tkbbAA+MCgDA1W6lk8xVxE2MbvWotLllFs29WOSe1TTL525A3Q/eHQH0rS060k+xOXZS3ftQBBeSPdW7AttQAD8fSug8Op/ZugyXUw+Z+VHf0FVtGjW6YxNHkE8k+grW14RtDDaAYTOcD2oA5TUZ/NYSHjPQng/nVa1uWMioRwAeB6Vuy6ZHJCUUldvQehql/ZuE9c9eP5UAEdwBC3B9setSW+pAyeWcdO/FQzWr7FCDIx1HUU2OzZgC5CvnPAoAuQag0cy7W2nv9K14dV/chieD1IrMtbaIsA8q5xkfSkntSsb7H79KANZ7iC8G1HCvjiuC8VbofN+YllB6ZxUupwXySpLDIA4P8JqhfarHOrrfqRnqff3oA8D8avJcampmjIYA9KK6PxXpnn6hvi5TnBAzRQB5taXs0joboJIepJbBX8q+kfgV4ettc0DUL26uGurKaTyvJkUdVAyTXyxYWF7cZnBxbjq6HOfwr6y+D92ng34WXF9qMf2ZZHaaGNuWbgAce57UAclf69p48Y/2X4MtPtVyH8veFwijoSfpWnqNrq02p/2ECrXeowvkBwOBya0/h5DpsOorfaq1vbm8clESHYSSf4j/AIVa1bw9bz/E+21JLtLZEQhAGIfkHoPSgD5M8S6O2k6vd2zR/PFIycc4wazYnRZYpGwTgrnPSvZfEvhS1vLm5uG1i2W98xyY8/M6AntXJXMXhDT4YvLFxPfI2Jg/3N3sKAPQ/wBnmxm068/tdU3295m28pejerE+1dX4h0bwKNcurm6+zpKjsoDTbMMfbvXk1j47upbCLSNEc2G1zJHtON/GCv49q801q7luL2ebUXlFyrHzAxyWagD6i0X4aeG7m6XU7G4uFtHcEhGBVMcnnFfQNpPDNApgkV1CjBBzxXwD4P8AFWoWqlft11a6a+IZRC54U9Wx3Ne9fAnWf7MbV7c6lJqELOPJuJcjIA9CTj6UAVfjZdvJ4gknims4y3EYYfNJtOOR+FeZeEPH7eGdZnOtaXZzrIpRSE+ZQe61R/aB8RXOqfEK6uHjSJIVSOHy+BgDk/XOa521urfWdDLNHuv4Rkue4H/1qAPqnwp4i0iMnWrWJ5IbgD50OfKbGOQabc+L7a+lMd2iggkLLjof9r2NeCfDfxpNYBrZwJLOXCNGRwDnqK9Kt7KwmM/nSTcfvFQKBx16+lAHU2l9qen3KpHGFh4b5BtznuD3r0R746r4ehlGHYjBDAZOK4TwrfW2pW7WN1uKRDEchwSgHQV21lZXFno0o3IzL88ZHQr9KAGWYU2oXCh1YnArp7KXzrdY5Wy20c1jaTFFdWQlcbXVidp71YRWVi4c4z27UATzwzJchAxwx/OpdVm+y2YhRv3jDrmr1ufNiV3HzDoaytWiLsTLx6UAZdo8khI8xiAcHJrZtmZlOOe1ZNpiFHHByeKvWc43qCTljQBfvF3W/TPtWTK8UEQDqA3uc1s3O0QjOTnpXL6wY5WAbGRxj1oAc1+h58gYXnngkVnahrkVvEGML56UKRvySFA9ulY3iBkaH5G+4cscdqAGTavb7E8yGVXk53KMCrkGu262zoPPJAxjg1zcztJbNI3IHJz1APtW34G0ZtWnEhXFqpy5/pQB2/hySKz0M6hcFgrDILjBIrHj1e21CYsJjvLlsnp9Ki8b6ks01vY2nNtEcNt6E+lclsktWYxtgA5C+maAPSZCRGrRupB4JBzmoTuEpU8Z9vWsHRr5p4MSSKu0feBzW1bzySo3mFXCrncKALMsYjj80HHPQVQZ+G+0hWjxnHQ09tRin/d7TlentUM6bo8sVBPT6UAQzwqxBtGwOwY9PxqJ3uIHRZSdq/xN0NSpGVJXGw9hT0DuQGywHUN0NAFA3xummARcr0x/WuE8UXBDsduQSQwruhZCG5m8ogM3JXt+FcR4whkVWeZNpUHBx1oA8h8R6pcQ322KR0XngUVl+I5pBfnZgjHcZooA9C+Hfw3sG8QabHqWqJkjzVsoR1Uf3q7j4y6+uk6pbadFZPIsEe+Mfw+mfwrxWx1GfwZMlw1w51eVACx/gU4JHNZXxc1W4bxBZTreTSM1qku52JI3c4oA6/QPEjXHiK1vNUu42nhkVooS21ACccepr0zxlqj2WqWd4i+bNdLsJ9F5HH5182+GLeXWPEFpcLGfs8Lo9wueMDn9a9t8fa9o/jprex0l47K/tiAIicBuOADQB5J4oM0eqSG5RxGr8Asc49Qa5i6tz5FxLHKrkONykjJHqK29ZurxZpNOk+dI3K7H5IPeshtLMyxrHMInB2hSM7qAKGm3PkElyQckK2entVDUbmW6vBJISxJ59K7iXwJqpt1nmt/ItcDMkvy/iBXZeEfh7oVgFvNS1GK8mGHjQfdAHt3NAHGeH/Bmo6h5aWsbR2cy5Ej8Ase31Fe56f4SuPB/gptVl3Bo4yTGg5lPQGvLPEPxCuGuzpumbIrKCXO0D75Hf2r3Cf4neHPEnha2jVDNc2oV3hMnlkMo5+ooA+VteuLi6muZNWQs8z7gT1iYmq+nXj+HLq3nUCWMjLp6g+tejeKbSfxZrVxdWCQvbyklYwAu3Feca3pt2920citui+QgLjp0NAHYWVlbpqttf2bh9OvFMwOfuN/Ep9D6V694Jv5dYX7Fejy2I2wu4AwP7pPXFcT8FtGtbyKbSb98+cN8fHKt6ivWbTwmujb53ZZWi4DBsnj1FAGVaaVd2GtTRq/lyZIdWboPau98PeIJLa4S2uR5qhACSevrWQEa+sZJSqyyQ9ZO5Tt+INYlxdKtwNysMMCpzg0AezRwwPG32NsK/wA4XtT7GKSSYo4PHWs/QZkudOUI+1l5XscVuSTGzst8pHmtwPrQBX1e58kKiZAUg8d6fBPFqFsqy8N2PvXI6jr08MpWUIx9HWn6ZrzyW5VrcBsZGKANa7tJ7SbBBZD0ZaSwcGZQMg571m6b40AlNvf23ybtuQckfWujtoba+CXGnzLtJyQKALsq7oOvGM15t4w1IRahHbxybMgksOtekXiSi1ZQC2FP3a8j12yurrVlm8iTemQFKkUASxXcjSCMsck5/Sn3TLLbuDuz16ZyantdAvZdjpDI5YZ4XGK6TSPB7oQ99NtTqVHU/U0AcVomh3uqXqWsSbYgd0khHAFdt4g1Sz8O6WNK00/v2XBIPK+pPvWpqd7FZWZtNK2K2MFh/D/ia8/k8Py3LtKJTIxP3j1oApxyb0jZycqdxB6kZq3dgGLkYfPHOcCrFzohjZIyHKgc4HBqSTTSio29squCKAMSBpIoJY1BDOc4PHArc0K9Yyhd5WM8EMc4NRz6fE7lkkIJH61csdLREK7tzE5PNAE+pQhZiwBJbkMOKqJeTW52keYhPHqtarWgYLukZsDFUb+ykt4mIPzNxux0oAuLqUB+S5QFvUDmrMEqTB2RsoB+VYK2jM2GBZR3zzW1YQeXDyFweh/xoAiRGaV3cHax+Vh6Vi6/bedbuJcMmDwa7WKS38nYwGexrnfFVsv9nyOjDbt4oA+ZPFlhH/ar+SwVRng/0oq/4jjB1By+AxJooA8Y1HXZ9SvDPeuZGJyzHv7Ve8QXNzrj2F0hDERiInPQjsax0sow+JpNo/uqea2LTVodMsZLaCFlEqFmL4Jz2oAmuteXRbIafop/eOA09wTklu4HtUeiavBCjzzu4uEIkQqere9c7DaXF02YYnfJ7Cuz8L/DjV9YgaYwtHBkKWx0J9aAJ7e6XWbhppo9szjczq3BP0966Tw1BaaWsVzLbveXKOSqEfJnHGcdea9N+G/wqsbe28ue386UHmaQ9PoPSu+vPC2nWskEUNpnamPlAA+tAHgEth4j8U38sl88mepV2wuD04rtPCnw8kW8sPPndo2iZXCjA9cV6PB4bAcRpCwXGCy8H8K9I0fTbe1RpZYkBjHlqTycYoA+YT8M44Nevo1jClpP3bEZBB75rUn+Hc2hW97PNbK8xQRJgYOW717lrOnL5SPaRh58nBbjHNY7R3s7ywzSLtlwsigcqe3P1oA8N0LS7nRrq5C2xLIMdOcH37Guju/B03ifTzcJalL+HhxgDev0rQ1u1lllumgmY3OWjlAOOQcDFavwtjnXxFCJmZ1lUh9xJ6elAHA+AdA1DQPE1tdtE3kRSgEgjPXmvcPFelhpDeWi7jJ+8IQYIHqa47xfpf2XX7wNEkUPmFkaAncM+tTX19cGzjhjllE0USsr5J3DH680AdN4XtDNbzw3DFGlXBCgZNczr+lpb6lDExeVWbknt6YqzZvdXW2W2zHdQld6rnk+pFdRcWgvNv2vb5uQd2KANrw7ZKywsPuRqCT6mreuSgsUdNygZq5bRCy09EUckCqVwyu3zjOKAMrNvdKkdxaIx/hJ7GqNnJbQ3Jh+youcj7xrUMkaXCttwMjrVHU9PjF+ZC/BO7gevegCC9sLNpywt+SeTmtDSES2Um3DIcgDBzU81shhicYPGM9zUtkoXCrwTyPegDVa5ligyQrkDPNYj+KWjnCSW0ZB6EPW2yBrbByTjmvDde1/+z/ENzbzZVI+Bke9AHo2t+OZrMqLezRtw6sxOPwFVJPEF1qAiWSTaTztXgV4x4k8ValFet5NwI42PBQAfjml0LxfrE0ckhu9wU8EqKAPbIWKDe2NzDtzVqyliwS7YboBXh2reMtWhCNHeNzjhafF461BFik8xmI5xigD3UTIskhc4IHB9artcQviMlDng5FeVj4gXkmEnCfNgjjt71APHcu6RZYEAVsgjvQB640VtM/y7QEH8NRfZcS5UsOxPWuBsvF8ckbzSOsbAYKA/wBatw+LknjLJ8m3vuyD7UAdoGkSJyuCFb6HFSx3CTweVONhPIzxXI/8JhbMhNwRvx1UVJNr9rf22IHBbGQCMYoA6C4dY38tFIJ4z60ttc7I3WXb8p471yV3riNEWikJJHzKR6elZ0evHyzCCSBwDnk0AdddakYjIFfk+p/lXI694ne2zGxygByD3rnb7xFcWkj5ClG688f/AFq5PXvEkV4pSXarAe3zUAGt6rY3VyJMCInOQRRXkfiHWXa9/dvtUZ4ooAi8O+HrnU5GuHVkt1YBjj17D3ru7f4Zz3ZDbXJc53t2B6DH0r2jwv4Ktra3srHyw4R8uy9Gfv8AhXe6dpJJYxRoihshsentQB5b4C+FEEMe+eMmRD1YcfWvVdO8NQaZp/2eFAschDsoHGR0ro9HsTAmc/I3HStc2aqckgqMGgDF0PTzGCPLKr2yOuasNpoaQs5VQOpPp2xVxriTzQka4TpxTL+FnT5CQOpPvQBFEllGQHADZ4CnPPuat3cgmtQ0eFTd39u9Z6xgzMMlif5VLpg3iS3ds5O4H09qAEVDc2mMkOORWTcWXnXKDGHDZJ/GugiTyX5PNULxNsiyKc8kcUAeda94alttUmETE+bIWJBrS0BDp2qWnyEtuI3DvXSahZXFzOrImCRkk1bsdJVJ1kJw4IPHrQBxuv6VfDW7p5EBSZsr83XPSlsvDly8UbyEAo2wr1yv19a7u9WG6cxkHcT8p7g/4VTjAMbISVkQ554zigDnrW1h0i9EiNhs9Cc5Fb9h5WqXu+PaVBBJX+VcL4h1JIbkh3UuG2/Wup8Bk22j3mpTZCu2EHsP/rmgDqr6YFxGpwB6VSeMNnByCaZDKJoVeTh8nJ9acmxmJEnA7dKAI7iEYUDOR+ZqDUF3FVPJxjGKvSI2QyspI96rXUDE7kAzjrnqaALCQq1qiqBwKjt/kdByMHj2p9kJBEA5A56E9aljj+cZYdfWgDSQlohjoRXi/wARPDkD+IXunk2Bh93PU17NCeQB0ArzjxsiXWryK5PTj8KAPMdS8LC/sy0Ssygc+uPak8J6ABcG3kbA5IBHANdtbw+Q/lqofdxkfnUttpxt7pbgEBgfrQBzGq+A2e2lZi4Y8Lt7fX0rBg8Clf8AWzSErwQTjFezBnkQBwMcHd71FcWSM+6MDLfMRjvQB5zY+BYpYk80y4J2/e6fjWmngWxbJ2ylABjc/evQ47XbCgX5Srd6etqFJJU7ex7UAcfpngywW2kWW2VlbqrE81qad4U0y1TZFZxkdTuGfwrqoYgEAPFKIwMt0oAzYfD2lygq9nCD/ujmrcHhfSo3YLbRgHg4FX7aPC7j1qaNyrDdnnn3oAxbvwPpUsZ8uDYxOcqcVyuq/DJJJHNrdSxMRle+DXqkEgdfapHQMCepoA+XvGPgrXtNiuZEVLuNe6cfjivDNcmngnlN0jxyZPDDHNfoLeWiGNg0YYMMHI614J8avAdq9nJdWUKCQ9scH6UAfIN7MZp2ZuvSit3UPDNzFOVWNvfiigD770mxCQqC22ZQOQOua6GC1j2fMFz046GsSWYWsQ2/NJkjnseKuWdxJKP3hAI7dqANlTFHkcH6UNLnk5A+lZ8e5iCvynPAParmCRg/TNACxlSxIHtUbsxYjqM/lSupwAnUc9aiVDuG7J79aAJNqrg5602OJROGUc5pZG+ZQtSQ5DBj0HagAitwxYsKc8AQggcdcVIzMpwozzUTGUk5I9hQASEAcjkdKqiUrISnO0E/Sp9hJIYk+4qMRgq4z2xj1oA5+6kcEsHZecgg9KrX+piONGdCSwxvz1x2rduLdTCVCg98DrWbPp7SR7DtB6ggdKAPL/EqK96r2xaRHkwBnkH0NemX0ZsdC0vTI1PmOAzY68f/AF6yNE0DPiJXdQ0Gctkde+a6bU5oxq29E3MgEYPp9KAJrSEBFQthgMEGo7m2fDABt2c8CrMX3hs4+nrUtz5hJ2n8utAGFJBcDLFWx0AAqhNb3PQRy8E8nPet1pJBJtZyMVAJZmkYM5255zzQBUsYZRGgYOCK2bMMZF/ujrVeGaVm2k5HStC2Ztp4oAt9uPSvLvFx/wCJ3K3QkDGDXpyNhskGuH8V2EM2sBo8hgu4rjvQBkaJbK4YuSSCBn1FWJBtm25P3to47Vq6VpKQkyF+eu2tCOxQbpJFVieRQBnWMTsASMfWrjR7Z95OO2M1o2MSMSSoHtjpVqazimG/880AZrtvA/2R0zU8KZQFj2pktmyMTEc+xqVYnUDcpb0oAnkaNY0VRl1656VDnKkDJ78dqhlDIc7Tz7dKmjO4jC8eooAmOcgjipN4J+ZenHFRYww+vftUny8E/wA6AJAxXOBjB9auRS7gMfrVEt2GMVNFzgc4HIoAvNh0Irh/FhjnlFtIoaMg5zXVSTsBtC1iTWqXV4zyMMnjFAHl2seCUvbgNFCMKMcCivZIbKNEA25/GigDHtkxkyZ3d/erUAJDcgKO1NiXaSWwR1qZCPM8vAyckDFAFm14AJHPY+tW0bJJPFQRqoTJHSlGT0H4UASF/n65b2pQpkA470iDkHPFSggEECgAWIdeMAU4EKeOvoKbI4Py44pm/b1IxQBKzk0hJ6ge9QCUZyD9c1GXJP3sZoAmZwTgsPpTVYKcBxz2quRxz+NIyg4wRnPFACtcRjgsMVXcoGVkdc5+6TTJY/mO3sao3KBxnByDjPpQBr6TEUuZ5ZBhEXg9qyLGTzL2USch2LZz0rQhZ7Xw3cSsSzMDjJ7dK5Xw88r6suS4UnJGeKAO0SJxIBjC+1K7nceehqbc3IJyBUDkZ5oApzqsvyjJ5wT2qKWMrkDJq452jCnPoMVWIG5Wb65NAEkY2AHA7datWrFyVJGeaqrt2lWOcHrmp7Zwsu1CD70AXFDb8HtXL6ng60zuRtC9fSuouJCsDuOqjoK871SW5fVJW3Y3HjB9qAOitZF2CTfsQ9O2al+2R7euQTgelZOnwnylDsWPrViOIqxUhip6ZNAF5b8Ic7cDpU02oIRtjbn2qiUwCpA47GmJG3B2e/SgC9bzSNj592TitHrgnsaxbdHVmbpj17Vei3KSckj86ALfDdunalAUdF56ZBqISKwyeAe+Kk3DPBoAY0bFs849KRgd4GQB3zU4Pbv3pXT5hjoaAIVXJ5J5qZHxwajK7R39femK5yWIoAvogdRwKrpbKk5cDk8Gn2rkAAnqPSpAdxzng0ATKwAoqMsAecCigDKEfY4z7U9I8EN3xU5Q7vlP/wBelRQ+QeB0zQAL82OwqUADpjFKAOKa2QSBkexoAepAbr+lBYA8n+lRSSDJCn/Coucrzn1oAmMhOcelIvXsaYMg4FP6HkdRQADgnimjAAwOKf6+tJzk4+nWgBknJHT2xUbnnGcAdjUhCqD1xUfBJVenrQBGwO0kcH1qlcK24gcA/kavMWAJJ4FVzGzTIuM88UAWdWQrpVvb55bBNZmn28dvMsmMvnqa19bP7yJccBaow73lQIuT/KgC6Z1bO4EU3zIWU5cdPypZISBll59KpSoYwMD8BQBYZos8z9PwzULNDwBMv41Umjc5IUkdOO1VHhkDsSrdgOOKANMCPcCZYz9KltmjD8SBiBnisoRhdgbOexq/pyg5PBJODj60AaE0u9GQHOa5+6tV+2CQ4YEV0AiLElRWZKv7/b/EDyKAII+FygAIPp1qyBu4RaI4huyMDtVxFCKQOOaAIkgXbgjv3p4iAA4Az2qU8DjoOtCkHgE80AV0iCt6E+1SbQFBUZyfWpWAJIHUUBeTx0oAYV4Pp9KRByfX2qQrjtwaTaexH19aAHbhhTjtUscg7VCwBYcUzJXOBxQBbfLAcdOtMMYPTGe9NjlDD9KlH3c0ARodufypk8hUk546YFTFQfrUMibjjGeO4oAg+1Akh8ZFFRyRFGwPxooA0UAfAKjPX6VJgc+v1pEXGMcYpWIAz+tABn5c5H1qvK7E4Apxf5cL1pg5JHegBvPOfwo9M9M1IVycUxl+bP6UAKDnByc+lO3Hgckim/d454o5J5FADwxB6n/GkLdMDn1pMc4HNLGvr03H60AKRn3FJsH0NP28nA4xT1TuRigCuUUZPPNFrEftSZHFWCqgHH1qS1X98pGeBQBn6p++vyi5PQGrMEaQfKg+Y8FqryY/tdi3PPFTuWy3qDQBYVgSeM4GeTUM0h2/Ki1JGcIcnjHNMf5gQB1oApNdSKD8q4z0xULXsgz8i5B9KddLhgM85qHyCGXpljyaAHGdmcZUDI7VoWeONyiqEEZD7Tg4465rRt/ve+cUASl87m2lQKp30KTL5qjB74NTvnJ+vSmr8qkngY70AUIVOBwc5z9KnyRznj0oQBiARyecVPgAdvpmgCEnCjkdelKDnoMAfrTmjBIxxS7GAGBmgBBzn1NOwR93H5U0HHPanBwMjrn1NAAfegjgYqLzCTgjBpkkrDIzj096AJJGwD1qJrjA5Wq5m5GcECkZwRkGgCbzsNgDB9u4q7DLuXI79KxZ5gq5HYYxUljd84J47UAbX1FEnPPeoo5Aw96ex6c4oAgk3McklaKsbck4BJ6UUASKeB14FQSuC+0Hmh5gOOrfSoRyxJGSKAHoDxlufSnnGcH6UiLhcgZpSqsBkA4O4Z9R3oAeo54IxRxwKOPx7570n8We59utAC4wcnigLyKkXBP9KcsYzjA9+aAIQMMeP1pwj/entketWDGAM4HNIyjqB8woAaiY7DPrT8ep4pCev8hTXcAH09aAEY9hx6GpLQ5kxxwOgqq+TnOf8Kn08fvGI6Y6UAZl5lLh5Ac4b9KtwyeaoLDpwSKr3SAh8880luQilc8NyKANAbSmE/Gom479ufeiDIyD+tPdWI4GR7UAVScjHf1pTxg5JIFSNE3Hyn14ppjkP8OM0AQ5O4jAAz2q1bDg5PeojDIC3AAPNSwDaCcjrigBWdGbAyD65qlfXO3Ma9TxTpsoxJIPfjrVOUb5N/FAFu2YFieuKt4BAOeaoxgqDt4zUm3eBg5/nQBZK4PHSnEjBNUZZWjfCEjmmm62Y345oAtYByT6dRUUkZwCCM0RSiRQU7+tT7dynmgChISjFscHmmeYGBOPYGrM+D8o6dzVKdDGcD1zQBAWUNkY564pnmjDMByPakDjccgZ64HaklIAyc+uBzigCvI+Y+QRzjJFVobtI2wWOB+dS3Ei7Su4DPY/41llWMjBPugcAHBNAHXw3A8lWDZOOtWbW48xirkEiuZ0+7cAxMMgdOOladrclZPmOPegDoCxHTA+tFV4Jw65zmigCmr7pG+bGDxVtDxzniqUIwACCGzVlAcZGRnn8KALKEYB9O1OAGPbtUUTDaB3NS578igBCT35OeOKlVcnINEajrwSamAHGPWgBEGPTPrUmOPem454p2fUfrQA7gj396jJ9KduJGO3TNHU88elAEYGRknmmsDjGD71N39zSNgHrmgCvKDt+nFSaeMM/wBKZLwvFP0/70nPUZNAFGTDMc8nJ6Go0iLHLYCjpgVK43MQV7/lVm1iAwv8IHNAFfayr8pOB6nNMMrBmwx/OtJoUIJzgVUmgUoxLYFAFCSSTBxI2Oo5qoZpBk5Oc9c1qyWwI/14GP8AZ4qs1oqkEzrknP3aAK4kfAO9hn0NW7MkxnLZ59aU20IILye+AOtW7OKIKSCSOetAESx7wBjPHNV5YfLIyQQTxWuiRjA7+vpVW4QbiO4PegCCIdMntQ7BW+XOAOakAKrz+FUL+42DGD+dADGZsls85qtckk4UfSmrNngD3P0pjMWU+3egCWxmKEqfr9KtyXe5Rk4zx1xWSjHPy/SiYHOWBOB1z1oA00kGfmJFOPzMQWBrGLAfMJfl67RzU0F0hO3I3fSgC3PGjgK3Q8cHFU543CkE5HarP2jAA5OehFI0itGAV3A8YFAGJcjqHHOMVVtjhiXPOcc9q1L+PdEdqAkDtXM3ryxlcptO7GM8GgDpLRU8w/Tn0qxd9RgfiKztNkcY83cfpWthWZCTjntQBdtTmPgkUUyEA7sk47UUATJyM4A9c9auJyQWwP8AGqUTDqw5PGO1XI84BYY3UASqBtGAM1NGhzgkkdabCh64zmpk4OfSgB/T6inAhR0NN79MmmFTuGc8HI/KgCTPpQOOtG0nORyKdjgUAGSKcpH93pSH9KRRjnpQBITge1Qk/N3p7HI9cUxhxxxQA2XH58U6yADtjPSmscjJ7U+0OJSvtQBVfAL7eueafbMMuO+KbN8rHkjnmi3Kmbk8nPWgCwhLZ55qOVCTkYz71Nt2pxUbnnpkn1oApSRsSAGIwOgNQ+U2ATyQe9XmIIPHPvQfmCg4xigCmB8+WxxxV+1QLFgepNQ7Vz0J5qeEkrx0zQAuf3gx/KmTnMhHtVpYhncTiqszqWY5GB3oAZI5CEflmsi/UMCDjBODipbi72OWBJXrgVnz3yyH5QSx44FAFO6k8sA5bPQc0kDFhhc5zjr2qO7hmkZAcge/etWyWKBccFuhzQBEtsUT95ySKp3Mpa4KAjgYHNaU8qspBOSKxrqFg7kHgnOBQAjIGII4xxxUTSD5/XpWgkedPBXmRWySKynJaUnoT2FAEiXEsSqc5UHp17etWre8BUgjB7Ams5CX7FeMZx/OoZ1A+Un5scEd+aANtp1dCG5PtxVNrFbvKlehz1qgt4wRstnnqB2rU0KfzpJC5GF4XmgBkUISYJjp+taUQyW4GKl8lZN3tz+NNhTa5zgEGgCzBHlehoqxCQV/iH0ooAZCpBABAHX6VcQEgHAA9KqwnceWyccCtCFQADg0ASgED+XtTkPHvTCQq+tLb5ZQzIVY9VJ5/SgCQc8nNOXB69jR1GT2pw68daAF6YNKOfTn0penSkGOM9KAHYBpTzjnp3pOBjmhcjrxigAY44FMbp2z2FLknPORnjimnPFADDkZx370+2z5wzSMMqQckdOOKIcC4X3oAZcKPMfpUMS/Pu6HPWrF4Sshx0qCN/mwepoAmVsN0JBp8gyTnFIu0HOATRIdzEK4VR7ZzQBHt4Oeg9KaqnOB26H1qYtGqgbicDn3qMTRnja9ADMcceverMPC5PQ1EZIuDhvwp6OgUlc8dKAF3ZJXNUb0bEbvkc1fB3DIFY2rSFCc9T69KAMi5YvKVj5yelWo7dLWJnkC7vWqdi/m3m4g7QMn60ut3hMscSHI+8QBzQBVvL55seVjjjBFUGmnD5LqF7jBp8x2KCQc9sdOlV5FGdwyB1I70AX9OujLLsds45zmrN/aSkb41JXHTOOawrd2iu1cfdzk84xXc2TK8IZuMr60ActazSw5V1bnIZWHWmTtENzAFCOx9an1ieNb6UZyV7EdKzJG3Zb72Rg98UAEcpZCd/XOO9MkjdhvzgrwCR1pyoS2CVxjPBzzTnw0fU8nmgDNvgQzAsVxj7p61o+GyAXbkL7nkZpjWwfIGNo4Jz3q1Z25towygA8nIzzQB0dmRIwHfP51YuI8S8flWZYSFeRwp5HetlOcFsnPWgCGNdwOQDRUczBHI5x2NFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A right selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A left selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulmonary venous phase shows abnormally dilated distorted pulmonary veins, but no right-to-left shunt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32986=[""].join("\n");
var outline_f32_13_32986=null;
var title_f32_13_32987="History septic appearing infant";
var content_f32_13_32987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Linking history and diagnosis in the septic-appearing infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        History",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likely diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mother with genital lesions",
"       </td>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not using an extremity",
"       </td>",
"       <td>",
"        Osteomyelitis, septic arthritis, or long bone fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanism of injury not consistent with developmental ability of the child and/or severity of injuries",
"       </td>",
"       <td>",
"        Abusive head-trauma or other inflicted injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhythmic twitching, brief jerks, tonic rigidity, repetitive blinking, chewing, nystagmus, bicycling movements of extremities",
"       </td>",
"       <td>",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fever; progressive weakness, poor head control, floppiness, constipation, breast fed",
"       </td>",
"       <td>",
"        Infant botulism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressively worsening, projectile, non-bilious emesis",
"       </td>",
"       <td>",
"        Pyloric stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilious emesis",
"       </td>",
"       <td>",
"        Malroataion with volvulus or other gastrointestinal obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweating with feeds",
"       </td>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unusual odors",
"       </td>",
"       <td>",
"        Inborn errors of metabolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32987=[""].join("\n");
var outline_f32_13_32987=null;
var title_f32_13_32988="Osteoporosis medicines PI";
var content_f32_13_32988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicines for osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample US brand names",
"       </td>",
"       <td class=\"subtitle1\">",
"        How it's taken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Bisphosphonates",
"        </strong>",
"       </td>",
"       <td>",
"        Alendronate",
"       </td>",
"       <td>",
"        Fosamax&reg;",
"       </td>",
"       <td>",
"        1 pill a day or 1 pill a week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risedronate",
"       </td>",
"       <td>",
"        Actonel&reg;, Atelvia&reg;",
"       </td>",
"       <td>",
"        1 pill a day, 1 pill a week, or 1 pill a month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibandronate",
"       </td>",
"       <td>",
"        Boniva&reg;",
"       </td>",
"       <td>",
"        1 pill a day or 1 pill a month, or 1 IV dose a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zoledronic acid",
"       </td>",
"       <td>",
"        Reclast&reg;",
"       </td>",
"       <td>",
"        1 IV dose a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         \"Estrogen-like\" medicines (SERMs)",
"        </strong>",
"       </td>",
"       <td>",
"        Raloxifene",
"       </td>",
"       <td>",
"        Evista&reg;",
"       </td>",
"       <td>",
"        1 pill a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Hormone medicines",
"        </strong>",
"       </td>",
"       <td>",
"        Estrogen-progestin therapy",
"       </td>",
"       <td>",
"        Prempro&reg;, Premphase&reg;, Climara Pro&reg;, others",
"       </td>",
"       <td>",
"        1 pill a day or a patch you wear on your skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen therapy",
"       </td>",
"       <td>",
"        Premarin&reg;, Cenestin&reg;, others",
"       </td>",
"       <td>",
"        1 pill a day or a patch you wear on your skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth control pills (for women before menopause)",
"       </td>",
"       <td>",
"        Many different brand names",
"       </td>",
"       <td>",
"        1 pill a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testosterone (for men)",
"       </td>",
"       <td>",
"        Androderm&reg;, AndroGel&reg;, Fortesta&trade;, Testim&reg;, others",
"       </td>",
"       <td>",
"        Gel you put on your skin, skin patch, injection (shot), or tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Parathyroid hormone (PTH)",
"        </strong>",
"       </td>",
"       <td>",
"        Teriparatide",
"       </td>",
"       <td>",
"        Forteo&reg;",
"       </td>",
"       <td>",
"        1 injection (shot) under the skin every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Calcitonin",
"        </strong>",
"       </td>",
"       <td>",
"        Calcitonin",
"       </td>",
"       <td>",
"        Fortical&reg;, Miacalcin&reg;",
"       </td>",
"       <td>",
"        Nasal spray or injection (shot) every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Denosumab",
"        </strong>",
"       </td>",
"       <td>",
"        Denosumab",
"       </td>",
"       <td>",
"        Prolia&reg;",
"       </td>",
"       <td>",
"        An injection (shot) under the skin&nbsp;2 times a year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32988=[""].join("\n");
var outline_f32_13_32988=null;
var title_f32_13_32989="Regulation of ADH release I";
var content_f32_13_32989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osmoregulation of ADH release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Feedback loop governing the regulation of antidiuretic hormone release and thirst by changes in plasma osmolality or effective circulating volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32989=[""].join("\n");
var outline_f32_13_32989=null;
var title_f32_13_32990="Suction device";
var content_f32_13_32990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suction device to remove tight fitting contact lenses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 175px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACvAZwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8m+PH+s0EgZOLj/wBp15xpySR+b5nKHBHI5PNelfHNC0uglT93z+PX/V15wgLKHC9PevAxv8eXy/JH0eC/3aK9fzL8HzuAnC4z9DV23Ifjdlh2rOhLc7yVX1B6VoWqqqhcj64NcyNmX4cKx5+o9KuIQR7CqEJAfbnNW4ipPr71a3MpF637lc1bRwOtUI2468VOrqP4q6YOxjKJeEyYqRJO44qgrqH/ANrtUqsiIxIPHOfWtVLqZSj0L7SgquWGD1prXPBwQB2ArBuL6PLHzNqr97g1mahr8UDRRhgFbPODk4x09ql1V0HGg2dU9xtTJPJ4HvUElypOwsB3ridQ8Uon72WULEON4yefQDrXMzeMpJ03QMFjyVYsDmo9pJ/CjdYbuz1f7XH1LfJjPPpUE12jfOrYjGea8pm8X/u98r4ycqueuP5YrObxdO8wLuTGg/dxcjJ7k/pSbqtbFqjFdT1o327kNnPGelRveENtDZc9BXm0et3s0YZ5kWZuijoB7Vu6Lczbg1xKrFeeM96xldGypJK52MdwxKhzhvSpjMc+1czc6mjE+QwL+vpViLUfkGWB9wetCnZE+yb1OgEpP3etOjG1cMcn1rEgvweScZ6cGrqXIONx61UZ6kSg0X8jNO8xVwM9aq+aNvXrQGUgZPSr53chosyOMDmq5YZ60jyLtO44qq0oycHNDYuU9yooor3j54KKKKAEZgqlmICjkk9qxp9fh3FbVfNwfvnhT9PWuX8b+Iw+ptpMD4ihAM5HVmPIX6Y61RsrnIGDUuRSidtDqczHJ2H/AGcVp21ws68cOOq1yFpPkDFacE+x1dWAcfjSUhtHR0VVt7yOVRuIV+4NWqsgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy343oWOibev7/AP8AadebJFuAAPI7etem/GkZfRcn/nvx6/6uvOU5QrjBJGBXgY3+PL5fkj6DBP8AcR+f5j7YFXdWGCcY9qvQt03cMOtVxnJJHzEAY+lSIhyDnk9RXMdNy9EwJIXknv6VPGyqCA3GOuKqQybFct27etLGr9SMbj0z0q0yHuXreT5cZzzVhX55PPQD1qpAp3kAcCpmkjiRpHIHGFz6+tWmS0WldEH7wggdcis7WdRZLlLOB/3pBaV/+ea8YrN1PxJbW8byptc7iqDB+Ygdf1rg7/xAbO0kcSGe6ujvJOdxbnCn0UevStIpy2BQS95nRa/4jgtrqOxt5xkIzSNg/KeOTn8a4271dmlxcsqsDhVySQg5x7ZrnJ79UBmdzLdPneAM+Y3qPYVmvdXFzLmcO924BYAfd9q6IUFEzda2iNa41Se5lR5gFjC7dq9FBNU7y9WORIbdi6p3AIPPofWqxjkRiJsBAPu7hk/4VUxKXxbncAeQOSPSt4xijJzm9C9HLELkm+meNeuApZm+p/nUF9rUMeVggV3Y4MzZyfoPSql3DeSMCd2Tx92q40u5JzKGOfu1a5FuyGqz0UbDv7YuGmJjuZQy9CeAB7VaXxFqFurlbmTzGA+bOQRVK60uWPZ5kZXuORzUSWeFbcD6nPNNuLVzPlqp9Tas/Fd/GykyHyu9dTpfjAL8rr8/B5BOa8+hi2EqQdp74q1ADk4JyCCCOtYVKUJo6qFWpB2ep7Fp/iO1vohNBKQy8MpB/wAK6K2vQdpdsf5xXjmivJHdOVA2MoLKOgIPUfnXf6ZOTHErbvMC7GJPX5sj+tedUgqctD0oe/G7PQoZARyam6DNZVkSFB3cknitQSAqAW5FKL0Oeas9BsjYXgZ7VTcfNy2Kszg7OBWdNL8/BqhJH0JRRRX0R8wFFIxABJ6CvGPH3jjVLmaa10mRrW2UlS6ffb8e1AJHMaheTJ4i1J7jO+S5kY57/McVvaXe7wvPNcdY3AukFtdsTN/C7HJb6mtLTPNW7SA9M8t7Vm0aI9EsZyy53EJ6jqfpWrby7uBhR6L/AFNcfb3ymXYjDavAxW1bXIwDn6D1pDOjQRkYAbd7GtzTLgvH5ch+dehPcVylu7Sj962Bj7qnp+NXoY4zgqCGHQhjn88007CaudXRVHTJmaPy5ZC7joW6ke9Xq0M3oFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmPxp/1mif9t//AGnXnnMhQgYAOM59a9E+NJw2int++/8AadedhtyhQuT1z6GvDxkb1pfL8j38G/3Efn+ZOvyvs5JPGKmQFc7Tj2x0qPcVdT97A7DoackmV+dmRjyBjGa5bWZvqyaIq5yzggZJqxHIHxgrk8LmqCxifI2/u1IJxxuNOmv4bOB5pXRY4x8wbuPQflTuPlZcursWSHzCVYjJ3dgK4HVvE7Xk7QW0itBypbBA/M1y3i/xjJfzSRRT5iychTkv9f8A63vXKSXlxdp5EZW3jI+Zz94+2K6adByV5aEurGHmzX1bxIsV6IoJCUiJG4g9e+Kw2v7q+lZYVbzGXBJPJ9vpV7TdFe4IhtYmdevmOQB+ZrrdG8NXyoxihMaDG+TAH8+vfpXQ6kKatHczVCdV3nszl7XTpYY1luI5Y4wMDccD6DvVmBZrjclhbTODjKxxEY+pPNegab4Pd5BcTyEr/tevsDXU2Xhi3jUq0ksJ64jbGffNZvEO+ht7GnFWueU6d4ZuZX/0u22g465FbaeGFjyIHjOMblwOPTn869Fj0Kwt5PMD3Er9w7kgVO1jbxLligB9BzWE6kpM0hKEdIo81bQZkGImJz1GBimtpLKv+lCPI+7gV2tz5ccpEJUg5zVG5RAC0hHTIqOdo6E7rY4S80/fuWUAenesttK25wOCD+ddZqDI2CrANzkYrOLZ4OG/pWsajS1G6MWczLprKjfJuGB0I60+10wgcocgg4zXSRxLK2On4VPb2gVj5nQ1TrOxCw0b3MuzsFi3E5DMeO9dbo8YaQHr8wyfaqlvbgAbl5zXQWFsVKhUwfrXLUk5M0cVFG7aghRg4Gfzq9EoO44qK1jxGMjrVxVIHIx6U4o4pvWxVlbanzdKxLmZEmYO2D9K3rkH5e244xXDa9qsWnai8E6fPgN68Gqtdko+q6KKK+iPmQryz4jeETEJNR06MtCxzLEo+77j2r1OkZQ6lWAKngg96AR8k6kjRsSnynqDV7QdWeW1mNydtxbDaGH8QPQ11PxN0FNO1mYQRFIJPnXI4/CvOTvspmZQCrrtYeoqbFpnbWNw9vIEcngZFdTpt4HVW43Hv6CuA0fU49TtXhbAvoQOD/EM4yK29Pumjfa55HrUFHodrPkDmtS3myB2rj9Pvd23J5retJ84GaBHSQynPBx3BFbNlc+cu1uHH61y9vLnoa0YJDhWBO4dMVSYmrnQUVDaziePI4YdRU1WQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeZ/Gc4fReM/6/8A9p15uJMZVWAHr616L8as7tF4OP32SB0/1deab4gpLMpC/ia8fFL96/66Hv4L+BH5/mWVYkgAsn+0KJr5YxsYSSH3GM/nVbzTImYo2YerMVqsyz4Y+Wqn19Pxrhm9bHZGN9x2pazdWsLGyit4ieockk/SuA1uHUdZUPqd63kKSQijaBn+fSujv5YHnB3G5mTPyg8Cs6Wyu7yQGZwsfZOy1dOXLqdCpRtqjjF0yCOcR2MQ3f8APRuSa6HR/DeXMlwoROM751BPX0zXT6Z4bsSTvUyMccE4/WtqOzs7Q7IrZd3cfe/U1o6zatcz9lFO9tStpiWNtEInMcqDH7iAMS31bGP1reWea4liC2hS3Uc54x6fWoYvOWPMBjTHReuf04qzJcvkeezf7ITv61mnqJ7mmvklQSoUDoM1DcXcQctukLDgnBx7YrMuroKq5bB5+XqaxdS1tYIwHuAgbOD64pq7dkEaXVnRzajFEMeaFY9iDzWPqOsQ5yZM9c8EVw15rkt6ZBpcUl3MDhioJAqpLpWtXV5bQanIbSOfISTqAe4JHQ/Wt4UZS3WgTqUqSvfU6WfxFZoJCsse5PmOc1g3fiyCQHEmXzuUc9fSuek0awh1i9sNTuGQW7Jhsk7g2c9PoPzrD1eLTYL+6GnznEafuGwcOfT2/GulYNJ31OR5g7XSR1DayZZZW38BN4GD1zyP5VpWNws8j4wzOdw9hXmMWpNEjQs2Mp5Q79SCT+ldj4dm/wBHTGd5+Z2/HgVFagoxbNsJi3VmonXwg54xu7VoxK64LgMfT0rLsX3sCxwRW3bxknpnODXC10PSbRYthkhdvHrXQ6bCTyRzWRbQtuX5eD7102mQtz8vp3+tRZ8xzVpKxdtYWReRmrwjDDkdKdbpgYIqyqAjgV0RgedOepn3ESiPpzmvBPjLqZ0/xkYckA28bDgnrmvot4xsII615V8RfBL6/r0d5FDvxAsbHco5Bb1PuK0ilGV2RzXWh9U0UUV7R4IUUUUAVNS0601KAw31vHMnow6fSvAPiV4SfQ79zChNnLkxsO3tX0VWfrmk2us6fJaXiBkYcHup9RQNM+OZIZra/gu4G2TwNuX39j7V3enX9vrVuZbc7LlP9ZEeo/8ArUeOfCVzod68ciExc+XIBwRXDn7RYXS3NixjuE/Jh6H2qWij0m0u2hdVfjFdPp97kL61wejatb67bkxjyr2MfvYieh9R6j3rVs7p4JAshI+tSxo9GtJ898Vr202a4jTr4MF5roLS53Ac0hnU20xV1dCcjqPWtiKRZUDKeDXK204P1rXs7nyznqp6gfzqkyWjWopFIZQRyDS1ZAUUUUAFFFFABRRRQAUUUUAFFFFAHmXxpP8AyBgRwTNk56fcrzGGI/vDnvleBXp3xoAzoxJ6ed/7TrzUsGAC8Z615GKX7x/10PfwX8CP9dSpK9ypIQxA+rE/pVG7gu7lAtzK7RnOAp2j/wCvWlJGAQW6jpVWadmIC84zx6VwtanoQZRTTBAoIwV+mCPrVlECqCuCe9RXM7MgUZwetVXkZFUBs0WvodEbvc2I5xECWUAjpzT1ugzMy4DVgPOeGL8jt60n2tlQ7Wz601Bj5Fe50JvAh45J6n1qpeayqRgpIpbn5e9cze6ukKb2lwB1x1/CqunWV1rtyzPL9isyMu5B3Mvt+X610Qot6sxqTjDUmutcuLlzBY75pT1Kdvx6Vt6R4GF6oudeupJMfN9nQ8fmP6VNHr/h3wvaSiGKN2YA8KcuRkenvXDa38SdT1JRY6YFtogxQuO4Pqe1d1GglY8rEYyTvbRHca5q+ieF5rF7eRgGYxG2hXG1eMkn8uteZ+IvH808N5YWbubCW4EwMhy6sA20Z/OsGa2uNQuzDLcD7QMk75AAx4wQx4A61ua38PjpfhLUNc1LWdOlaMKsNvbXSyku3GCB0wCTXWoLZnmVazlqjirvVLme7muLli5kwxO7rxgfypHR5IPOiJIPbPSs2E7iFbqev0HSum0SLG5ZFwhC7cnr1qKkuRXRWGpqtNR7lWw0uW8KbSoIILbmC4/M12No62q+RakXE/AKr/D+PSrPh3T7OebbdxllyBhccV30HheKElraNY4yOOBk1wVsQpOzPdwuC+ru7e5zuj71B845dSD9evFdfp4BGW78/wD1qy30p4mAIPXrW5pNoQDgEjiua3MzsqNKOhpW0L4GFz+NbtjuCsGGOneq1rAdowpzV+3hYtzwalxs7nDKpdGhAT0rRgTI5HWs+3DZ+ZcY9604Dke9b09dzkqMc0YyBis+e1JkJ21sImUORzTfJz161py3MVOx6DRRRXqnkhRRRQAUUUUAZ2vaPa61YPa3iBlI4bup9a+dvHPhC60O7ZJIyYj9yTGQRX01Wfrek2usWL2t4gZGHB7qfUUDTPjt7eSC5W4tpGhuE+669/r7V1mha7FrCi2vNsGor26CQeo/wrW8deC7nRLpt0e63Y5SQDgj3rz69syW3DcsqHKsOCDUtXKR6VbSvDJskJ9veul02+DBeea8y0DxCZWSx1kgSgYiuD0Y+h966aKWS0lw33M9RUjPSLS5HBzWxa3HSuE03UA4HOK6OzuQcc0hnXWN15Y2tyh6+1aoIIyOlcraz9K2LK6C4RiNh6H0q0yGjSoooqiQooooAKKKKACiiigAooooA8y+NIy2jZ6fv8j/AL915qu4Ywo2/UcV6b8YwDJo2en77/2nXm8ibmwgyD3ryMU37Rr+tj6DA/wI/P8AMzr1gWUbsEZrOLuVZkIwOtatzATszgjkDI+lUbi3C7gCAD0x3rjd7npU0rGdNIxbAbIHWqcs4HA696nu1IbjP+NZk0u0kNxTitTosOklA5OT6e1U7vUIok+X5pTnAqO6ldinkc4zk9MVXFr0eNDJL3b/AAzW8UiJNpaFVQsV0t3qQ3KeUQnIH1A/CqWreMrr547Y7YQCi4HOKvajol7NbPLdjyLdegLAsSfQA5PSruieC7e9tw+mXCyXAA3RSjByfr0/Gu2ly6XPHxPtHfl2OHtbG+1W6jDM53A7d3SuosPB0yuFkjASVdkhBHIrsrHw9cadcQLeRbXBOMAEds4IrrbS2COd6jaRwfSu+Fr6HjVFJvU8D8XaaNL1VLdADbqmzLjORXEO7gOnyhSeVHFe+/FTRUvLeOeJMtGSSQMeleTXWkRXTGX7hPGOlTUlyy8hKDcbIw9JhM1zgEAYwa7yPS5ZoIxbpvZF6gd6qaNp1raKd2CcdTXp3hjQ9U/s+KfT41WWVlZHkxgenXtzXHXk2ro9PLqS9oud2SOc0/T9U0q4gS7sLje4DKqRlmPvgc17V4YZriBYr2B4pAB8siFT39a7bw9aNbWsRupBPqDovmysBwR2HoOadrKebHuLBnGcMBzWMsG7c7ep2VszjUfslHTuc5qWiwuFIUDGaq2um+SDjFb1tc+aGjZRuUDrTfJw5YD5QaiME9UZSqSS5WyisDfLx0qeKHBPFW2i7qPr7U1Hh3bTLGT6BgabgSpNrQfGg/HvVlBtIxUeAFBX7tKjep49KFGxm9S/GTjBqTFU45MDrx2FWlbIHNaq1jGUWju6KKK9A8wKKKKACiiigAooooArajY2+o2j295EskTjBBFeD+P/AARLo87yxrvtGOUfHT2NfQNQXtpDfWslvdRrJE4wymgaZ8fXdiPmVwTWroertbqtjqbFoOkcp6x+x9q7rx94Ol0W4aWEM9m5+R8dPY1wE9rwVK/nUvUo6uGR7SQEHMZ5VgeCK6bTNQDAHdmvOdI1B7Nfst5l7U/dY/wf/Wreike0dSrboW5DDmpYz02zucgEH8K2LacNgnBFcBpeoq2MMK6eyugQDmlsM7GxucAI5BU9D6Vo1y9rP09PStm0ucAJIfl7H0q0yGi/RRRVEhRRRQAUUUUAFFFFAHnfxbiMraTgZx53/slefNCY8YXk/SvSPikpY6X7eb/7JXBun3T2ryMV/Ff9dD3sFL9zFev5lNkJwGww7Y7Vnz2Ks5JBP9K6BIlyBjrUiWYZiVGT6Vhy3OtTscRf6ZIQCFyDnGKx5dIAXdJwfQ16i9ijKcjBNUpNDSY4bBX1PapdNo2hiktzzNNLkc4VML+HNaFpYSW5aR48LxgHn616FaaLb25b5C3TGaW605G5IC+nFVGMlqN4pS0OHWQJPBNsWRoiSFZcgZ749eK1bR7B9St52j+zXEzkyOq84HoB1zmtJtPhHGzDk/eqJ7Mx3cUyHOwHDDGB0reE3HcybhN6G5Gr7sLEkloUBxKRkEHn+YomsLW4QsjCJUJUgdj9Kxrh2kAxuUk9FPT61JLfzLA4YImTuAzyT0raOItscdTCc4zU9JjuImgiKTA53cgY4z369a8x8Q/DvUReM2nhNpBJBZcfzrrLq4uXvom8wIqKwDIeDyD/AEFYfiCXUUEb2l1Kwj/5ZlvvjgH+X603ir6MccvMbTfBRspo7vxDeRi3TlYohuLev3c+1d5a+MbE3Vla25MMcfAEilQw4xjIrzpmkFy21pUjmCugL5wec1u2tnJfQOl0o5xtY4JB9R6HpWU66TOyngeWB6frPje10q2hkeRS0pIXr2x/jWhoniuz1JAUlXdxxz3+teNN4B1bULmOOXUrdbdcsrvuJx6Y9a3Jvh3c24WTw1fzNcqMmCdgN5H90k4HfrXZHFQbsedLB2Wp7Ni3mIZdu89xTkiYSY3Ar2z0HvXiFj421TQ7sWGv2sttcAhf3g4P0I4NdB4h+IMbeGblbCQC8nXy0IByAep6cVco02uYinQquagtSp4v8bT6rqMtlpUzQWEDFHdcgzN/QcfrWn4OgMhRnUsz4I+bivONMjCiKIcsT3/iJ6mvaPAtgWMfyfKmMnI4Nc1Jc0rnvYpRw1Dlidbb6dIlsjIx3H+Emq7rgkNwynDV1EcQCgY6ViapFsuiVHyOOvv3rWtTSV0fN063PKzKinbg+vQ1L8p+9kn1qJiQmV6CnoQVBK1zGzVz0iiiivTPHCiiigAooooAKKKKACiiigCC9tIb21e3uoxJE4wVIrw3x74Sk0S6LRgtZSf6uTH3fY17zVbUbG31GzktruMSROMEGkNOx8ryRFeGGQatadem2/cy5a3Y9P7n09q6fxv4Vn0K8YEF7Rz+7lx29D71yEy7CByAfWkUb0UptnV4m3QsMgiun0jUgwHzZrgrG7MA2ON8JPI9PetO3lNtIJEbMJ5yDUjPVLK6GzcWAUdSTVmTXljhYxBVjHWWQ/yFcLY3r3ab3yLdOT6saivpLu8b5EKxj7q9hU3KsbmpeL52+W3diB/E5P6CsKXxFfCQP9qcMPQ4xVX+yrhxlyR9Kik0oKMkljSvcpJHo3w/8Wy6ldGwvXEkmMq5616BXjPw2sWHiuJ0GFRCTXs1aQd0ZTVmFFFFWQFFFFAHDfE0ZOm+v73n/viuIQBt2eT613XxJznTRgf8tP8A2SuJZTxgda8zEJe0bPawj/cr+upJbR7wdwwRVhYZA2QvH1FJaAjPHpV+P593HTFZpI1lJoq+UxJyP1qRYgF96sBTnpmjb04xQ9yea5W8sZFIYs59KuhB2pwQZ6UK9xcxky2sDfeGDVaXT4SVMa7z9cYrdeFT26VH5GM7TinYaqW6mDNpryrtDlfTgCqk/h6SSPEkq47cda6hoyPemGMsOeKhwT6GkcRJbHFP4ekjUqjow9Ko3HhoyFWmkIVQRhR6137W+MlePWqVzC2wgY5rOULbG8MTK55adCt7cKMMzLxlu1aWmWx3E7chcYFbN1a4lbeMsOlS2UC/Pk84BArG7vqd3tfdsWbEKhx3rc06LcTkDtnNYccsIk2I3zjGRg10emqSmfpW1F6nBXbsTanpGn61bfYtUs476FuP3gwVPseor548S6Vp+j+K9RsNJlmktLVwgExyQ3dc+g9a+itQvRpel32oMR/o0DyDPcgcD86+ZY5JLid55yWllbe7Hux+Y/zreUtLHTlVJyqOb2R0Xh6Ey38OFyCRXv8A4KsjDabmXByM/rXjXga0aS6i4xjGa+gdDg8uyUV14aOhjnla3uI0FU5AArG1YB3RQxDZOCO3SttyEQnPQVzt2WluzH/DjOfSt6jSjqfP0U73XQrMkg4dAPcHrTfmHGKuCRcbH+8OD3qvNqFpA5jeVAR2rGVGL1izdVpbWPR6KKK6jzgooooAKKKKACiiigAooooAKKKKAKmq6fb6pYyWt2geNx+IPqK8E8b+GbjQrxlkUtbsf3cg6Ee/vX0NVLV9MtdWspLW9jDxsMc9vcUmhpnyzGwVirZFXdOkYTiJDvV+oqx400caHrclqsgeMZKHOTj3p/giNbrxBbRPyBl8fSplsaI9D0rS1gsYY5FywGW+pq+1qqjCoPwrQWIYpHTHbk1mUZEsQ54/Gs+5gwCcYzXQvDuHIqTSNHbULkeYMW6HLn19qLdh3stS74A0o2tvLeyLhpvlTI/h9a6+mxosaKiAKqjAA7U6tkrKxg3d3CiiimIKKKKAOI+JY503nH+t/wDZK46Jeeuc11vxPIB0wE4/1v8A7JXI27qqkFuvtXmYj+Iz2sJ/BX9dS3ECDgVbhPXFVIXU8A8Y64qxBgoeeB3rKO5ckWWIGOaQHJ4qMkcAHNLGwyRnmqvqTYmUcjmpD8o6c1EpBP0qTOaolocDn60FecURjnpU4TLZ7VVtCHoQFRkAdaRl29qmkXB461EzDgMeaairDTInXcKzrtSVIFaMgG3OMisy8l4AzwM8elY1NDaC1MK6Vd7ttw3fmqHmBS2TtJxj+tWrz5mY56VkzRu0qlCSB1rkkenDzLtsC0oIHQ8mus09wFCg8nFczZAg9PrW1FOqjO7CqPmPpVU5WephWTkrHPfF7VhbeGBYxsTNfPjA/uLgsfzK/nXjUH+tRR6AY/z9a6fx7qrarrcsgbMERMcQ5xgYyfxrBsI83ClhxWt+Z3PbwFH2VFd3qeo/Di3DS5I/u4/WvcLFfLgVTxXkHw7jC7Meo/rXsSFRGuDzj0r08OrRR8vnEm6xHfSKsBOcDoa57T90k0sh5G7A/CtHXpSLTbH8zE9M4qtZRmK2XzPvnJalWetjjpRtTv3MrXb1NOuLSSaRYkmm8kM3TcRwKSTR7KXa9xavJMR8zbu9c98XLU6h4VMaNtKXUcgbpjGRn9a5/TLTyrNFnv7mRuzGVulcU8Yqb5Gj0qOBVSkpqVnr0PpaiiivWPnQooooAKKKKACiiigAooooAKKKKACq2pXS2VjNcN/ApP41ZqK6t47q3eGYZjcYNAHy/wCK7iW91Ke6lJJZj+Aqp4b1NdJ1u1vGyURsP67Twa9p1X4XWt07G3vHiBzwy5xWQnwXty2ZtVkx32pU2LTR1Nhc299bLPaTJLEwyCpzT3KI4R2Xeeijkn8KqaL8L9F0w5869l9vOKD8lrsdP0yy09cWdukXuOSfxPNTysfOjKtdKluMGZTBF6H75/wrdt4Y7eFYoVCovQCpKKtJIhtsKKKKYgooooAKKKKAOA+KjbW0oevm/wDslcUkhUjAzXY/Ft9jaSO587/2SuGtpARndXlYh/vWv62Pewcb0I/11NaOXJB6Y/WpI5SAQOp7VTicH+IH8Km3bRk8Vnc0tqW/O5Ck81PE46DnFZyvuAKnJFTxuBjccUX1E4mhG4Jap48ck1midVb5jjPSrML7+jcCrizOUbF7PAOcinIc53nA9PWqoOD978KfnnrWnNpYycSy3OMdBUUgXOc0zeADz0qKaXaASetJy0sOMHcbJKqqQxxnpxWNfkkfIcjnNXZ38z8KzppETO489hiuWpO51U4WMiQMC2BkGoFVw4AGCatzyoDknGfaqL3O0ny+W+lc7Z2xuWPPCAF2AA9jVXV77Za4ifLS/KABVe5nMowv8PLVRgV7u6O1ciPofr2/SiLuWqdtWcJqwIlyQcZIyR1qXSgjuoHJPQYNdtNoRuVjS5gJ2Dhhjv2/QVo6Z4YtVdSiMuOtdEL22PSWLpwhZ7m94ChZAm0YPH9a9Fe6ZcBjXJaPYraofLkcdAa10tgnHmMc8kk5r0qc7RsfL4y1Wo5MluQbqRcthAc5p0jYDYPy9qkhRueOKiuiAoGeaU5XTZhHflRxXxKn8vw1I2ePNQfrXCpqv7tAH6D0rovi5dbPDO0Hlp1FeXR3bFRgmvGrLnk2fW5ZRi6Ccu7Pt+iiivpT88CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNPjIWEmi7c/8ALbP/AJDrgYZAshBPy44zXcfG2Vo20Xa20ET5/wDIdecW0oKFpOh6H1rxsU7Vn/XQ+mwEL4WL9fzZtRzER5J781ZSYvHnOR2rC+1xBlG7A78GrcNxhiAcqelZKeh0Ok7Xsa8TFQd3FSPIDtwaoxO4z5oxn8afvycA/SmncxcdS6HG05NT21ztDAn0rIkldSAoz6806ORiTu4NNSsxunobf2ndnBqSO4BUgnJHSsmKY59xUkchLPg/Wr52ZuBqhw5GDj1qKdgCATkjOBWfLdCLbk81FNd+bt2/L/WplNfMI0ne5amYov3sjmsS7nbzPmGB2NTT3S7V3vjd04PNZ9zciTancZIPr/nFckp62Z0U6dtRLiVCE+bnntVCZyQwVwoPU0szqAeeV5PtVaZgwHzYY9B61F76HTGIkLMWMSfOz8D3rqNK0vyoM7cE4yeOaoaFYg/vXGWOCv05zXaWUIG3I4xkV0UIdWcuIq2bSK0Fg3YA+taFtYDd9zmrcCqTn1q4gK8scr/KvQpxSR5068tivFbbeQv61YCbQBUiY20OOmK1sc7m3uIpAzzWffSqOQfWrzfKuT0rF1VsIQO4NZVZWizWhHmkebfFeGbUNKgt7VS7ibeVHHA+teVFZojsljkVh22k/wAq7P4n3c8up2sFtK6CNGLFTjrj/A1wxe9UkeY7e+6vO33PrsKnCkoo/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32990=[""].join("\n");
var outline_f32_13_32990=null;
var title_f32_13_32991="Body stuffer wrapping method large bag step 2";
var content_f32_13_32991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Body stuffer wrapping method: Large bag step two",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After drug is in the corner, it is folded up once or twice. Next, the upper corners are tied into a knot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Aks, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_13_32991=[""].join("\n");
var outline_f32_13_32991=null;
     